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Abstract 
 
Neuromuscular junction (NMJ) research is vital to advance the understanding of neuromuscular (NM) 
pathologies and development of novel therapies for diseases associated with NM dysfunction and 
deterioration. Several in vivo animal models manifest phenotypes observed in NM diseases. 
Unfortunately, in vivo NMJ research with animal models present many challenges due to inaccurate 
reproduction of human disease. For example, the most widely used animal model for Duchenne 
muscular dystrophy, the mdx mouse, is a good genetic and biochemical model, presenting total 
deficiency of the protein dystrophin in the muscle. However, this in vivo model is not useful for clinical 
trials due to the very mild phenotype expressed. Therefore, in vitro models were established, yet 
limitations exist. For example, inclusion of serum influences translation of animal data into human 
trials, inclusion of complex neurotrophic/growth factors can interfere with drug discovery, the initiation 
of skeletal muscle (SkM) contractions requiring electric pulse or chemical stimuli, and time consuming 
culture methods to induce spontaneous SkM contractions. Therefore, the aim of this thesis was to 
establish and characterise a simplified co-culture system that allows in vitro research of functional 
NMJs, representative of in vivo conditions. Immortalised human SkM stem cells were co-cultured with 
motor neurons (MNs) from rat embryo spinal cord explants, using for the first time a culture media 
formulation free from serum and neurotrophic or growth factors. This co-culture resulted in NMJ 
formation and contractile SkM cells. The de novo formation of NMJs was validated via characterisation 
of pre- and post-synaptic structures of the junctional apparatus. Interactions between the specialised 
membranes of presynaptic MN terminals with postsynaptic motor end plates (MEPs) located on SkM 
cells, along with supporting neuroglia, permitted chemical transmission of acetylcholine from MNs 
across structural bridges to bind with receptors on the MEPs. These interactions were associated with 
contractile activity and advanced differentiation of innervated SkM fibres. Functionality of NMJs was 
verified through the application of known agonists and antagonists to the co-culture system and 
confirmed that the contractile activity observed in the innervated SkM fibres were driven via NMJs.  An 
ELISA-based microarray identified the presence of trophic factors required for MN, SkM, and NMJ 
development. Ultimately, engineering of this novel in vitro NMJ system represents an accessible 
platform to investigate NMJ formation and function, as well as providing a breakthrough assay via the 
system’s ability to respond to drug interventions through measurable output, initiate spontaneous SkM 
cell contractions, and induce advanced differentiation of SkM Cells. Therefore, this novel system 
provides a tool to screen pharmacological or genetic therapies for diseased linked with SkM, MNs, and 
NMJs.   
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Chapter 1: Introduction 
 
This thesis describes the generation of a novel in vitro platform consisting of immortalised human 
skeletal muscle stem cells innervated by embryonic rat neurons in order to model neuromuscular 
junction formation and development. The in vitro differentiation of stem cells into the required 
terminal cells necessitates the recapitulation of the molecular signalling that transpires in vivo during 
development. Thus, a comprehensive understanding of the generation and development of cells being 
studied and used in this research project is required. The forthcoming introduction aims to set the 
context and scope of the project by detailing the developmental biology of skeletal muscle cells and 
motor neurons, beginning with embryotic development through postnatal maturation before 
discussing the fundamental genetic regulation of neuromuscular synapse formation and 
neuromuscular junction function.  
 
1.0 Myogenesis 
 
1.0.0 Embryonic Myogenesis 
 
The genesis of skeletal muscle cells (SkMCs) is initiated during embryonic development. The primitive 
germ layers of the early embryo give rise to the paraxial mesoderm, which leads to the formation of 
the somites (Aulehla and Pourquié, 2010). The somites are prompted by factors from the dorsal 
ectoderm, neural tube, and notochord to differentiate further (Buckingham et al., 2003; Pourquie, 
2001). As the somite transforms, the dorsal region produces the dermomyotome, which contains the 
precursors of the skeletal muscle (SkM) progenitor cells. The paired-homeobox transcription factors, 
paired box protein 3 (Pax3) and paired box protein 7 (Pax7) are two of the first genetic regulators of 
myogenesis observed in the genetic hierarchy of SkMC formation. The expression of one or both of 
these genes has been detected in all vertebrate animals, including humans (Balczarek et al., 1997). Both 
Pax3 and Pax7 are expressed upstream of myogenesis by dermomyotome cells that will differentiate 
to SkMC progenitors. Research has demonstrated that the expression of Pax3 is vital for the primary 
formation of myofibers, whereas Pax7 expressing cells are involved with secondary myofibre 
development and generating a population of satellite cells (SCs), which are the quiescent SkM stem 
cells (i.e. myoblasts) found in the postnatal basal lamina of SkM, needed for SkM repair and 
regeneration (Bismuth and Relaix, 2010).  
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Low expression of Myogenic Factor 5 (Myf5), a member of the basic helix–loop–helix (bHLH) 
transcription factors is also expressed by these SkMC precursors (Buckingham and Relaix, 2007; Kiefer 
and Hauschka, 2001). The dermomyotome cells situated at the dorsomedial lip of the paraxial 
mesoderm form the myotome (Figure 1.0), which generates committed muscle progenitor cells 
(embryonic myoblasts). Elevated expression of MyoD, another bHLH transcription factors, and Myf5 is 
also observed in the committed progenitors (Kiefer and Hauschka, 2001; Ordahl et al., 2001). It has 
been demonstrated that MyoD performs downstream from Pax3 and Pax7, but Myf5 can act 
simultaneously alongside Pax3/7 (Tajbakhsh, 2009; Hutcheson et al., 2009). Both MyoD and Myf5 are 
known to direct muscle lineage specification toward myoblast commitment (Tajbakhsh et al., 1997). 
Upon formation of embryonic myoblasts, the myogenic process is controlled by the bHLH myogenic 
regulatory factors (MRFs). Initially by the MRFs Myf5 and MyoD for their function in myoblast 
determination, activation, and proliferation, followed by myogenin (aka MyoG, Myf4) and MRF4 (aka 
Myf6) for early differentiation of myoblasts to myocytes and late differentiation of myocytes to 
myotubes and ultimately into mature myofibers. 
One of the first bHLH transcription factors discovered was MyoD. This early research showed how 
MyoD could be used to transform certain fibroblast-like cells to commence cellular fusion and myotube 
formation (Davis et al., 1987). Shortly after the discovery of MyoD three additional bHLH factors were 
discovered, namely Myf5 (Braun et al., 1989), myogenin (Edmondson and Olson, 1989), and MRF4 
(Rhodes and Konieczny, 1989), for their ability to induce the myogenic features of myoblasts in different 
cell types.  Since it was determined that these bHLH factors were expressed throughout and involved 
with controlling development of SkMCs, they were labelled as the myogenic regulatory factors 
(Rudnicki and Jaenisch, 1995). The actions of the MRFs are executed by binding with regulatory regions 
of DNA. Heterodimers are formed with E proteins, which facilitate the identification of E-boxes, a 
pattern located in the promoters of numerous genes specific to SkM (Shklover et al., 2007).  
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Figure 1.0: Schematic representation of somite maturation underlining embryonic myogenesis.  
Somite development and maturation follows a rostral to caudal gradient. The myotome arises from the 
dermomyotome to generate myogenic precursor cells. Myogenic genes and regulatory factors direct 
precursor cells toward a muscle lineage specification and myoblast differentiation. Adapted from 
(Sachidanandan and Dhawan, 2003; Buckingham, 2001) 
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1.0.1 Adult Myogenesis 
 
The ability for SkM to repair and regenerate is a strictly regulated process involving four precisely 
programmed stages, which include deterioration, inflammation, repair-restoration and finally 
remodelling (Carosio et al., 2011). Damage to SkM induces prompt necrosis of SkMCs, which leads to 
the progressive infiltration of SkM by inflammatory cells, eliciting an inflammatory response in the 
damaged area (Tidball, 2005). Following inflammation, a regenerative phase is initiated by the 
activation of quiescent SCs. Under normal physiological conditions, upstream embryonic myogenesis 
generates Pax7 expressing cells within the dermomyotome, which become the SC population of SkM 
stem cells that remain present after birth and are required for future SkM regeneration. The specialised 
quiescent SCs are situated amongst the basal lamina and sarcolemma of SkM fibres and are governed 
by the same genetic hierarchy as embryonic myogenesis. Thus, SkM regeneration can only occur when 
the mitotically quiescent SCs are activated and develop into myoblasts (Siegel et al., 2011). Upon 
activation, the SCs become proliferative myoblasts and promptly re-enter the cell cycle and commence 
proliferation (Sousa-Victor et al., 2015). As the proliferative threshold for myofibrillar protein synthesis 
is reached, a population of SCs undergo asymmetric division for self-renewal and replenishment of the 
SkM stem cell pool. This population of SCs return to the periphery of the muscle fibres and remain in a 
state of quiescence with the intention of responding to future muscle damage upon subsequent 
activation (Relaix and Zammit, 2012). After several rounds of proliferation the committed myoblasts 
exit the cell cycle, they migrate to the site of injury and begin fusing into myocytes and then myotubes. 
As the myotubes mature, they fuse with pre-existing intact myofibres as a scaffolding and replace the 
damaged area to complete the muscular repair and regeneration (Simionescu and Pavlath, 2011). 
Finally, the regenerated myofibres continue to mature, remodelling of the extracellular matrix (ECM) 
occurs, and function is restored (Carosio et al., 2011). There are many parallels between embryonic 
myogenesis and SkM regeneration, which are both regulated by genetic and myogenic transcriptions 
factors. During SkM regeneration, SCs express the myogenic regulator Pax7 in the initial stages of 
activation (Seale et al., 2000). Studies have shown SC activation and proliferation are dependent on 
Pax7. Inhibiting Pax7 expression leads to a diminished capacity for self-renewal, thus a diminished pool 
of quiescent cells for future sequences of repair (von Maltzahn et al., 2013). Research findings have 
demonstrated that activated Pax7 expressing SCs can travel amongst myofibers and can surmount 
obstacles such as the basal lamina and connective tissues to migrate across muscle during regeneration 
(Hughes and Blau, 1990; Jockusch and Voigt, 2003; Watt et al., 1987; Siegel et al., 2009). Investigations 
of Pax7 deficient mice revealed the premature arrest of myoblast proliferation and accelerated 
myoblast differentiation, which ultimately resulted in diminished muscle growth and significant muscle 
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degeneration and a total deficiency of functional SCs (Kuang et al., 2006). This validates the vital 
functions of Pax7 in the initial phase of SkM regeneration and is necessary for normal myogenic 
development. Furthermore, Pax7 initiates the successive activation of the MRFs Myf5, MyoD, 
myogenin, and MRF4 (Jones et al., 2015). Myf5 expression is detected in the early stages of the 
regenerative process after injury, suggesting a primarily proliferative function. Variable amounts of 
myoblast differentiation can be initiated in vitro by MyoD, myogenin, and MRF4, but not Myf5, 
signifying its functions as a MRF involved with the primary proliferation of SCs (Yin et al., 2013). Mice 
devoid of Myf5 display minor impairment of SkM regeneration, manifesting as endomysium fibrosis 
and adipocyte accumulation (Gayraud-Morel et al., 2007). Similar impairments are observed in MyoD 
deficient mice (White et al., 2000). During SkM regeneration, SC proliferation persists until a protein 
synthesis threshold is reached. Subsequently, proliferative MRFs decrease while differentiation MRFs 
increase. Myogenin is recognised as a mandatory MRF for the normal myoblasts-to-myocytes-to-
myotube differentiation. Thus, Myogenin deficient mice exhibit severe deficiencies in muscle 
regeneration (Venuti et al., 1995). Research has revealed that a flawed muscle regeneration is possible 
without myogenin, mice devoid of myogenin can regenerate muscle, but are one-third the size of wild-
type mice (Knapp et al., 2006). Suggesting MRF-independent mechanism can moderately compensate 
during postnatal myogenesis. During normal SkMC regeneration, the final MRF to be expressed is MRF4 
(Charge and Rudnicki, 2004). Modifying the timing of MRF4 expression impairs SkM regeneration. Early 
expression of MRF4 in transgenic mice causes a transient delay in SkM regeneration (Pavlath et al., 
2003). Premature myotube development and delays in SkM regeneration are also observed when 
MRF4 is expressed early. In summary, the complex and essential process of proliferation and 
differentiation via MRF expression during adult myogenesis occurs upon activation of quiescent SCs 
(Figure 1.1), ensuring proper SkM repair and regeneration.  
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Figure 1.1: Adult myogenesis. The activation, proliferation, and differentiation of SCs from a state of 
quiescence to mature muscle fibre is regulated by the precise expression of myogenic transcription and 
regulatory factors. Adapted from (Hernandez-Torres et al., 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
1.1 Skeletal Muscle 
 
1.1.0 Anatomy 
Accounting for ~50% of the mass in healthy adult human males (Yin et al., 2013) and consisting of over 
650 designated muscles, SkM is the largest metabolically active tissue in the human body. Distinct from 
both the other major muscle types (cardiac and smooth); SkM is regulated via the somatic nervous 
system, allowing the individual to command its function. Preparation, regulation, and implementation 
of voluntary locomotion of the body is regulated in the motor cortex region of the brain (Biswal et al., 
1995). Upper motor neurons transmit information from the motor cortex of brain through the spinal 
cord to lower motor neurons. Although the primary function of SkM is to power physical movement, 
metabolism regulation via macronutrient storage and substrate oxidation to replace depleted 
adenosine triphosphate stores (ATP) (Leto and Saltiel, 2012) is also vitally performed by SkM, as well as 
executing crucial tasks in respiration and endocrine functions (Pedersen and Febbraio, 2008). Local and 
systemic environments in the body are also influenced by the growth factors, myokines, and cytokines 
secreted by SkM fibres into the ECM (Pedersen, 2011).  
Development of SkM involves the fusion of myoblasts to form multinucleated fibres called myotubes, 
eventually maturing into myofibres. These singular contractile cells of SkM are innervated by a motor 
neuron (MN). A single MN can innervate hundreds of muscle fibres, but each mature muscle fibre is 
innervated by just one MN. This arrangement of a MN and all of the muscle fibres innervated by that 
neuron is known as a functional motor unit (Sherrington, 1925). Individual myofibres are ensheathed 
by endomysium and arrange in bundles. These bundles of myofibres known as muscle fascicle are 
bound by perimysium. Subsequently, fascicles are wrapped and encapsulated by the fibrous outer 
connective tissue called epimysium, to procedure a whole muscle (Figure 1.2), with numerous motor 
units residing within (Light and Champion, 1984; McComas et al., 1971).  
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Figure 1.2: Gross anatomy of a skeletal muscle belly. A specialized cell membrane termed the 
sarcolemma wraps the individual skeletal muscle fibres. The fibres are bound together with a fine 
coating of connective tissue called the endomysium, which also functions to deliver nerve axons, 
nutrients, and oxygen via blood and lymphatic vessels. Bound muscle fibres are packed together with 
perimysium, this thin fibrous layer of connective tissue separates a muscle belly into fascicles. The 
muscle fascicles are then enveloped by the dense fibrous epimysium, constructing the complete 
skeletal muscle. Image “1007_Muscle_Fibes_(large).jpg” available for free public reuse at OpenStax 
CNX (https://cnx.org/contents/FPtK1zmh@12.8:bfiqsxdB@6/Skeletal-Muscle), licenced under 
Attribution 4.0 International (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/).  
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1.1.1 Skeletal Muscle Fibres 
 
Mature myofibres are comprised of sequences of myofibrils, which include the thick filaments protein 
myosin and thin filaments protein actin (Rayment et al., 1993), supported by the protein titin. The 
repeated arrangement of these proteins in the myofibrils are known as sarcomeres, which are the 
single contractile units within myofibres (Figure 1.3), manifesting as striations on the myofibres. Actin 
molecules at the ends of a sarcomere are anchored to a position called the Z-discs, which are the 
defined boarders between each sarcomere. Actin bound to a Z-disc at one end of the sarcomere 
projects towards the M-line at the centre. Myosin filaments, which interact with the fixed actin 
filaments, are located centred over the M-line, with the myosin filament ends delicately attached to 
the Z-discs by titin. When prompted by nervous input, a cross-bridge is formed and the actin filaments 
are drawn and slide along the myosin filaments, shortening the sarcomere to induce contraction of the 
myofibre (Denoth et al., 2002).  
 
 
 
 
 
 
 
 
10 
 
 
 
Figure 1.3: Structures of a myofibril. A muscle fibre is full of myofibrils, which are composed of 
individual sarcomeres joined in series.  A single sarcomere is located between a set of Z-discs, making 
a distinct contractile unit, composed of a thin (actin) filament and thick (myosin) filament. The I-band 
of the sarcomere is the region where the myosin does not overlap the actin, giving a lightened 
appearance on the muscle fibre. The A-band appears visually darker on the muscle fibre as it contains 
the anisotropic myosin protein. This alternate banding gives muscle fibres the appearance of striations. 
The H-zone is located within the A-band where actin is absent. The M-line appears centrally in the 
sarcomere within the H-zone to provide structural stability. Image “1022_Muscle_Fibers_(small).jpg” 
available for free public reuse at OpenStax CNX 
(https://cnx.org/contents/FPtK1zmh@12.8:bfiqsxdB@6/Skeletal-Muscle), licenced under Attribution 
4.0 International (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/). 
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1.1.2 Skeletal Muscle Fibre Types 
 
Muscle fibres are commonly categorised as a type 1 (slow twitch) or type 2 (fast twitch) phenotype, 
according to their function, which is determined by the specific myosin heavy chain (a constituent of 
the myosin filament) isoforms that they express (Pette and Staron, 2000). Type 2 muscle fibres are 
further sub-classified as types 2a, 2x, and 2b. Type 1 fibres operate via aerobic metabolism attributed 
to a large concentration of mitochondria and myoglobin within the cells. This cellular composition 
means type 1 fibres produce low force contractions in a slow sustained manner with a high resistance 
to fatigue. Conversely, type 2x and 2b fibres generate fast, short, and high force contractions, which 
are quick to fatigue, due to the mainly glycolytic metabolism of these fibre types. In type 2a fibres, a 
combination of aerobic and anaerobic metabolism is observed. Therefore, this particular fibre type is 
able to generate force greater then type 1 fibres and fatigue more slowly than type 2x/b fibres 
(Schiaffino and Reggiani, 2011). Interestingly, it has been determined that only small mammals retain 
the type 2b fibres, which contract and fatigue at the fastest rate when compared to the other type 2 
fibres. Thus, the hierarchy of type 2 fibre contraction speed begins with 2a, followed by 2x, and 2b 
being the fastest. However, this also means the demand for ATP is significantly higher in type 2b fibres, 
which in turn increases tension cost (Rundell et al., 2004). It is thought that humans as well as other 
large mammals have evolved to lack the type 2b fibre to moderate energy expenditure. Thus, human 
SkM fibres are a combination of type 1, 2a, and 2x. Although these general classifications of fibre types 
provide valuable fundamental information, fibre types have the ability to adapt to environmental or in 
vivo stimuli and can switch between fibre types or exhibit hybridized characteristic of several fibre types 
(Stephenson, 2001). In general, a SkM is composed of a combination of fibre types, which have varying 
degrees of particular characteristics (Table 1.0) and are determined by the function of the particular 
muscle. For example, postural muscles of the neck and spine contain higher concentrations of type 1 
fibres as they mostly produce low force contractions and require a greater endurance for sustained 
activity. The high capacity for endurance of type 1 fibres means this fibre type is also observed in higher 
overall concentration in the muscles of athletes performing long distance events such as marathons. 
Conversely, the composition of fibres found in the muscles of the upper arms, shoulders, and chest are 
predominantly that of the type 2a/x fibres. This is apparent in athletes performing tasks that involve 
quick surges of explosive activity (Rockl et al., 2007).    
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Table 1.0: Characteristics of type 1, 2a, and 2x/b skeletal muscle fibres. 
 
Feature Type 1 Type 2a Type 2x/b 
Force production + ++ +++ 
Contraction speed + +++ +++ 
Fatigue resistance +++ ++ + 
Glycolytic capacity + +++ +++ 
Oxidative capacity +++ ++ + 
Capillary density +++ ++ + 
Mitochondrial density +++ ++ + 
Endurance capacity +++ ++ + 
Note: + = low; ++ = moderate; +++ = high 
 
 
1.1.3 Muscle Contraction 
 
Excitation–contraction coupling is the well-established molecular interaction and exchange involved 
with SkM contraction. Nervous input causes depolarisation of the muscle fibre membrane called the 
sarcolemma (Figure 1.4), the cascading action potential (AP) travels down the invaginated transverse 
tubule (T-tubule) of the sarcolemma into the cell. As the AP travels down the T-tubule into the 
sarcoplasm of the muscle fibre, it stimulates the opening of voltage-gated L-type calcium channels, 
subsequently depolarising the interior of the muscle fibre. The inner depolarisation of the muscle cell 
results in the opening of calcium channels in the terminal cisternae of the sarcoplasmic reticulum (SR).  
Since calcium ions (Ca2+) are higher in concentration in the SR than the cell sarcoplasm, they rapidly 
diffuse into the sarcoplasm.  The Ca2+ then bind with the protein troponin, which is located on the actin 
filaments. The Ca2+ bound troponin causes the troponin-tropomyosin-complex to undergo a 
conformational change, which exposes active binding sites for the myosin filament heads along the 
length of the actin filament, to allow for cross-bridge formation and cycling (Figure 1.5).    
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Figure 1.4: Arrangement and assembly of skeletal muscle triads.  A triad is formed when a transverse 
tubule originating from the sarcolemma is sandwiched between two terminal cisternae of the 
sarcoplasmic reticulum.  This tight configuration allows for efficient nerve signal transmission, 
depolarisation, and opening of gated ion channels. Image “1023_T-tubule.jpg” available for free public 
reuse at OpenStax CNX (https://cnx.org/contents/FPtK1zmh@12.8:bfiqsxdB@6/Skeletal-Muscle), 
licenced under Attribution 4.0 International (CC BY 4.0) 
(https://creativecommons.org/licenses/by/4.0/). 
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Figure 1.5: Cross-bridge formation. Depolarisation triggers the influx of calcium ions into the cytosol 
of the muscle fibre. The calcium binds with troponin and shifts the position of tropomyosin to expose 
binding site for myosin to form the cross-bridge needed for muscle contraction. Image 
“1010a_Contraction_new.jpg” available for free public reuse at OpenStax CNX 
(https://cnx.org/contents/FPtK1zmh@12.8:EtWWcJM-@10/Muscle-Fiber-Contraction-and-
Relaxation), licenced under Attribution 4.0 International (CC BY 4.0) 
(https://creativecommons.org/licenses/by/4.0/). 
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A cross-bridge cycle can only occur after the myosin head has been activated. An ATP molecule binding 
with the myosin head, which is hydrolysed to adenosine diphosphate (ADP) and inorganic phosphate 
(IP), triggers activation through the energy liberating action of ATP hydrolysis, which fixes the myosin 
head into a ‘cocked’ configuration. A cross-bridge is formed between the activated myosin head and 
actin; the IP is then freed increasing the binding capacity of the myosin head and actin filament. The 
ADP is then liberated causing the myosin head to pivot. The actin filament then slides towards the 
centre of the sarcomere, this action is called the ‘power stroke’. Another ATP then binds with the 
myosin head, the cross-bridge is weakened and the myosin head detaches from the binding site, before 
being activated again for another cross-bridge formation (Figure 1.6). Cross-bridge cycling will continue 
to re-engage while the binding sites on the actin filament remain available. Repeated cycling pulls the 
actin filaments together and the sarcomere shortens, inducing muscle contraction. Termination of 
Cross-bridge cycling occurs when Ca2+ are actively returned to the SR. The troponin-tropomyosin-
complex returns to its primary formation, blocking the myosin binding sites on the actin filaments, 
initiating muscle relaxation.  (ter Keurs et al., 2003).   
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Figure 1.6: Molecular mechanisms of muscle contraction. a) Calcium ions bind with troponin to prompt 
a change in the structural position of tropomyosin, revealing the actin binding sites. b) Cross-bridge 
formation occurs between the bindings sites on the myosin heads and actin filaments. c) The power 
stroke is executed through the release of inorganic phosphate (IP) then adenosine diphosphate (ADP). 
d) The attachment of adenosine triphosphate (ATP) uncouples the binding of myosin and actin. e) The 
conversion of ATP to ADP and IP configures the myosin head for cross-bridge formation and cycling. 
Image “1008_Skeletal_Muscle_Contraction.jpg” available for free public reuse at OpenStax CNX 
(https://cnx.org/contents/FPtK1zmh@12.8:EtWWcJM-@10/Muscle-Fiber-Contraction-and-
Relaxation), licenced under Attribution 4.0 International (CC BY 4.0) 
(https://creativecommons.org/licenses/by/4.0/). 
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1.2 Motor Neurons  
 
Motor neurons (MNs) are neuronal cells that originate in the central nervous system (CNS) and project 
axons into the periphery to form synapses with their target tissues. Vital for life in all vertebrates, 
effective and accurate MN activity and signal transmission with target tissues in the periphery, such as 
SkM, is required for fundamental behaviours such as breathing and locomotion. Although typically 
described as a distinct cell type, MNs have vast diversity with varied expression of genes, molecular 
profiles, and target muscles. This diverse nature of MNs allows for separate innervation of the 
numerous individual SkM groups in the vertebrate body (Kanning et al., 2010). For example, in humans 
there are over 600 SkM throughout the body with most muscles making up one part of a bilateral pair 
(Frontera and Ochala, 2015). Thus, strict regulation of CNS signal transmission to MN and MN outputs 
to the target SkM is vital for the refined, organised motor control observed in sophisticated motor 
behaviours. Some research has suggested that MN subtype identity regulates the MNs innervation 
sequence and connection with the target SkM (Milner and Landmesser, 1999; Landmesser, 2001). 
Therefore, MN subtype diversity needs to be explored to appreciate the function of MNs and their 
motor units.  
 
1.2.0 Motor Neuron Subtype Diversity 
 
Divided into three distinct classifications, MNs can be labelled as branchial, visceral and somatic (Stifani, 
2014). The MNs that reside in the brainstem and innervate muscles of the head and neck through the 
cranial nerves are known as the branchial MNs (Chandrasekhar, 2004). Visceral MNs are an element of 
the autonomic nervous system, which is comprised of the sympathetic division and parasympathetic 
division. Found in the preganglionic column (PGC) of the spinal cord, the sympathetic MNs innervate 
the adrenal medulla and sympathetic chain ganglia. Whereas parasympathetic MNs are found in the 
sacral division of the spinal cord, as well as the brainstem, innervating peripheral ganglia located close 
to vital organs of the body (Purves et al., 2001). Located in the hindbrain nuclei and spinal cord ventral 
horn, the axons of the somatic MNs extend from the CNS alongside the spinal nerves and into the 
periphery. Here the somatic MNs make contact with SkM and form the highly specialised synapses 
called neuromuscular junctions (NMJs) (Wu et al., 2010). By identifying their location within the spinal 
cord, the somatic MNs are separated into groups called motor columns, such as the PGC mentioned 
above, with each motor column innervating a specific collection of muscles. One of the five motor 
columns groups, called the medial motor column (MMC), tracks the entirety of the spinal cord and 
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contains the MNs that innervate the dorsal back muscles and axial thoracic muscles (Fetcho, 1987; 
Agalliu et al., 2009). Located exclusively at the limb regions of the spinal cord, the MNs of the lateral 
motor columns (LMCs) innervate the forelimbs via the LMC MNs in the brachial segment of the spinal 
cord, while innervation of the hindlimbs occurs via the LMC MNs of the lumbar segment (Landmesser, 
1978). Innervating the muscles of the ventral trunk, such as the anterior abdominal wall and intercostal 
muscles, the hypaxial motor columns (HMCs) are located at cervical and thoracic segments of the spinal 
cord (Gutman et al., 1993). Positioned at the thoracic segment of the spinal cord, MNs from the forth 
group of motor columns called the PGC innervates the peripheral nervous system sympathetic chain 
ganglia (Prasad and Hollyday, 1991). Finally, the fifth group is called the phrenic motor column (PMC) 
which is a MN group that provides the sole source of diaphragm innervation, thus responsible for 
respiration in mammals (Philippidou et al., 2012) (Figure 1.7). The most comprehensively researched 
motor column is the LMC, which is additionally partitioned into a medial subdivision (LMCm), 
responsible for ventral innervation of the limb muscles (e.g. flexors) and a lateral subdivision (LMCl), in 
control of the dorsal innervation of limb muscles (e.g. extensor) (Tosney and Landmesser, 1985; Kania 
and Jessell, 2003).   
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Figure 1.7: Spinal motor column organisation. The motor neuron (MN) columnar pools dictate the 
location of MN cell bodies along the spinal cord in relation to the body and regulates MNs to their 
target muscles. The MNs from the phrenic motor column (PMC) innervate the diaphragm. The 
preganglionic column (PGC) MNs innervate the sympathetic ganglia. The MNs originating from the 
medial motor column (MMC) innervate the dorsal axial muscles and the hypaxial motor columns (HMC) 
MNs innervate the muscles of the body wall. The medial lateral motor columns (LMCm) and its lateral 
counterpart the LMCl innervate the ventral and dorsal limb respectively. Adapted from (Davis-
Dusenbery et al., 2014) 
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Depending on morphology, function, and the intended SkM target, MNs from a columnar pool can be 
further separated into three distinct classifications. Specifically, alpha motor neurons (αMNs), beta 
motor neurons (βMNs), and gamma motor neurons (γMNs) (Kanning et al., 2010). The αMNs are the 
biggest most abundant subtype of MNs and are responsible for innervating extrafusal SkM fibres, which 
are the muscle fibres that produce physical movements upon contraction. The αMNs send the 
communication through their axons to the intended target where they synapse with muscles directly 
to induce muscle contraction (Dalla Torre di Sanguinetto et al., 2008). The smaller γMNs are responsible 
for innervating the proprioceptive intrafusal SkM spindle and are involved with modulation of sensory 
neuron sensitivity to stretch forces on the SkM spindle (Jessell, 2000; Proske and Gandevia, 2009). 
Interestingly, the functions of βMNs requires further exploration before their functional role is 
accurately elucidated, despite βMNs axon collaterals innervating extrafusal SkM fibres and intrafusal 
SkM fibres (Manuel and Zytnicki, 2011; Kanning et al., 2010). Finally, further MN subtype diversification 
of αMNs is implemented based on their functional properties. These properties are defined by the 
metabolic and molecular attributes of the motor unit formed with the type of SkM fibre being 
innervated. The αMN subtype innervating type 1 SkM fibres are known as slow-twitch fatigue resistant 
(αS), type 2a SkM fibres are innervated by fast-twitch fatigue-resistant (αFR) MNs, and innervating the 
2x/b fibres are the fast-twitch fatigable (αFF) MNs (Figure 1.8). Containing an assortment of the MN 
subtypes, the motor pool regulates the ultimate contractile function of SkM depending on the ratio of 
MN subtypes within the pool.  However, hormones, physical requirements, and neuronal activity 
permits conversion of SkM fibre types, as observed in vivo (Staron, 1997; Pette and Staron, 2000; Friese 
et al., 2009). 
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Figure 1.8: Functional classification of alpha motor neuron subtypes. Fast-twitch fatigable (αFF), fast-
twitch fatigue-resistant (αFR), and slow-twitch fatigue resistant (αS) motor neurons (MNs) innervate 
their corresponding type 2x/b, type 2a, and type 1 extrafusal muscle fibres. The smaller gamma motor 
neurons (γMNs) innervate the intrafusal muscle fibres. Adapted from (Davis-Dusenbery et al., 2014) 
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1.3 The Neuromuscular Junction  
 
In order to appreciate the vital function of neuromuscular junctions (NMJs) and the cellular 
specialisation they exhibit, the complex regulation of NMJ formation, development, and maturation 
need to be understood in relation to fundamental molecular and cellular mechanisms. 
 
1.3.0 Agrin 
 
In the initial stages of NMJ formation, clusters of acetylcholine receptors (AChRs) emerge centrally on 
myofibers in advance of nervous input in a process known as intrinsic pre-patterning of muscle (Lin et 
al., 2001; Yang et al., 2001). While this preliminary pre-patterning occurs without a nervous component, 
the differentiation of postsynaptic structures can only occur after synapse formation and presynaptic 
input. One of the fundamental components that regulates postsynaptic differentiation is agrin. 
Produced and secreted by motor neuron terminals (MNTs), agrin is a mandatory heparan sulphate 
proteoglycan needed for NMJ formation (Bezakova and Ruegg, 2003). The obligate nature of agrin has 
been shown in agrin-deficient mice, which present with failed NMJ formation and death (Gautam et 
al., 1996). Agrin deficient mice also fail to undergo presynaptic differentiation and have persistent MN 
growth. It is suggested that a lack of regressive termination signalling from postsynaptic structures and 
the lack of intrinsic agrin discontinuation signals cause the failure of presynaptic differentiation and 
excessive axon sprouting (Campagna et al., 1995; Campagna et al., 1997). However, when agrin 
deficient mice express a miniaturized form of agrin from their developing SkMCs, which have muscle-
specific tyrosine kinase activating domains essential for AChR clustering, a restoration of NMJ 
formation is witnessed (Lin et al., 2008).  Equally, the forced over expression of agrin in non-synaptic 
regions of SkMCs leads to the formation of postsynaptic structures usually only observed at the NMJ, 
such as developed junctional folds (Bezakova et al., 2001). There is also genetic expression of AChR 
genes usually only found at the synapse (Jones et al., 1997). These studies present evidence that the 
secretion of agrin from MNs to agrin-receptive SkMCs instigates the preliminary formation of NMJs. 
Formation and maturation of the NMJ is also facilitated by agrin through the binding of the dystrophin-
glycoprotein complex, which is dystrophin-associated transmembrane glycoproteins, namely 
dystroglycan (Bowe et al., 1994; Gee et al., 1994). Some research also implies that the downregulation 
of agrin, facilitated by proteolytic cleavage, regulates maturation of the NMJ by manipulating AChR 
clusters and the topology of junctional fold (Bolliger et al., 2010).  
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1.3.1 Muscle-Specific Tyrosine Kinase 
 
Agrin regulates the formation and development of the NMJ via a single transmembrane receptor 
tyrosine kinase, known as the muscle-specific tyrosine kinase (MuSK) receptors at the motor end plate 
(MEP) (Wu et al., 2010). MuSK signalling activation occurs after binding to the low-density lipoprotein 
receptor-related protein 4 (LRP4), which is a MuSK co-receptor (Zhang et al., 2008; Kim et al., 2008), 
prompting differentiation of postsynaptic structures after binding to neural agrin. Structurally, the 
activation of MuSK occurs when two heterodimers of agrin and LRP4 form a tetrameric complex. 
Communication with the cytoplasmic adaptor docking protein 7 aka downstream of tyrosine kinase 7.  
(Dok7) and the 43 kDa receptor-associated protein of the synapse (rapsyn) is also essential for MuSK 
activation and formation of the NMJ (Okada et al., 2006). As already mentioned, during preliminary 
NMJ formation intrinsic pre-patterning of muscle occurs on myofibers through the emergence of AChR 
clusters, along with supplementary postsynaptic proteins. Although pre-patterning of muscle occurs in 
advance of nervous input, the establishment of the MuSK–LRP4–Dok7–rapsyn complex (Figure 1.9) is 
required. During myogenesis, MuSK induces clustering of AChRs on aneural myotubes and facilities the 
assembly of postsynaptic structures needed to secure AChRs in mature developed MEPs (DeChiara et 
al., 1996; Lin et al., 2001). Furthermore, transcriptional specialisation of myonuclei at the synapse 
occurs after MuSK-mediated recruitment of the vital myonuclei. A lesser retrograde signalling from 
MuSK to MNs also occurs to induce presynaptic differentiation 
Expression of MuSK is first observed at the premature myotome and is expressed throughout SkM 
development and thereafter. Following innervation of SkMCs, a down regulation of MuSK expression 
occurs in the myonuclei adjacent to the NMJ. However, recruited myonuclei at the synapse have 
sustained expression of elevated MuSK. Upon denervation, the NMJ-adjacent myonuclei begin to 
upregulate MuSK expression once again (Bowen et al., 1998). Accordingly, expression of MuSK mRNA 
occurs during myocyte to myotube fusion following the same expression pattern as AChR subunit genes 
(Kim and Burden, 2008). Research with MuSK knockout mice has provided valuable insight into the 
functions of MuSK during NMJ formation. Mice devoid of MuSK exhibit the same failed NMJ formation 
and death after birth due to respiratory failure as observed in the agrin-deficient models (DeChiara et 
al., 1996). Noteworthy, mice lacking LRP4, Dok7 or rapsyn suffer the same fate (Okada et al., 2006; 
Weatherbee et al., 2006; Gautam et al., 1995). MuSK devoid mice also have persistent MN growth 
engulfing the myotube as witnessed in agrin deficient mice (Lin et al., 2001). Additionally, MuSK-
deficient in vitro cultured myotubes lack AChR cluster prepatterning and are unresponsive to the 
application of exogenous agrin (Glass et al., 1996). Interestingly, marginally defective regulation of 
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MuSK signalling during development may have minor effects on the primary formation of the NMJ. 
However, subsequent development and maturation of the NMJ can be disturbed by MuSK signalling 
dysfunction, only manifesting after birth or develop at delayed postnatal stages as congenital 
myasthenic syndromes (CMS) (Engel et al., 2010). Research conducted using loxP/Cre recombination 
to inactivate MuSK expression in mice during postnatal development results in the advance of 
symptoms consistent with myasthenic syndromes, leading to death from severe muscle weakness. A 
diffusion of AChR clusters, errors in postsynaptic configuration, and withdrawal of innervating MNs 
were also observed in conditionally inactivated MuSK mice (Hesser et al., 2006). When examining 
humans with CMS, distinct abnormalities of the postsynaptic apparatus are observed. The junctional 
folds lack the characteristics of MEP maturation and a significant decline in clustering of AChRs is 
displayed. These dysfunctions are a consequence of MuSK mutations that restrict MuSK expression and 
hinder communication with Dok7 (Maselli et al., 2010). Similar observations are made in CMS mouse 
models with MuSK mutations. Postnatal development of the CMS mouse reveals underdeveloped 
junctional folds, a decreased clustering of AChRs with obvious fragmentation, improper plaque-to-
pretzel formation of AChRs, and faulty MN transmission (Chevessier et al., 2008). Along with being 
compulsory for the launch of postsynaptic NMJ differentiation, the initiation of postsynaptic assembly 
can be activated by MuSK alone. This has been confirmed via MuSK dimerization and subsequent 
overexpression of MuSK through self-activation (Punga et al., 2011; Sander et al., 2001), crosslinking 
via antibody mediation (Hopf and Hoch, 1998) or through transmembrane domain mutant dimerization 
(Jones et al., 1999). Applying any of the mentioned MuSK activation techniques to aneurally-cultured 
myotubes induces AChR cluster formation.  The formation of postsynaptic features are also detected 
in innervated SkMCs on non-synaptic locations of the myofibres. MuSK activation also includes the 
aggregation of synaptic myonuclei, important for upregulation of AChR and MuSK gene expression 
(Jones et al., 1999; Moore et al., 2001). Minor presynaptic differentiation of MNs in Agrin deficient mice 
is possible when MuSK is overexpressed in SkM via self-activation. However, the mice have a short 
lifespan and only a few weeks of stunted growth (Kim and Burden, 2008). MuSK expression can act on 
MNs via indirect methods as well, to assist their presynaptic differentiation. MuSK-induced secreted 
factors from SkM such as the laminin isoform laminin-β2 has been shown to regulate the formation of 
MNT active zones during MNT differentiation (Jones et al., 1999; Nixon et al., 2008). Possibly regulated 
in a similar way by MuSK, collagen IV and fibroblast growth factor (FGF) proteins  are increased in the 
synaptic basal lamina and can influence MNT differentiation (Fox et al., 2007).   
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Figure 1.9: The Agrin-MuSK–LRP4–Dok7–rapsyn-AChR complex. Agrin and acetylcholine (ACh) are 
released by the motor neuron terminal. Muscle-specific tyrosine kinase (MuSK) phosphorylation occurs 
following the binding of Agrin and low-density lipoprotein receptor-related protein 4 (LRP4), which 
stimulates the organisation of Musk-LRP4. The recruitment of docking protein 7 (Dok7) stabilizes MuSK 
through dimerization. Subsequently, activated MuSK sites anchor AChRs with 43 kDa receptor-
associated protein of the synapse (rapsyn) after the tyrosine phosphorylation of Dok7. Adapted from 
(Amato, 2018).  
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1.3.2 43 kDa Receptor-Associated Protein of the Synapse 
 
Expressed in SkMCs throughout the early development of NMJs and in mature SkM, rapsyn is a 
cytoplasmic support protein underlying the postsynaptic cytoskeleton, with expression principally 
limited to the synapse. A high-density protein construct is formed by the rigid binding of rapsyn with 
AChRs and dystroglycan (Unwin, 2013; Bartoli et al., 2001). This complex is believed to maintain 
cytoskeletal-anchoring of AChRs. However, the AChR-rapsyn clustering initiated by MuSK activation is 
poorly understood from the perspective of molecular signalling pathways. Both in vivo and in vitro 
studies have confirmed rapsyn as an essential protein in the formation of AChR clusters. Thus, evident 
failure of postsynaptic specialization of the NMJ in rapsyn deficient mice is witnessed (Gautam et al., 
1995). Unlike the stark phenotypes reflected in MuSK, Lrp4, and Dok7-null mice, rapsyn deficient mice 
have some respiratory function and laboured breathing allows them to live a few hours. Inspection of 
the failed MEP exposed a lack of cytoskeletal specializations and unsuitable AChR clusterisation. 
Nevertheless, aggregations of synaptic basal lamina constituents such as laminin-β2 and 
acetylcholinesterase are still supplied in abundance. Surprisingly, an accumulation of MuSK below the 
MNT and elevated expression of AChR genes by the synaptic myonuclei are exhibited (Apel et al., 1995; 
Gautam et al., 1995). These findings established that rapsyn is not involved with synaptic gene 
transcription but is vital for affixing of AChRs at the MEP apparatus. It is also implied that miniature 
muscle contraction are possible at premature NMJs before proper anchoring of AChRs by rapsyn is 
complete. 
 
1.3.3 Acetylcholine Receptors 
 
In addition to the vital functions AChRs perform during signal transmission, they are also involved with 
MEP formation during NMJ development. Rapsyn has been shown to form clusters in non-myogenic 
cells when forced overexpression is induced. However, SkMCs require AChRs to initiate clusterisation. 
For instance, a loss of associated rapsyn clusters occurs when AChRs are removed from in vitro myotube 
cell membranes using lasers or antibodies to induce the AChR depletion (Bruneau et al., 2008; Marangi 
et al., 2001). Research has also revealed that AChRs are joined with and escorted by rapsyn early in the 
exocytic pathway (Marchand et al., 2002; Moransard et al., 2003). Further findings support the notion 
that AChRs are fundamental for formation of the MEP, since deletion of the AChR γ-subunit gene, which 
is needed for fabrication of physiological AChRs during embryogenesis, results in unbridled MN growth 
(Liu et al., 2008). Noteworthy, mice in these experiments still conveyed clustering of MuSK at the 
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diaphragm, whereas rapsyn clustering was imperceptible. Ultimately, AChRs are perceived to 
participate in MEP differentiation, as well as assisting in distribution of rapsyn to the MEP apparatus.  
 
1.3.4 Neuromuscular Junction Function 
 
Contractions of SkM are governed by the CNS. MNs transmit communications from the CNS via nerve 
impulses to SkM fibres to induce contractile activity in muscle. The fusion of a MNT with the MEP of a 
SkM fibre forms a highly specialised chemical synapse where signal transmission takes place (Figure 
1.10). 
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Figure 1.10: Neuromuscular junction signal transmission. 1) The action potential (AP) propagates 
down the motor neuron (MN) to the axon terminal. 2) Calcium channels are opened once the AP 
reaches the axon terminal, inducing influx of calcium ions (Ca2+) into the presynaptic terminal. 3) 
Increased intracellular calcium concentration at the axon terminal prompts synaptic vesicle fusion with 
the membrane of the axon terminal. 4) Upon fusion, the vesicle releases acetylcholine (ACh) into the 
synaptic cleft. 5) ACh crosses the synaptic cleft to bind with acetylcholine receptors (AChRs), opening 
voltage-gated sodium ion (Na+) channels on the motor end plate (MEP). 6) An AP generating muscle 
contraction is produced. 7) Termination of synaptic transmission occurs upon ACh degradation via 
acetylcholinesterase and presynaptic reuptake. Adapted from (Song, 2014) 
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This synapse is one of the first to be formed during embryonic development and is called the 
neuromuscular junction (NMJ). Although initial NMJ formation occurs early, full maturation requires 
several weeks of structural and molecular configuration (Sanes and Lichtman, 2001). The NMJ 
maturation process is significantly longer than observed in the formation of CNS synapses, which take 
just hours to mature in comparison and have a rapid turnover rate. Following NMJ maturation the 
synapse is maintained throughout life for appropriate signal transmission (Sanes and Lichtman, 1999). 
Consequently, erroneous formation, development, or impaired maintenance through aging could 
instigate muscle weakness, paralysis, or manifest as various neuromuscular (NM) or neurodegenerative 
(ND) diseases. Disorders that directly target the NMJs function are characteristically genetic (e.g. 
congenital myasthenia), autoimmune (e.g.  Myasthenia gravis, Lambert-Eaton myasthenic syndrome), 
or neurotoxic (e.g. botulism). Additionally, particular disorders of the NM system target MNs directly, 
causing presynaptic signal transmission deficiency, such as amyotrophic lateral sclerosis (ALS) or spinal 
muscular atrophy (SMA). There are also nine major forms of muscular dystrophy (i.e. myotonic, 
Duchenne, Becker, limb-girdle, facioscapulohumeral, congenital, oculopharyngeal, distal, Emery-
Dreifuss) that attack the postsynaptic SkM MEP. The peripheral nerve is also venerable to MN disorders 
that impair myelination, for instance, Charcot-Marie-Tooth disease.  
The NMJ shares many fundamental similarities with chemical synapses located throughout the central 
and peripheral nervous system. The presynaptic MNT of the NMJ is occupied by vesicles containing the 
neurotransmitter acetylcholine (ACh). The synaptic cleft, which has a width of ~50-80 nm, separates 
the presynaptic terminal from the postsynaptic SkMC sarcolemma. The MEP has deep indentations 
called junctional folds that are saturated with AChRs; the binding of ACh with AChRs opens voltage-
gated sodium channels. The diffusion of sodium ions (Na+) into the sarcoplasm depolarises the MEP at 
the junctional folds, triggering an AP on the flanking sarcolemma, which spreads outward from the NMJ 
(Flucher and Daniels, 1989).   
The basal lamina and ECM coating SkM fibres has a unique muscle specific composition, comprised of 
molecules derived from the SkMCs. Correspondingly, the ECM components at the synaptic cleft have 
their own unique molecular constituents, as secreted molecules at the cleft are derived from the SkMCs 
and MNs (Patton et al., 1997). Along with SkMCs and MNs, the anatomy of a NMJ in vivo consists of 
two other essential cell types, the terminal Schwann cells and kranocytes. Schwann cells at the NMJ 
are specialised non-myelinating neuroglia that cover the MNT, generating their own distinctive basal 
lamina, which interacts with the ECM of SkMCs in close proximity to the NMJ. Finally, the insufficiently 
understood kranocytes cover the Schwann cells, encasing the entire NMJ (Figure 1.11). Both the 
terminal Schwann cells and kranocytes help to maintain NMJ stability and regenerative response to 
injury (Son et al., 1996; Court et al., 2008). For successful transmission of nervous input at the NMJ, an 
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AP induces Ca2+ influx in the MNT. The incoming Ca2+ stimulates synaptic vesicles to fuse with the 
membrane of the MNT at specific locations known as the ‘active zones’. The ACh released into the 
synaptic cleft by the membrane-bound vesicles quickly diffuses across and binds with AChRs on the 
SkMC. As mentioned, AChRs open voltage-gated sodium channels, but are also permeable to potassium 
ions (K+), as well as Ca2+ to a degree. The fusion and release of ACh from a single presynaptic vesicle, 
called quantal release, produces a depolarising current in the SkMC of ~3-4 nA. This small depolarizing 
quantal release of ACh is known as a miniature endplate current, which is the minimum stimulation 
that can be sent between neurons. The fusion and release of ACh from a group of membrane-bound 
vesicles simultaneously produces what is known as the endplate potential (EPP). The EPP is generated 
when a presynaptic AP causes vesicle release to generate a current that is hundreds of nanoamperes 
and depolarizes SkMCs by ~30–40 mV. The EPP produced is considerably larger than needed to 
generate an AP in SkMCs. This greater than that required EPP is called the ‘safety factor’ and allows NM 
transmission to remain operative through varying physiological conditions and stressors (Wood and 
Slater, 2001).  
The magnitude of the safety factor is determined by NMJ physiology and morphology. Firstly, the 
quantity of active zones at the MNT and the density of voltage-gated calcium channels, determined by 
the size of the MNT. The density of synaptic vesicle fusion upon stimulation of an AP and the amount 
of ACh released also influence safety factor. The concentration of AChRs found on the postsynaptic 
SkMC also controls the quantal current amplitude, though in a non-sequential manner, as the 
concentration of AChRs is usually greater than required for effective commandeering of ACh from the 
synaptic cleft. Additionally, voltage-gated sodium channels and AChRs on the junctional folds of MEPs 
orient in a specific manner, with AChRs located at the peak of the fold and sodium channels in the 
trenches (Flucher and Daniels, 1989).  This orientation ensures effective transmission and reliable 
initiation of the AP in the sarcolemma (Slater, 2008). 
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Figure 1.11: Cells comprising the neuromuscular Junction. The anatomy of the in vivo NMJs is 
comprised of the four main cell types. Motor neurons, muscle fibres, terminal Schwann cells and 
kranocytes.  Adapted from (Court et al., 2008)  
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1.4 Aims and Objectives 
 
In this introduction, many studies were used to detail the in vivo formation and development of NMJs, 
as well as SkM and the contribution of MNs toward synapse formation.  By examining the current 
literature, it is clear that the existing methods to study how degenerated NMJs contribute to NM 
diseases are limited. Accordingly, most in vivo NMJ animal models do not properly reflect disease in 
humans. Thus, in vitro models of NMJs have the potential to elucidate NM disease pathogenesis and 
provide a platform for testing novel therapies. Previously established in vitro NMJ models suffer from 
a variety of limitations, due to the complex nature of the systems, resulting in inadequate experimental 
reproducibility. The limitations of the existing in vitro NMJ models will be explored in detail in the 
forthcoming chapters.   
 
Thus, the primary aim of this project is to establish viable in vitro nerve-muscle co-cultures that 
generate functional NMJs, providing a practical system for the examination of NMJ formation, 
development, maturation, and functionality.   
 
The main objectives are: 
 
1. Develop and optimise cell culture conditions to compare young (25 years old) and old (83 
years old) immortalised human SkMC lines. 
 
2. Generate and optimise methods for a co-culture of human SkMCs innervated by nerve cells 
obtained from wild-type rat embryos at embryonic development day (ED) 13-14. 
 
3. Use immunofluorescence and confocal microscopy to confirm SkMC innervation and NMJ 
formation via staining of pre- and post-synaptic proteins.  
 
4. Use the application of known agonist and antagonists treatments to determine NMJ 
functionality via regulation of innervated SkMC contractions. 
 
5. Use microarray analysis to identify the concentrations of endogenously generated growth 
and neurotrophic factors during NMJ formation and development. 
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Chapter 2: Materials and Methods 
 
2.0 Materials  
 
2.0.0 Cell Lines 
 
The two immortalised human skeletal muscle cell (SkMC) lines used for this project were generated at 
the Institute of Myology (Paris, France) and provided to our research group. Both young and old SkMC 
lines were established using primary human myoblasts obtained anonymously from Myobank, a tissue 
bank affiliate of Eurobiobank, authorised by the French Ministry of Research (authorisation # AC-2013-
1868). The primary myoblasts originated from biopsies of the semitendinosus muscle of a young 25-
year-old male and an old 83-year-old man, both free of genetic defects and disease. Myoblast 
immortalisation was achieved through cyclin-dependent and telomerase-expressing kinase 4-
expressing vector transduction (Mamchaoui et al., 2011). This project was the first use of these cells by 
our research group, meaning these cell lines were previously unestablished in our laboratory. 
Accordingly, training of cell culture techniques for the two cell lines used in this project was completed 
at the Institute of Myology.  
 
2.0.1 Animals 
 
Ethical approval for the animal work was obtained from the animal facility under a general S1 Home 
Office licence at the University of Manchester. Animal welfare was in accordance with the guidelines 
detailed in the Animals Scientific Procedures Act 1986, which regulates the use of living vertebrates 
and cephalopods in scientific procedures within the UK. Time-mated female Sprague Dawley rats 
obtained from Charles River Laboratories (Oxford, UK) were sacrificed with CO2 when embryos were 
approximately embryonic development day (ED) 13.5.  
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2.0.2 Laboratory Equipment  
 
Equipment  Company Catalogue # 
3-16KL refrigerated benchtop centrifuge Sigma Laborzentrifugen 10360 
appJET pipette controller Appleton AEL540 
Axiovert 40 C inverted phase contrast microscope Zeiss MIC-990-130D 
Axon Instruments GenePix 4000B microarray scanner Molecular Devices GENEPIX 4000B-U 
BVC control, fluid aspiration system with  VacuuHandControl VHCpro Vacuubrand 727202 
Hausser Bright-Line 3100 haemocytometer Hausser Scientific 3110 
JB Nova unstirred water bath Grant JBN12 
LabGard NU-437 class II, type A2 biosafety cabinet Nuaire NU-437-400E 
Leica DMI6000 B inverted fluorescence microscope Leica Microsystems DMI6000B 
Leica TCS SP5 confocal microscope Leica Microsystems TCSSP5 
M3B stereomicroscope Wild Heerbrugg 1171 
MTS 2/4 digital microtiter shaker IKA 0003208002 
NU-5100E air-jacketed automatic CO2 incubator Nuaire NU5100E 
Omni tissue homogenizer (TH) package Omni International THP220 
Synergy HT microplate reader BioTek 7091000 
 
2.0.3 Laboratory Plasticware 
 
Plasticware  Company Catalogue # 
µ-Dish 35 mm, high glass bottom, D 263® M Schott glass Ibidi 81158 
CRYO.S™ 1 mL, conical bottom internal thread, polypropylene (Cryovial)  Greiner Bio-One  123278 
EasYFlask™ 175 cm2, polystyrene  (T175) Nunc 159910 
Microlance™ 3 hypodermic needles 21G x 1.5” (0,8 x 40 mm) Becton Dickinson 304432 
Nalgene® Mr. Frosty™ freezing container Thermo Scientific 5100-0001 
Nunclon™ 6-well x 3mL MultiDish cell culture dish, polystyrene   Nunc 140675 
Nunclon™ Delta Surface, petri dish with lid, 150 x 20mm, polystyrene   Nunc 168381 
Sterilin™ Sterile sample container – 100 mL, polystyrene  Thermo Scientific 185BM 
Tube 15 mL, 120x17mm, polypropylene Sarstedt 62.554.001 
Tube 50 mL, 115x28mm, polypropylene Sarstedt 62.559 
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2.0.4 Reagents 
 
Reagent Company  Catalogue #  
(+)-Tubocurarine chloride pentahydrate Sigma-Aldrich 93750 
1(S),9(R)-(−)-Bicuculline methiodide (Bicuculline)  Sigma-Aldrich 14343 
4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI) Sigma-Aldrich 10236276001 
Anti-calcium channel L type DHPR alpha 2 subunit antibody [20A] (DHPR) Abcam ab2864 
Anti-choline acetyltransferase (ChAT) Sigma-Aldrich AB144 
Anti-glial fibrillary acidic protein (GFAP) Sigma-Aldrich G3893 
Anti-MUSK antibody (MuSK) Abcam ab92950 
Anti-neurofilament H antibody (NFH) Sigma-Aldrich AB5539 
Anti-rapsyn antibody [1234] (rapsyn) Abcam ab11423 
Anti-ryanodine receptor 1 antibody (RyR) Sigma-Aldrich AB9078 
Anti-synaptotagmin antibody [ASV30] (Syt1)  Abcam ab13259 
Anti-vesicular acetylcholine transporter (VAChT) Sigma-Aldrich ABN100 
Beta-3 tubulin monoclonal antibody (2G10-TB3), Alexa Fluor® 488  eBioscience 53-4510-82 
Dexamethasone Sigma-Aldrich D4902 
Dimethyl sulfoxide (DMSO) Fisher BioReagents 10103483 
Donkey anti-goat IgG (H+L) cross-adsorbed secondary antibody, Alexa 
Fluor® 568 
Invitrogen A-11057 
Donkey serum (DS) Sigma-Aldrich D9663 
Dulbecco’s modified eagle medium (DMEM) Lonza 12-914F 
Dulbecco’s phosphate buffered saline 1X (DPBS)  Lonza 17-512F 
Fetuin from fetal bovine serum Sigma-Aldrich F3004 
Gelatin from porcine skin, type A Sigma-Aldrich G2500 
Gentamicin  Gibco 15710-049 
Goat anti-chicken IgY (H+L) cross-adsorbed secondary antibody, DyLight® 
488 
Invitrogen SA5-10070 
Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa 
Fluor® 555 
Invitrogen A-21422 
Goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor® 
568 
Invitrogen A-11011 
Goat serum (GS) Sigma-Aldrich G9023 
Hanks' balanced salt solution w/ calcium, magnesium (HBSS) Gibco 24020117 
Heat-inactivated fetal bovine serum (FBS) Gibco 10500-064 
Horse serum (HS) Sigma-Aldrich H0146 
Human recombinant basic fibroblast growth factor (FGFb) Gibco PHG0026 
Human recombinant epidermal growth factor (EGF) Gibco PHG0311 
Human recombinant hepatocyte growth factor (HGF) Sino Biological Inc. 10463-HNAS 
Human recombinant insulin Sigma-Aldrich 91077C 
L-Glutamic acid (L-Glut) Sigma-Aldrich G1251 
L-glutamine Lonza 17-605E 
Matrigel® growth factor reduced basement membrane matrix, *LDEV-free Corning 354230 
Medium 199 with Earle’s balanced salt solution Lonza 12-119F 
Myosin 4 monoclonal antibody (MF20), Alexa Fluor® 488 (anti-MHC) eBioscience 53-6503-82 
Paraformaldehyde Sigma-Aldrich P6148 
Penicillin-streptomycin mixture (Pen/Strep) Lonza 17-602E 
Perm/Wash™ buffer (PWB) BD Biosciences 554723 
Plasmocin™ - mycoplasma elimination reagent InvivoGen ant-mpp 
Quantibody® human growth factor array 1 RayBiotech QAH-GF-1 
Rabbit monoclonal anti-Ki67 antibody [SP6] (Anti-Ki67) Abcam ab16667 
Rat Agrn / Agrin ELISA kit Sigma-Aldrich RAB0881-1KT 
Skeletal muscle differentiation medium PromoCell C-23061 
Texas Red®-X phalloidin Invitrogen T7471 
Triton™ X-100 (TX100) Sigma-Aldrich T8787 
Trypan Blue, 0.4% solution Lonza 17-942E 
TrypLE™ express enzyme 1X (TrypLE) Gibco 12605-028 
TWEEN® 20  Sigma-Aldrich P1379 
α-Bungarotoxin, Alexa Fluor™ 647 conjugate (α-BTX) Invitrogen B35450 
γ-Aminobutyric acid (GABA) Sigma-Aldrich A2129 
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2.1 Methods  
 
2.1.0 Human Skeletal Muscle Cell Culture  
 
All cell culture work was carried out in a class II, type A2 biosafety cabinet, with strict adherence to 
aseptic techniques and practices. Two cryovials were retrieved from liquid nitrogen storage, each 
containing ~1x106 25-year-old immortalised human myoblasts (C25) or 83-year-old immortalised 
human myoblasts (C83). The cells were cryopreserved in a 1 mL suspension of 90% fetal bovine serum 
(FBS) and 10% Dimethyl sulfoxide (DMSO). The frozen vials were placed into a water bath set to 37°C 
and rapidly thawed within 2 minutes. Subsequently, the thawed myoblasts were transferred into 
separate 15 mL tubes. Next, 9 mL of pre-prepared complete growth media (GM) (Table 2.0) was added 
to each tube to initiate myoblast proliferation. 
 
Table 2.0: Complete growth media for skeletal muscle cell proliferation. 
 
Media components Concentration 
Dulbecco’s modified eagle medium (DMEM) 59% (v/v) 
Medium 199 with Earle’s balanced salt solution 19% (v/v) 
Fetal bovine serum (FBS) 20% (v/v) 
L-glutamine 1% (v/v) 
Penicillin-streptomycin mixture (Pen/Strep) 1% (v/v) 
Fetuin from fetal bovine serum 25 μg/mL 
Basic fibroblast growth factor (FGFb) 0.5 ng/mL 
Epidermal growth factor (EGF) 5 ng/mL 
Hepatocyte growth factor (HGF) 2.5 ng/mL 
insulin 5 μg/mL 
Dexamethasone 0.2 μg/mL 
Gentamicin 10 μg/mL 
Plasmocin 25 μg/mL 
 
The separate 10 mL suspensions of C25 and C83 were transferred into separate T175 flasks. The flasks 
were positioned onto a levelling plate and incubated at 37°C with a 5% CO2 atmosphere (ATM), until 
the density of cell growth was 80% confluent, which was determined by the percentage of area covered 
by cells in any random microscopic field of view. Phase contrast microscopy analysis with the Axiovert 
40 C and DMI6000B inverted microscopes were used to assess and compare any difference in the 
percentage of confluence between the two cell lines at 24, 48, 72, and 96 hours. ImageJ, a Java-based 
image processing application developed at the National Institutes of Health and the Laboratory for 
Optical and Computational Instrumentation (Madison, WI, USA) (Collins, 2007; Schneider et al., 2012) 
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was used to quantify confluence at the stated time points by calculating the total myoblast area. 
Calculated by using the formula < [(total area of myoblasts in a field)/(total area of the field)](100) >  
(Ren et al., 2008; Ricotti et al., 2011). Ten fields chosen at random were visualized on a DMI6000B 
inverted microscope with the N Plan 10x/0.25na Ph1 objective.  
 
2.1.1 Cell Count 
 
When the flasks reached 80% confluence, the GM was aspirated and the cells were washed twice with 
10 mL of Dulbecco’s phosphate buffered saline 1X (DPBS) to remove any GM components that may 
inhibit the function of disassociation enzymes. The monolayers of cells were then disassociated from 
the flasks using 2 mL of the highly purified, recombinant cell-dissociation TrypLE express enzyme 1X 
and incubating at ATM for 5 minutes. The 2 mL of disassociated cell suspensions were pipetted from 
the flasks into separate 15 mL tubes. The flasks were then separately washed with 8 mL of GM to 
capture any residual cells that may have remained adherent to the flask after disassociation. The 8 mL 
of GM was collected from each flask and added to the corresponding 15 mL tube of C25 or C83, which 
contained the 2 mL of already collect cells. The 8 mL GM, 2 mL TrypPLE cell suspensions of both C25 
and C83 were separately mixed by pipetting the cell suspension up and down in the 15 mL tube 5-10 
times before aliquoting a sample for cell count. Comparison of total viable cells between C25 and C83 
was quantified using established cell count protocols (Phelan and Lawler, 2001). The cells were counted 
by mixing a 1:1 dilution of cell suspension (50 µL) with Trypan Blue, which labels non-viable cells by 
penetrating the membrane and dyeing the cell blue, whereas viable cells remained transparent with a 
white halo around the membrane. The viable cells were counted using established techniques with a 
haemocytometer (Phelan and Lawler, 2001) viewed with an A-Plan 10x / .25 Ph1 objective on the 
Axiovert 40C inverted microscope . The number viable cells/mL of cell suspension was determined using 
the formula: [(Average number of live cells in eight large corner square) (dilution factor) (104)]. For 
example, (50)(2)(10000) = 1x106 cell/mL of suspension, thus a hypothetical 10 mL suspension of 
harvested cells would yield 1x107 cells . Dependant on experimental demands the counted cell 
suspension was either sub-cultured, cryopreserved, or seeded on tissue culture surfaces as required.   
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2.1.2 Subculture 
 
Following cell count, aliquots of cell suspensions containing 1x106 cell were transferred from the tubes 
of counted cells to new 15 mL tubes. A volume of GM needed to bring the total volume of the 
suspensions to 10 mL was added to the new 15 mL tubes of cells. Thus, the new cell suspensions of 
both C25 and C83 would have a concentration of 1x105 cells/mL. The cell suspensions were 
homogenised with the GM in their respective tubes then pipetted into separate T175 flasks and 
incubated at ATM until 80% confluent.  
 
2.1.3 Cryopreservation  
 
Large stocks of cells were generated for storage and retrieval for experimental use when required. Both 
C25 and C83 were continually expanded and sub-cultured as described above to generate cells. Thus, 
the myoblasts retained a low number of passages to ensure fidelity throughout this project. Following 
disassociation and cell count (described in 2.1.1), the 10 mL cell suspensions of C25 and C83 were 
transferred to separate new 50 mL tubes. An equal volume of DPBS was added to the 50 mL tubes, 
diluting and washing the cells within the suspension. The 50 mL tubes was then centrifuged at 300 x g 
for 10 minutes at 23°C. After centrifuging the cells, the supernatants were aspirated from the tubes, 
ensuring the pelleted cells remained undisturbed. The required volume of FBS was added to the 50 mL 
tube to bring the concentration of cells to 1x106 cell/mL, dependant on the cell count before 
centrifugation. The cell pellet was then thoroughly dispersed and homogenised in the FBS via pipetting 
the solution up and down in the tube 10-20X. A volume of 900 µL of the FBS cell suspension was 
pipetted into individual cryovials and 100 µL of DMSO was added to each vial thereafter. Thus, each 
vial contained ~1x106 cells suspended in 90% FBS and 10% DMSO. The vials were then placed into a Mr. 
Frosty freezing container and stored at -80°C for 24 hours. Subsequently, the vials were transferred 
from the -80°C storage freezer to liquid nitrogen tank for long-term storage at -200°C.  
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2.1.4 Differentiation Parameters 
 
Following cell count, a quantity of cells was transferred from the 15 mL tubes of counted cells to new 
50 mL tubes. The number of cells allocated to the 50 mL tubes was dependent on experimental needs. 
The volume of GM necessary to dilute the cells to a concentration of 1.5x105 cells/mL was added to the 
50 mL tubes in preparation for seeding in tissue culture plates. Before plating the cells, 6-well plates 
were pre-coated and dried with 1% gelatin solution for 1 hour. Subsequently, 2 mL of the GM cell 
suspension of both C25 and C83 were separately pipetted into the 6-well plates. Thus, the 
concentration of cells in each well of a 6-well plate was equal to 3x105 cells or expressed as a density 
of 315 cells/mm2. After seeding the cells, the 6-well plates were placed on a levelling plate and 
incubated for 24 hours at ATM, at which point the cells reached ~90-100% confluence. Following 
incubation the GM was aspirated from the wells and the cells were washed twice with 1 mL of DPBS. A 
volume of 2 mL of a simplified complete differentiation media (DM) (Table 2.1) was added to each well 
and the cells were incubated for 96 hours at ATM. 
 
Table 2.1: Complete differentiation media for immortalised human skeletal muscle cell.   
 
Media components Concentration 
Dulbecco’s modified eagle medium (DMEM) 98% (v/v) 
L-glutamine 1% (v/v) 
Penicillin-streptomycin mixture (Pen/Strep) 1% (v/v) 
Insulin 10 μg/mL 
Gentamicin 10 μg/mL 
Plasmocin 25 μg/mL 
 
Immunofluorescence microscopy were used to determine any difference in the proportional decline of 
proliferating cells and to assess the phenotypic differentiation (alignment, elongation and fusion) of 
both the young and old cell lines as they differentiated over 96 hours. The expression of the 
proliferative marker Ki67 (Schonk et al., 1989; Bullwinkel et al., 2006) and the comparison of 
differentiation parameters were measured at 24, 48, 72, and 96 hours. At each time-point, the DM was 
aspirated from the wells and cells were washed twice with 1 mL of DPBS. Cell fixation was then 
performed by incubating the cells in a 500 µL 4% paraformaldehyde solution for 10 minutes at 23°C. 
The paraformaldehyde was then aspirated away and the cells were washed thrice with DPBS, followed 
by cell permeabilisation with a 1X concentration of Prem/Wash buffer (PWB). A volume of 1 mL of PWB 
was added to each well and then incubated for 30 minutes at 23°C. Once permeabilised the PWB was 
removed and the cells were washed once with 1 mL of DPBS. Subsequently, 1 mL of pre-prepared 
40 
 
blocking solution consisting of DPBS with 0.2% Triton X-100 (TX100) and 10% goat serum (GS) was 
added to each well and the cells incubated for 1 hour at 23°C. The blocking solution was then removed 
in preparation for primary antibody labelling. A 250-µL antibody diluent solution consisting of DPBS, 
3% GS, 0.05% TWEEN 20, and anti-Ki67 at a dilution of 1:100 was applied to the cells and incubated for 
18-24 hours at 4°C. Next, the primary antibody solution was removed from the wells and the cells were 
washed thrice with DPBS before the addition of fluorescent-labelled secondary antibody conjugates. 
The secondary antibody diluent had a volume of 250 µL and consisting of DPBS, 4′,6-Diamidine-2′-
phenylindole dihydrochloride (DAPI) at a dilution of 1:10000, anti-rabbit Alexa Fluor 568 at a dilution 
1:500, anti-myosin heavy chain (MHC) Alexa Fluor 488 at a dilution 1:500, and phalloidin at a dilution 
1:500 was applied to the cells and incubated for 30 minutes at 23°C. The stained cells were then washed 
a final two times with DPBS and maintained in DPBS thereafter for analysis. Visualisation of stained 
cells was achieved with fluorescence microscopy. ImageJ was used to measure and compare the 
differentiation parameters (Table 2.2) and quantify the percentage of Ki67 expression between both 
the young and old cell lines. Ten random fields of view were assessed for each experiment (n = 5) with 
a HCX PL FLUOTAR L 20X/0.40na CORR objective on the DMI6000B inverted microscope. The data was 
presented as mean with a ± SD of all the counted fields of view in the total number of experiments 
conducted. 
 
Table 2.2: Differentiation parameters (Ren et al., 2008; Ricotti et al., 2011; Grubisic et al., 2014) 
 
Differentiation 
parameters 
Formula 
Myotube area (MA) [(total area of myotubes in a field)/(total area of the field)](100) 
Fusion index (FI) (total number of nuclei per myotube)/(total number of nuclei in the 
field)](100) 
Aspect ratio (AR) (myotube length)/(myotube width) 
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2.1.5 Co-culture 
 
In vitro studies of muscular dysfunction utilising aneurally cultured SkMCs are limited by the lack of a 
nerve component, resulting in limited differentiation and non-contractile myotubes (Delaporte et al., 
1986). For a valid reflection of physiological conditions found in vivo, SkMCs require MN stimulation. 
Accordingly, to overcome the limitations of aneurally cultured SkMCs a novel co-culture model was 
successfully established where functional innervation of myotubes was achieved using spinal cord 
explants (SCEs) from rat embryos (Figure 2.0). 
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Figure 2.0: Timeline of human immortalised myoblasts co-cultured with rat embryo spinal cord 
explants. The time course of co-cultured cells is expressed in days, respective to plating of spinal cord 
explants with differentiating myoblasts. The first spontaneous myotube contractions were observed 
~72 hours post co-culture. The co-cultures were characterised and functionally assessed on Day 14 post 
co-culture. Dorsal root ganglions (DRGs); embryonic development day (ED 13.5). 
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2.1.6 Isolation of Rat Embryo Spinal Cord 
 
The uterine horn was dissected and removed from the sacrificed pregnant rat and transferred to a 
sterile sample collection container, containing Hanks' balanced salt solution (HBSS) with 10% FBS. 
Embryo dissection was carried out under sterile conditions in a biosafety cabinet using a 
stereomicroscope. The uterine horn was transferred to a 150 mm dish and saturated with HBSS plus 
10% FBS. The embryos were individually cleaved from the uterine horn and transferred to a new 150 
mm dish where they were dissected under a stereoscopic microscope using two sterile 40 mm 21-gauge 
hypodermic needles. The embryos were first decapitated, and then the spinal cord was dissected away 
from the main body as one piece. The surrounding connective tissue was removed from the spinal cord, 
ensuring the dorsal root ganglions (DRGs) remain attached. Following removal of connective tissue, the 
isolated spinal cord was transversally sliced into ~1-2 mm3 explants and transferred to a 15 mL tube 
containing HBSS until ready for plating with SkMCs.  
 
2.1.7 Preparation of Skeletal Muscle Cells for Co-culture 
 
Preceding co-culture, 25-year-old immortalised human myoblasts (C25) were disassociated from a pre-
incubated T175 flask and counted (as described in 2.1.1). The cells were then diluted to the desired 
concentration of 1.5x105 cells/mL in GM. The cells were seeded at a density of 315 cells/mm2 by adding 
2 mL of GM cell suspension onto 35 mm glass bottom dishes, which were pre-coated for 1 hour with a 
1 mL solution of DPBS supplemented with 100 µL of growth factor reduced Matrigel. The dishes were 
then incubated for 24 hours at ATM, at which time they reached 90-100% confluence. Following 
incubation, the GM was aspirated and the dishes washed twice with 1 mL of DPBS before the addition 
of 2 mL of DM to each dish. The dishes were then incubated for 24 hours at ATM before adding rat 
embryo SCEs.  
 
2.1.8 Innervation of Skeletal Muscle with Embryonic Rat Motor Neurons 
 
Following 24 hours of incubation with DM, the SkMCs were primed for innervation as they were in the 
initial phases of differentiation, transitioning from myoblast to myocyte, before substantial cell fusion 
and myotube formation occurred. The DM was removed from the dishes and the cells were washed 
twice with 1 mL of DPBS. Then, 750 µL of DM was added to each dish, thinly coating the cells on the 
glass bottom. Between three and six evenly spaced embryonic rat SCEs were placed into each dish then 
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incubated for 6 hour at ATM to allow the explants time to adhere with the SkMCs. Following incubation, 
the SCEs become slightly affixed to the SkMCs, at which time an additional 250 µL of DM was added 
dropwise to each dish to prevent dehydration of the SkMCs and the SCEs. However, adding too much 
DM too quickly or forcefully would not allow the SCEs to remain adherent to the SkMCs, causing SCEs 
to float. The dishes were then incubated for an additional 24 hours at ATM to reinforce unification of 
SCEs with the SkMCs before adding a further 1 ml of DM to each dish, bringing the total volume of DM 
in the dishes to 2 mL. Notably, the SCEs must be plated on the SkMCs after the SkMCs have been 
exposed to DM for 24 hours. As myoblasts fuse into immature myotube between 24 and 48 hours, 
sprouting neurites from the SCEs innervate the fusing myotubes at this stage of development. The co-
cultures were maintained by changing half the DM every 72 hours and incubating at ATM. Live cell 
visualisation and real-time myotube contractions were video-captured at 24 frames per second with 
HCX PL FLUOTAR L 20X/0.40na CORR objective on a DMI6000 B inverted microscope.  
 
2.1.9 Differentiation Parameters: Co-culture 
 
In parallel experiments were conducted to compare the differentiation parameters (Table 2.2) of both 
aneurally cultured and co-cultured myotubes. Preceding assessment of phenotypic differentiation, 
aneurally cultured myoblasts were seeded and differentiated as described in 2.1.4, while co-cultured 
myoblasts were prepared for analysis as described in 2.1.7. The differentiation parameters were 
assessed at 72 hours, when spontaneous myotube contractions were first observed in the co-cultured 
myotubes. Phase contrast microscopy with a Leica DMI6000 B inverted microscope and the ImageJ 
image processing software package were used to quantify the differentiation parameters. Ten random 
fields of view were assessed with the N Plan 10x/0.25na Ph1 objective for each experiment (n = 3). The 
data was presented as a mean ± SD of the total number of fields observed in all experiments conducted. 
 
2.1.10 Disassociation of Rat Embryo Spinal Cord 
 
The efficacy of SCEs to induce myotube contractions and modulate contraction frequency (CF) was 
compared against myoblasts co-cultured with a disassociated rat embryonic spinal cord cell suspension. 
The spinal cord cell suspension was prepared by isolating spinal cords from ED 13.5 rat embryos as 
described in 2.1.6. Individually isolated intact spinal cords were transferred into 15 mL tubes containing 
2 mL of DM. The spinal cord was then mechanically disassociated with a tissue homogenizer to generate 
a 2 mL cell solution of rat embryonic spinal cord cells suspended in DM. Young human immortalised 
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myoblasts were prepared for co-culture as described in 2.1.7. Following 24 of incubation with DM, the 
pre-plated myoblasts were co-cultured with SCEs as described in 2.1.8 or they were co-cultured with 
the 2 mL spinal cord cell suspension. The co-cultured myotubes were observed every 24 hours for 7 
days to compare the initiation and frequency of contractions among the two culture conditions. The 
co-cultured cell dishes were positioned onto an inverted microscope stage, which was enclosed by an 
incubation chamber to maintain atmospheric conditions of 37°C with 5% CO2. Worth mentioning, 
maintaining these conditions during assessment was vital to ensure persistent spontaneous myotube 
contractions, as fluctuations in temperature and atmospheric composition significantly influence 
spontaneous myotube contractions frequency. Following 5 minutes of live observation of 
uninterrupted spontaneous myotube contractile activity, live video analysis was conducted at 24 
frames per second with phase contrast microscopy using the DMI6000 B inverted microscope with an 
N Plan 10x/0.25na Ph1 objective. Myotube CF was expressed as a mean ± SD. 
 
2.1.11 Rat agrin ELISA 
 
In parallel experiments were conducted to compare the concentration of agrin in aneural myotube 
cultures, co-cultured myotubes, and SCE only cultures. Both aneural and co-cultured myoblasts were 
prepared, seeded, and differentiated for 72 hours as described in 2.1.4 and 2.1.7. Similar to co-cultures, 
SCEs only were prepared and plated in 6-well plates pre-coated with a 1% gelatin solution and cultured 
in 2 mL of SkMC DM for 72 hours. Supernatant samples were collected from the three culture 
conditions for assessment using a rat agrin ELISA kit at 72 hour, when spontaneous myotube 
contractions were first observed in the co-cultured myotubes. Preparation of standards and reagents 
in the ELISA kit were completed using manufacturer guidelines. Subsequently 100 μl of standards, 
controls and supernatant samples were added to individually assigned wells of the agrin antibody-
coated ELISA plate. The plate was then sealed to protect from light and incubated for 24 hours at 4°C 
on microplate shaker fixed to 500 rpm. After incubation, the wells were aspirated and the ELISA plate 
was washed four times with 300 µl of wash buffer, followed by inverting the plate and blotting it against 
clean paper towels to remove all residual wash buffer. Next, 100 µl of 1X biotinylated rat agrin detection 
antibody was added to all wells and the plate sealed. The detection antibody was incubated with the 
samples at 23°C for 1 hour on a plate shaker set to 500 rpm. Following incubation, the wells were 
washed four times with 300 µl of wash buffer then 100 µl of 1X HRP-Streptavidin solution was added 
to each well. The plate was sealed and incubated once more at 23°C for 45 minutes on a plate shaker 
set to 500 rpm. Following incubation, the plate was washed again four times with 300 µl of wash buffer. 
A volume of 100 µl of ELISA colorimetric TMB reagent was then added to each well before a final 
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darkened incubation for 30 minutes on the plate shaker set to 500 rpm at 23°C. Subsequently, 50 µl of 
stop solution was added to the wells and absorbance read immediately at 450 nm on the Synergy HT 
microplate reader.  
 
2.1.12 Co-culture Fixation 
 
The co-cultured cells were fixed in their dishes for analysis and characterisation on Day 14 post co-
culture, which was 11 days after persistent spontaneous myotube contractions, though it was possible 
to maintain co-cultures beyond 30 days with regular media changes as described in 2.1.8. The DM was 
aspirated from the dishes and the cells washed thrice with 500 µL of DPBS. The cells were then 
incubated with a 4% paraformaldehyde solution for 12 minutes at 23°C. The paraformaldehyde was 
then removed from the dishes and the cells washed thrice with 500 µL of DPBS. The fixed cells were 
then stored in a DPBS solution for up to 7 days at 4°C. Alternatively, immunocytochemistry (ICC) was 
immediately performed for the evaluation and characterisation of pre- and post-synaptic components 
of neuromuscular junction (NMJ) formation in the co-culture model.  
 
2.1.13 Co-culture Immunocytochemistry  
 
After fixation of co-cultured cells, the cells were incubated with 500 µL of a 1X concentration of PWB 
for 30 minutes at 23°C to permeabilise the cells. Once permeabilised, the PWB was removed from the 
dishes and the cells washed twice with 500 µL of DPBS. A 500-µL volume of blocking solution consisting 
of 0.2% TX100 with 10% GS or donkey serum (DS) was applied to the cells and then incubated for 1 
hour at 23°C, to block unspecific binding of antibodies. The blocking solution was removed after 
incubation and the cells washed once with 500 µL DPBS. A volume of 250 µL of primary antibody diluent 
consisting DPBS, 3% GS or DS, 0.05% TWEEN 20, and the primary antibodies (Table 2.3) was added to 
the cells and incubated for 18-24 hours at 4°C. 
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Table 2.3: Primary antibodies for co-culture. 
 
Antibody Concentration 
Anti-calcium channel L type DHPR alpha 2 subunit (DHPR) 1:100 
Anti-choline acetyltransferase (ChAT) 1:100 
Anti-glial fibrillary acidic protein (GFAP) 1:100 
Anti-muscle-specific kinase (MuSK) 1:100 
Anti-neurofilament H (NFH) 1:100 
Anti-receptor associated protein of the synapse (rapsyn) 1:100 
Anti-ryanodine receptor 1 (RyR) 1:100 
Anti-synaptotagmin (Syt1) 1:100 
Anti-vesicular acetylcholine transporter (VAChT) 1:100 
 
Following primary antibody incubation, the diluent was aspirated from the dishes and the cells were 
washed thrice with 500 µL of DPBS prior to adding the fluorescent-labelled secondary antibodies. A 
secondary antibody diluent consisting of 250 µL DPBS supplemented with DAPI at a dilution of 1:10000 
and the corresponding secondary antibodies (Table 2.4) was added to each dish and incubated in 
darkness for 30 minutes at 23°C. The secondary antibodies were aspirated from the dishes and the 
stained cells were washed a final two times with 500 µL of DPBS and maintained in 1 mL of DPBS during 
analysis. Confirmation of myotube innervation and characterisation of NMJ formation was conducted 
with confocal and immunofluorescence microscopy using a Leica DMI6000 B inverted microscope with 
HCX PL FLUOTAR L 20X/0.40na CORR and N Plan 10x/0.25na Ph1 objectives; and a Leica TCS SP5 
confocal microscope with HCX PL APO 40x 1.25-0.75 Oil CS ∞ and HCX PL APO 63x 1.40-0.60 oil CS ∞ 
objectives. 
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Table 2.4: Secondary antibodies for co-culture. 
 
Antibody Concentration 
Anti-β-3-tubulin Alexa Fluor® 488 conjugate 1:400 
Anti-chicken IgY DyLight® 488 1:400 
Anti-goat IgG Alexa Fluor® 568 1:400 
Anti-MHC Alexa Fluor® 488 conjugate 1:400 
Anti-mouse IgG Alexa Fluor® 555 1:400 
Anti-rabbit IgG Alexa Fluor® 488 1:400 
Anti-rabbit IgG Alexa Fluor® 568 1:400 
α-BTX Alexa Fluor® 647 conjugate 1:400 
 
2.1.14 Quantification of Neuromuscular Junction Morphologies  
 
In parallel experiments were conducted to compare the development of NMJ morphologies in co-
cultured cells in contrast to aneurally cultured myotubes. Innervated and aneural cultures were 
differentiated, fixed, and stained on Day 14 post co-culture with α-bungarotoxin (α-BTX) and DAPI using 
the methods and concentrations detailed above. Distinctive NMJ morphologies were quantified into 
five previously established NMJ morphology development classifications (Valdez et al., 2010; Lee et al., 
2013; Kummer et al., 2004; Sahashi et al., 2012). Specifically, NMJ morphology was classified as mature, 
fragmented, faint, premature or denervated. For each experiment (n = 4), individual wells were 
observed to assess twenty random fields of view for each morphological classification using the Leica 
TCS SP5 confocal microscope with a HCX PL APO 40x 1.25-0.75 Oil CS ∞ objective. For example, twenty 
fields from twenty different wells where assessed to determine the percentage of mature NMJs only, 
a different twenty fields from an alternative twenty wells where assessed to determine the percentage 
of fragmented NMJs only, until all classification were counted. The data was presented as a mean ± SD 
of the total number of all fields observed in all experiments conducted. A minimum of 100 NMJs was 
counted for each morphological classification over all experiments.  
 
2.1.15 Quantification of Transversal Triad Formation 
 
In parallel experiments were conducted to compare the development of transversal triads between co-
cultured and anural myotubes. Innervated and aneural cultures were differentiated, fixed, and stained 
on Day 14 post co-culture for dihydropyridine receptors (DHPR), ryanodine receptors (RyR) and DAPI 
using the methods and concentrations detailed in 2.1.13. Myotubes were considered to have 
appropriate transversal triad formation, which is an indicator of advanced differentiation, when DHPR 
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and RyR staining was organised in an alternating sequence on a minimum of 50% of the myotubes 
length. In each experiment (n = 3), twenty random fields of view from five different plates were 
assessed using a Leica TCS SP5 confocal microscope with a HCX PL APO 63x 1.40-0.60 oil CS ∞ objective, 
to determine the percentage of myotubes displaying transversal triads. The data from all experiments 
was totalled and used to calculate the mean percentage ± SD.  
 
2.1.16 Quantification of Peripheral Myonuclei  
 
In parallel experiments were conducted to compare the positon of myonuclei in co-cultured myotubes 
as opposed to aneurally cultured myotubes, as peripherally located myonuclei are indicators of 
advanced differentiation. Innervated and aneural cultures were differentiated, fixed, and stained on 
Day 14 post co-culture for anti-MHC and DAPI using the methods and concentrations detailed in 2.1.13. 
Myonuclei were considered as peripherally situated if they were observed protruding the myotube 
membrane. In each experiment (n = 3), twenty random fields of view from five different plates were 
assessed using a Leica TCS SP5 confocal microscope with a HCX PL APO 40x 1.25-0.75 oil CS ∞ objective, 
to determine the percentage of myotubes displaying peripherally located myonuclei. The data from all 
experiments was totalled and used to calculate the mean percentage ± SD.  
 
2.1.17 Quantification of Striation Formation  
 
In parallel experiments were conducted to compare the striated myotubes in co-culture against 
aneurally cultured myotubes, as striations are indicators of advanced differentiation. Innervated and 
aneural cultures were differentiated, fixed, and stained on Day 14 post co-culture for anti-MHC and 
DAPI using the methods and concentrations detailed in 2.1.13. Myotubes were considered as striated 
if MHC expression was arranged as alternating banding on a minimum of 50% of the myotubes length. 
In each experiment (n = 3), twenty random fields of view from five different plates were assessed using 
a Leica TCS SP5 confocal microscope with a HCX PL APO 40x 1.25-0.75 oil CS ∞ objective, to determine 
the percentage of myotubes with striation formation. The data from all experiments was totalled and 
used to calculate the mean percentage ± SD. 
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2.1.18 Quantification of Myotube Thickness 
 
In parallel experiments were conducted to compare the thickness of myotubes in co-culture to 
aneurally cultured myotubes. Innervated and aneural cultures were differentiated, fixed, and stained 
on Day 14 post co-culture for anti-MHC and DAPI using the methods and concentrations detailed in 
2.1.13. Phase contrast microscopy with a Leica DMI6000 B inverted microscope and the ImageJ image 
processing software package were used to quantify the myotube thickness. In each experiment (n = 3), 
twenty random fields of view from five different plates were assessed using the HCX PL FLUOTAR L 
20X/0.40na CORR objective, to measure and compare the thickness of innervated and aneural 
myotubes. The data from all experiments was totalled and used to calculate the mean myotube 
thickness ± SD. 
 
2.1.19 NMJ Functionality Assessed via Measuring Spontaneous Contractions 
 
Co-cultures were functionally evaluated to validate the formation NMJs via live phase contrast video 
analysis of myotube CF in response to agonist/antagonist treatments (Table 2.5). On Day 14, the co-
cultured cell dishes were positioned onto an inverted microscope stage, which was enclosed by an 
incubation chamber to maintain atmospheric conditions of 37°C with 5% CO2. Following 5 minutes of 
live observation of uninterrupted spontaneous myotube contractile activity, the co-cultures were 
treated with cholinergic antagonists to block AChRs at the NMJ.  
 
Table 2.5: Treatments to inhibit or augment myotube contraction frequency via NMJ signal 
transmission. 
 
Drug Concentration 
1(S),9(R)-(−)-Bicuculline methiodide 10 µM 
γ-Aminobutyric acid (GABA) 1 mM 
L-Glutamic acid (L-Glut) 400 µM 
(+)-Tubocurarine chloride pentahydrate 8 µM 
α-Bungarotoxin (α-BTX) 1:400 
 
The co-cultures were also treated with the glutamatergic and γ-aminobutyric acid (GABA) receptor 
agonists to stimulate glutamate and GABA receptors on the motor neurons (MNs). The specified 
concentrations where selected based on previously established studies (Das et al., 2007; Guo et al., 
2011; Morimoto et al., 2013; Borodinsky and Spitzer, 2007). The myotube CF was measured 30 seconds 
before the application of the treatments to the cells, to establish a baseline spontaneous CF. 
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Subsequently, agonist or antagonist treatments were added to the dishes at the centre of the field of 
view. Modulation of CF was measured immediately upon application of the treatment to the cells. Live 
measurement of CF in response to treatment were also conducted again after 1 minute, 2 minutes, 5 
minutes, 10 minutes, 30 minutes and 1 hour. Following 1 hour after treatment, the cells were washed 
thrice with 500 µL of DPBS then fresh untreated DM was added to the cells. The dishes were placed 
back onto the microscope stage in the incubation chamber and CF was immediately measured again 
following the washout and resupply of DM. The CF was measured once again at 1 hour 30 minutes and 
24 hours after the initial treatments. In each experiment (n = 5), live video analysis of twenty random 
fields from one 6-well plate was conducted at 24 frames per second with phase contrast microscopy 
using the DMI6000 B inverted microscope with an N Plan 10x/0.25na Ph1 objective. The data from all 
experiments was totalled and used to calculate the myotube CF, which was expressed as a mean of all 
experiments ± SD. 
 
2.1.20 Human Growth Factor Array 
 
In parallel experiments were conducted to compare the concentration of 40 human growth factors 
(Table 2.6) in aneural myotube cultures and co-cultured myotubes. Both aneural and co-cultured 
myoblasts were prepared, seeded, and differentiated for 7 days as described above. Supernatant 
samples were collected from both conditions for assessment using a human growth factor array kit on 
day 7, when spontaneous myotube contractions were first observed contracting in unison as a motor 
unit. Preparation of standards and reagents in the array kit were completed using manufacturer 
guidelines. Subsequently, 100 μl of sample diluent from the array kit was added to each well and 
incubated at 23°C for 30 minutes to block slides. The wells were then decanted and 100 μl of standards, 
controls and supernatant samples were added to the individually assigned wells. The slides were sealed 
and incubated for 24 hours at 4°C on microplate shaker fixed to 500 rpm. Following incubation, the 
samples were decanted from the wells and the slides were washed 5 times for 5 minutes each time 
with 150 μl of 1X wash buffer 1, then washed 2 times for 5 minutes each time with 150 μl of 1X wash 
buffer 2. Next, 80 μl of detection antibody cocktail was added to each well and the slides incubated for 
1.5 hours at 23°C. The detection antibody cocktail was aspirated from the wells and the wash steps 
with wash buffer 1 and wash buffer 2 were repeated once again. After washing slides, 80 μl of Cy3 
equivalent dye-conjugated streptavidin was added to each well then sealed and incubated in darkness 
for 1 hour at 23°C. Following incubation, the wash steps were repeated once again. The slides were 
then separated from the well gaskets and placed into the provided slide washer/dryer tube. The tube 
was then filled with 30 mL of 1X wash buffer 1 to completely cover the slides and shaken gently for 15 
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minutes. The 1X wash buffer 1 was removed from the tube and 30 mL of 1X wash buffer 2 was added 
to completely cover the slides and gently shaken for 5 minutes. The slides were removed from the 
washer/dryer tube and dried with compressed air to remove residual buffer solution. Subsequently, 
the array was visualised with a GenePix 4000B laser scanner at 532nm wavelength. Raw data from the 
visualised array images was generated and processed with the GenePix Pro 4.1 Microarray Acquisition 
& Analysis Software, further statistical analysis of the data was performed with the RayBiotech Q-
Analyzer® tool Software for QAH-GF-1. 
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Table 2.6: Descriptions of the human growth factors and neurotrophins quantified in aneural myotube 
cultures and co-cultured myotube supernatant. 
 
 
 
2.1.21 Statistical Analysis 
 
The results presented from the experimental outcomes of this work are representative of a minimum 
of three independent experiments. Results were analysed using GraphPad Prism v6.05 statistical 
analysis software. Data was expressed as mean plus/minus standard deviation (± SD). Statistical 
differences were analysed with unpaired t test or one-way ANOVA with Tukey correction for multiple 
comparison test as appropriate. Statistical significance was accepted if P < 0.05.  
 
 
Amphiregulin (AR) (Colorectum cell-derived growth factor) (CRDGF)
Brain-derived neurotrophic factor (BDNF) (Abrineurin)
Fibroblast growth factor 2 (FGF-2) (Basic fibroblast growth factor) (bFGF) (Heparin-binding growth factor 2) (HBGF-2)
Bone morphogenetic protein 4 (BMP-4) (Bone morphogenetic protein 2B) (BMP-2B)
Bone morphogenetic protein 5 (BMP-5)
Bone morphogenetic protein 7 (BMP-7) (Osteogenic protein 1) (OP-1) (Eptotermin alfa)
Beta-nerve growth factor (Beta-NGF)
Pro-epidermal growth factor (EGF) [Cleaved into: Epidermal growth factor (Urogastrone)]
Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)
Prokineticin-1 (Endocrine-gland-derived vascular endothelial growth factor) (EG-VEGF) (Mambakine)
Fibroblast growth factor 4 (FGF-4) (Heparin secretory-transforming protein 1) (HST) (HST-1) (HSTF-1) (Heparin-binding growth factor 4) (HBGF-4) (Transforming protein KS3)
Fibroblast growth factor 7 (FGF-7) (Heparin-binding growth factor 7) (HBGF-7) (Keratinocyte growth factor)
Growth/differentiation factor 15 (GDF-15) (Macrophage inhibitory cytokine 1) (MIC-1) (NSAID-activated gene 1 protein) (NAG-1) (NSAID-regulated gene 1 protein) (NRG-1) 
Glial cell line-derived neurotrophic factor (hGDNF) (Astrocyte-derived trophic factor) (ATF)
Somatotropin (Growth hormone) (GH) (GH-N) (Growth hormone 1) (Pituitary growth hormone)
Proheparin-binding EGF-like growth factor [Cleaved into: Heparin-binding EGF-like growth factor (HB-EGF) (HBEGF) (Diphtheria toxin receptor) (DT-R)]
Hepatocyte growth factor (Hepatopoietin-A) (Scatter factor) (SF) [Cleaved into: Hepatocyte growth factor alpha chain; Hepatocyte growth factor beta chain]
Insulin-like growth factor-binding protein 1 (IBP-1) (IGF-binding protein 1) (IGFBP-1) (Placental protein 12) (PP12)
Insulin-like growth factor-binding protein 2 (IBP-2) (IGF-binding protein 2) (IGFBP-2)
Insulin-like growth factor-binding protein 3 (IBP-3) (IGF-binding protein 3) (IGFBP-3)
Insulin-like growth factor-binding protein 4 (IBP-4) (IGF-binding protein 4) (IGFBP-4)
Insulin-like growth factor-binding protein 6 (IBP-6) (IGF-binding protein 6) (IGFBP-6)
Insulin-like growth factor I (IGF-I) (Mechano growth factor) (MGF) (Somatomedin-C)
Insulin [Cleaved into: Insulin B chain; Insulin A chain]
Macrophage colony-stimulating factor 1 receptor (CSF-1 receptor) (CSF-1-R) (CSF-1R) (M-CSF-R) (EC 2.7.10.1) (Proto-oncogene c-Fms) (CD antigen CD115)
Tumor necrosis factor receptor superfamily member 16 (Gp80-LNGFR) (Low affinity neurotrophin receptor p75NTR) (Low-affinity nerve growth factor receptor) (NGF receptor) (p75 ICD) 
Neurotrophin-3 (NT-3) (HDNF) (Nerve growth factor 2) (NGF-2) (Neurotrophic factor)
Neurotrophin-4 (NT-4) (Neurotrophin-5) (NT-5) (Neutrophic factor 4)
Tumor necrosis factor receptor superfamily member 11B (Osteoclastogenesis inhibitory factor) (Osteoprotegerin)
Platelet-derived growth factor subunit A (PDGF subunit A) (PDGF-1) (Platelet-derived growth factor A chain) (Platelet-derived growth factor alpha polypeptide)
Placenta growth factor (PlGF)
Kit ligand (Mast cell growth factor) (MGF) (Stem cell factor) (SCF) (c-Kit ligand) [Cleaved into: Soluble KIT ligand (sKITLG)]
Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Piebald trait protein) (PBT) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (p145 c-kit) 
Protransforming growth factor alpha [Cleaved into: Transforming growth factor alpha (TGF-alpha) (EGF-like TGF) (ETGF) (TGF type 1)]
Transforming growth factor beta-1 (TGF-beta-1) [Cleaved into: Latency-associated peptide (LAP)]
Transforming growth factor beta-3 (TGF-beta-3) [Cleaved into: Latency-associated peptide (LAP)]
Vascular endothelial growth factor A (VEGF-A) (Vascular permeability factor) (VPF)
Vascular endothelial growth factor receptor 2 (VEGFR-2) (EC 2.7.10.1) (Fetal liver kinase 1) (FLK-1) (Kinase insert domain receptor) (KDR) 
Vascular endothelial growth factor receptor 3 (VEGFR-3) (EC 2.7.10.1) (Fms-like tyrosine kinase 4) (FLT-4) (Tyrosine-protein kinase receptor FLT4)
Vascular endothelial growth factor D (VEGF-D) (c-Fos-induced growth factor) (FIGF)
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Chapter 3: Proliferation and Differentiation of Young and Old 
Immortalised Human Myoblasts. 
 
3.0 Background 
 
3.0.0 Introduction  
 
The persistent mechanical forces produced by skeletal muscle (SkM) and its corresponding cellular and 
metabolic functions place it at a relatively high risk for injury or damage. This risk is further exacerbated 
by disuse-associated deconditioning, muscle disease, and aging. Although SkM has a remarkable 
capacity for repair and self-renewal, a reduction in functional capacity along with the progressive loss 
of SkM mass manifest in a range of conditions. From simple disuse-induced physiological atrophy, to 
muscular dystrophies (e.g. Duchenne muscular dystrophy), MN conditions (e.g. amyotrophic lateral 
sclerosis), metabolic muscle disorders (e.g. acid maltase deficiency), conditions of the peripheral nerve 
(e.g. Friedreich’s ataxia) NMJ diseases (e.g. myasthenia gravis), neuromuscular myopathies (e.g. 
myotonia congenita), as well as the pathophysiological effects of aging, diabetic neuropathy and 
myopathy, cancer cachexia and heart failure.   
Muscle loss and compromised muscle function are traits universally witnessed in aging mammals. As 
aging occurs, considerable reductions in the regenerative capability of SkM is witnessed. A 1–2% annual 
muscle loss after the age of 50 years old is considered normal human ageing  (Kim and Choi, 2013; 
Kaasik et al., 2012), with those over the age of 80 years old losing upwards of 40% of their SkM mass. 
(McPhee et al., 2013). This progressive age-linked decline of SkM mass, quality, and function is termed 
sarcopenia (Dodds et al., 2015). The advancing loss of SkM also results in remodelling of the muscle 
with increasing connective and adipose tissue (Crane et al., 2010). The underlying mechanisms 
responsible for sarcopenia remain unclear. However, dysregulation of metabolic and hormonal factors, 
along with alterations to the immune system and inflammatory responses, as well as reduced SkM 
protein synthesis in response to nutrient and physical activity stimulus are all considered candidates 
contributing to the development of sarcopenia (Degens, 2010). It has also been indicated that age-
linked reduction in satellite cell (SC) concentration and activation attenuates self-repair of muscle after 
damage induced through physical activity, possibly promoting sarcopenia (Brooks and Faulkner, 1990). 
Typical disuse-induced atrophy of SkM is entirely a consequence of decreased myofibre size, whereas 
SkM loss observed in elderly individuals presenting with sarcopenia have reduced myofibre size along 
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with a reduction in the number of myofibres (Machida and Booth, 2004). Alterations to myofibre 
phenotype are also apparent, predominantly a decrease in fast-twitch (type II) myofibre size and 
number is witnessed (Nilwik et al., 2013), resulting in a muscle composition with greater quantities of 
slow-twitch (type I) myofibres (Gannon et al., 2009). Along with a transitioning fast-to-slow twitch 
myofibre phenotype, dysregulation of motor neuron (MN) denervation and reinnervation leads to an 
increasing net deficit of MN units (Drey et al., 2014). Moreover, aging produces deviations in the 
microenvironment of regenerating SkM, potentially contributing to further reductions in regenerative 
potential of ageing SCs (Dhawan and Rando, 2005). The maintenance and self-reparative capability of 
SkM is implemented through the actions of SCs (Lepper et al., 2011). Thus, the fundamental issue of 
whether SCs from old or young individuals diverge in their intrinsic myogenic function requires 
elucidation.  
To resolve the problem, experiments in this study were conducted by utilising SCs originating from 
young or old SkM to compare the in vitro responses of activated SCs (i.e. myoblasts) when examined 
under standardised conditions. The origin of the immortalised human skeletal muscle cell (SkMC) lines 
used in this study were generated from young myoblasts obtained from a healthy 25-year-old male and 
old myoblasts from a healthy 83-year-old male. Thus, the myoblasts used in this study differ in age by 
roughly six decades. The proliferative capacity, progression of myotube differentiation, and expression 
of proteins indicative of proliferation and differentiation were examined and compared to establish 
any differences in intrinsic myogenic behaviour among young and old myoblasts.  
 
3.0.1 Aims 
 
The hypothesis is immortalised myoblasts originating from young muscle differ in their intrinsic 
myogenic behaviour compared to immortalised myoblasts derived from old muscle. Thus, the aims are: 
 
1. Characterise and compare young and old immortalised human myoblast proliferation. 
 
2. Generate culture conditions for functional differentiation studies of young and old 
immortalised myoblasts. 
 
3. Assess old and young myoblast-to-myotube differentiation in culture.  
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3.1 Results 
 
3.1.0 Myoblast Revival  
 
Two new human SkM cell lines were used for this project, which were not previously employed or 
established in our laboratory (as described in 2.0.0). Therefore, optimisation of culture conditions, such 
as seeding conditions, seeding density, and differentiation conditions were required before further 
studies could be conducted. Individual vials of 25-year-old immortalised human myoblasts (C25) and 
83-year-old immortalised human myoblasts (C83) containing ~1x106 cryogenically preserved cells were 
retrieved from liquid nitrogen storage to compare cellular revival rates between old and young 
myoblasts following cellular passaging by quantifying the differences in adherent cells. Prior to seeding 
the revived cells (as described in 2.1.0), a cell count was performed (as described in 2.1.1) to establish 
a baseline seeding concentration. Following 24 hours incubation with growth media (GM) (Table 2.0), 
both C25 and C83 cells were collected from their respective flasks and counted to determine the 
percentage of adherent cells after seeding. The results showed that there was no significant difference 
(p = 0.31) in the number of baseline seeded cells between C25 (1.08x106 ± 6.1x105 cells) and C83 
(1.11x106 ± 7.5x105 cells) (Figure 3.0). There was also no significant difference (p = 0.97) between the 
number adherent C25 (7.7x105 ± 8x104) and C83 (7.8 ± 9x104) following 24 hours of being seeded in 
GM. However, a significant reduction (P <  0.0001) in the number of adherent cells 24 hours after being 
seeded in GM was observed in both cell lines. There was a 28.4% decrease in the number of adherent 
C25 compared to the number of cells seeded. Similarly, a 30% reduction in the number of adherent C83 
compared to the number of cells seeded was also observed. Thus, indicating a non-significant 1.6% 
difference in revival rate of C25 and C83 following cryogenic passaging of cells.  
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Figure 3.0: Myoblast revival after cryogenic passage. Comparison of the number adherent young and 
old myoblasts to the number seeded following 24 hours of incubation in growth media. Data quantified 
by counting cells in 10 random fields of view from 3 separate wells on each cell culture plate. Data 
presented as a mean, error bars signify ± SD.  n = 4 independent experiments. **** denotes P < 0.0001. 
25-year-old immortalised human myoblasts (C25); 83-year-old immortalised human myoblasts (C83). 
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3.1.1 Myoblast Proliferation 
 
Upon determining no differences between the revival of old and young immortalised myoblasts 
following cryogenic passaging of the cells, the ensuing experiment set out to ascertain any differences 
in  the rate of proliferation between the two cell lines. The cells were seeded in T175 flask as described 
in 2.1.1 and confluence was quantified by calculating the myoblast area of both C25 and C83 (Figure 
3.1). At 24 hours there was no significant difference (P = 0.058), as the myoblast area was 9.1% ± 1.4 
for the young cell line, where as the old cells had a myoblast area of 10.2% ± 1. After 48 hours the 
myoblast area of young proliferating myoblasts was 19% ± 1.5, while old myoblasts had a non-
significantly (P = 0.067) different myoblast area of 20.3% ± 1.4. At 72 hours, the myoblast area of young 
cells had expanded to 50.8% ± 2.3 and the old myoblasts increased to 49.1% ± 1.2, though the 
difference was insignificant as P = 0.063. Similarly, at 96 hours there was no significant difference (P = 
0.066). The proliferating young myoblasts had grown to cover an area of 88.5% ± 1.7, with old 
myoblasts covering a comparable area of 90% ± 1.6.  
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Figure 3.1: Young and old myoblast proliferation. a) The top row of panels are phase contrast images 
representative of young myoblast proliferation. The bottom row of panels are phase contrast images 
representative of old myoblast proliferation. b) A line graph showing the difference in proliferation 
rates between the two cells lines at 24, 48, 72, and 96 hours, quantified as myoblast area. Data 
presented as a mean, error bars signify ± SD.  n = 5 independent experiments. 25-year-old immortalised 
human myoblasts (C25); 83-year-old immortalised human myoblasts (C83). Bar = 100 μm. 
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3.1.2 Myoblast Viability 
 
Both young and old myoblasts were cultured for 96 hrs in T175 flasks at a seeding concentration of 
~1x106 cell in GM, at which point confluence of both C25 and C83 reached ~80-90%. The cells were 
collected and counted to determine any discrepancy in the total number of viable cells after 96 hours 
of proliferation. The results revealed there was no significant difference (P = 0.112) in total number of 
young viable myoblasts (C25 = 7.91x106 ± 6.2x105) compared to the total number of old viable 
myoblasts (C83 = 7.46x106 ± 3.3x105) after 96 hours of proliferation (Figure 3.2).   
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Figure 3.2: Total viable myoblasts. Comparison of the total number of young viable myoblasts to the 
number of old viable myoblasts following 96 hours of incubation in growth media. Data presented as a 
mean, error bars signify ± SD.  n = 3 independent experiments. 25-year-old immortalised human 
myoblasts (C25); 83-year-old immortalised human myoblasts (C83). 
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3.1.3 Optimisation of Myoblast Seeding Density 
 
Before functional studies of myoblast differentiation and development could be conducted, the density 
of myoblasts must be adequately concentrated to allow for cell-to-cell contact. Thus, to achieve an 
optimal cell density of ~90-100% confluence after 24 hours of being seeded in GM, four concentrations 
of C25 and C83 were concurrently cultured in 6-well plates pre-coated with a 1% gelatin solution (as 
described in 2.1.1). The myoblasts were seeded at 5x104 (C1), 1x105 (C2), 1.5x105 (C3), or 2x105 (C4) 
cells/mL. Phase contrast microscopy was used to assess 20 random fields of view at 10X magnification 
and ImageJ software was used to process the images and quantify confluence after 24 hrs by calculating 
the total myoblast area. The myoblast area was calculated for each seeding density to determine the 
percentage of confluence. For C25 the results showed C1 = 50.2% ± 4.3, C2 = 74.9% ± 2.4, C3 = 92.9% ± 
2.5, and C4 = >100%. Similarly, for C83 the results were C1 = 49.9% ± 4.1, C2 = 75.4% ± 2.1, C3 = 95.1% 
± 3.5, and C4 = >100% (Figure 3.3). A concentration of 1.5x105 cell/mL was established as the optimal 
seeding cell density for functional studies in both cell lines. Although the concentration of 2x105 cell/mL 
presented as 100% confluent after 24 hours, the cells were over confluent resulting in abnormal 
morphology and excessive cell detachment from the culture surface and death in both cell lines. 
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Figure 3.3: Optimal cell density for differentiation. a) The left panel is representative of young 
myoblast after 24 hours of being seeded at a density of 1.5x105 cell/mL. The right panel is 
representative of old myoblasts after 24 hours of being seeded at a density of 1.5x105 cell/mL. b) A 
graph showing the difference in confluence between the two cells lines 24 hours after being seeded at 
a density of 5x104, 1x105, 1.5x105, or 2x105 cells/mL, quantified as myoblast area. Data presented as a 
mean, error bars signify ± SD.  n = 3 independent experiments. 25-year-old immortalised human 
myoblasts (C25); 83-year-old immortalised human myoblasts (C83). Bar = 100 μm. 
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3.1.4 Optimisation of Differentiation Media 
 
To achieve optimal differentiation of myoblasts to myotubes in both C25 and C83 cell lines, the 
efficiency of the in-house DM formulation (DM1) (Table 2.1) was compared to the commercially 
available ‘low-serum cell culture medium for differentiation of skeletal muscle cells’ manufactured by 
PromoCell (DM2). The DM1 was also compared with the previously established in-house differentiation 
media for mouse myoblast (C2C12 cell line) differentiation in our laboratory. The C2C12 differentiation 
media (DM3) consisted of 96% Dulbecco’s modified eagle medium (DMEM), 2% horse serum (HS), 1% 
penicillin-streptomycin (Pen/Strep), and 1% L-glutamine. Optimal differentiation was quantified by 
using phase contrast and immunofluorescence microscopy to assess 20 random fields of view at 10X 
magnification and ImageJ was utilised to calculate the fusion index (FI) (Table 2.2).After 24 hours of 
exposure to DM1, DM2, or DM3, cellular fusion was imperceptible in both C25 and C83. After 48 hours, 
the first instances of multinucleated cells (cells with > 2 nuclei) were discernible in both young and old 
cell lines. Thus, FI was quantified 48 hours after the application of the DM formulations to C25 and C83. 
The DM formulation exhibiting the highest percentage of FI in both young and old SkMC lines after 48 
hours was established as optimal for functional studies. The DM1 formulation exhibited the largest 
percentage of FI in C25 with 69.7% ± 2.8 (Figure 3.4). The DM2 displayed a slightly lower, though 
insignificantly different FI percentage of 68% ± 6.3. The C25 cells exposed to DM3 had a FI percentage 
of 55.9% ± 5.8, which was significantly less (P < 0.0001) than both DM1 and DM2. Similarly, DM1 
prompted a FI of 71.75% ± 3.5 in C83 after 48 hours (Figure 3.5). The C83 cells exposed to DM2 also 
had a slightly reduced yet insignificantly different FI of 69.3% ± 3. There was also a significant reduction 
(P < 0.0001) in the FI percentage (56.8% ± 6.7) of C83 after 48 hours of incubation with DM3 compared 
to both DM1 and DM2. 
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Figure 3.4: Optimal differentiation of young myoblasts. a) Image panels are representative of young 
immortalised human myoblasts treated with in-house differentiation media formulation (DM1), 
commercial differentiation media formulation by PromoCell (DM2), or in-house C2C12 differentiation 
media (DM3). The cells were stained for actin with phalloidin (red), differentiated cells with anti-myosin 
heavy chain (green), and nuclei with DAPI (blue). b) Comparison of the percentage of cellular fusion in 
young myoblast when incubated with DM1, DM2, or DM3 after 48 hours. Data presented as a mean, 
error bars signify ± SD.  n = 3 independent experiments. **** denotes P < 0.0001. Bar = 75 µm. 25-year-
old immortalised human myoblasts (C25). 
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Figure 3.5: Optimal differentiation of old myoblasts. a) Image panels are representative of old 
immortalised human myoblasts treated with in-house differentiation media formulation (DM1), 
commercial differentiation media formulation by PromoCell (DM2), or in-house C2C12 differentiation 
media (DM3). The cells were stained for actin with phalloidin (red), differentiated cells with anti-myosin 
heavy chain (green), and nuclei with DAPI (blue). b) Comparison of the percentage of cellular fusion in 
old myoblast when incubated with DM1, DM2, or DM3 after 48 hours. Data presented as a mean, error 
bars signify ± SD.  n = 3 independent experiments. **** denotes P < 0.0001. Bar = 75 µm. 83-year-old 
immortalised human myoblasts (C83). 
 
 
 
 
 
 
 
 
 
67 
 
3.1.5 Differentiation Parameters 
 
To determine if there were any significant differences in the differentiation of young myoblasts to 
myocytes and ultimately myotubes compared to the differentiation of old myoblast, the differentiation 
parameters were calculated using the methods described in 2.1.4 (Table 2.2). Quantification was 
conducted using phase contrast and immunofluorescence microscopy to assess 20 random fields of 
view at 20X magnification and ImageJ was utilised to process the myotube area (MA), FI, and aspect 
ratio (AR) of both cell lines. There was no measurable difference in the differentiation parameters 
between C25 and C83 at 24 hours. Both young and old cell lines exhibited morphology consistent with 
mononucleated myoblasts and myocytes. Thus, the criteria for FI (>2 nuclei per cell), MA, and AR were 
not met, since there was no measurable myotube formation at 24 hours. After 48 hours, there was no 
significant difference (P = 0.09) in the FI of C25 (69.7% ± 3.2) and C83 (67.9% ± 3.3). After 72 hours the 
FI of C25 was 70.1% ± 5.1 with C83 being non-significantly (P = 0.07) higher at 72.8% ± 4.1. Similarly, 
there was no difference (P = 0.16) after 96 hours as the FI of C25 was 83% ± 4.1 and C83 at 84.7% ± 3.3 
(Figure 3.6b). The results of MA comparison at 48 hours between C25 (49.5% ± 4.2) and C83 (50.2% ± 
4.9) revealed no significant difference (P = 0.63). When measured at 72 hours, the MA of C25 was 58.5% 
± 4.2 while the MA of C83 was insignificantly (P = 0.38) higher at 60% ± 4.3. After 96 hours, the MA of 
C25 was measured at 72.4% ± 4.1 and C83 was 70.3% ± 4.4, though the difference was insignificant (P 
= 0.12) (Figure 3.6c). Finally, the AR was compared amongst the cell lines. At 48 hours, the AR was not 
significantly different (P = 0.34) between C25 (20.1 ± 8) and C83 (17.8 ± 7.4). After 72 hours, the AR of 
C25 was 15.4 ± 5.8 and C83 measured at an insignificantly different (P = 0.57) 16.7 ± 8.3. Similarly, there 
was no difference (P = 0.14) after 96 hours as the AR of C25 was 18.5 ± 7.4 and C83 was 14.8 ± 7.8 
(Figure 3.6d).  
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Figure 3.6: Differentiation parameters of young and old myoblasts. a) The upper row of images are 
representative of young myotube morphology during differentiation at 48, 72, and 96 hours. The lower 
row of images are representative of old myotube morphology during differentiation at 48, 72, and 96 
hours. The cells were stained for actin with phalloidin (red), differentiated cells with anti-myosin heavy 
chain (green), and nuclei with DAPI (blue). b) Comparison of the percentage of cellular fusion in old and 
young myoblasts incubated with differentiation media at 48, 72, and 96 hours. c) Comparison of 
myotube area between old and young differentiated myotubes at 48, 72, and 96 hours. d) Comparison 
of aspect ratio at 48, 72, and 96 hours amongst young and old myotubes. Data presented as a mean, 
error bars signify ± SD. n = 5 independent experiments. Bar = 25 µm. 25-year-old immortalised human 
myoblasts (C25); 83-year-old immortalised human myoblasts (C83).  
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3.1.6 Proliferation & Differentiation Marker Expression 
 
Protein expression was assessed to identify the differences in the proportional decline of proliferative 
myoblasts and the upregulation of differentiating myotubes during the preliminary stages of young and 
old myoblasts differentiation. The expression of the proliferative antigen Ki67 (Scholzen and Gerdes, 
2000), which is strictly associated with cell proliferation and is only present during the active phases of 
the cell cycle (i.e. G1, S, G2 and M), and absent in resting cells (G0) (Hooghe et al., 2008; Shirendeb et 
al., 2009), was used as a the marker of proliferation in the skeletal muscle cells (SkMCs).  Declines in 
Ki67 levels occur in later phases of mitosis (during anaphase and telophase) (Modlin et al., 2008). Thus, 
Ki67 expression is associated with the proliferative activity of intrinsic cell populations. Using the 
methods detailed in 2.1.4, the expression of Ki67 and the expression of myosin heavy chain (MHC), a 
marker of terminal differentiation in SkMCs (Schiaffino et al., 1986), were quantified and compared at 
24, 48, 72, and 96 hours after cultured C25 and C83 were switched from GM to DM. 
Immunofluorescence microscopy was used to assess 20 random fields of view at 20X magnification. 
ImageJ was used to calculate the percentage of Ki67 expression and the percentage of MHC expression 
in both cell lines. Following 24 hours exposure to DM, 69.5% ± 6.6 of young myoblasts were positive 
for Ki67 (Figure 3.7) and devoid of any MHC expression. Expression of Ki67 in old myoblasts was similar 
(P = 0.65) at 70.4% ± 6.2 with no MHC expression as seen in the young myoblasts. After 48 hours, C25 
expression of Ki67 decreased to 29.7% ± 6.6. A similar decrease (P = 0.57) was observed in C83, which 
decreased Ki67 expression to 31% ± 6.1. The expression of MHC had increased to 49.3% ± 3.6 in young 
cells and 51.2% ± 4.3 in old cell (Figure 3.8), though this difference was insignificant (P = 0.15). Following 
72 hours of incubation with DM, expression of Ki67 in young cells decreased further to 2.6% ± 1.2. 
Expression of Ki67 also decreased in old cells to 2.8% ± 1.1, though this difference was insignificant (P 
= 0.58). An insignificant difference (P = 0.08) in MHC expression was also observed between the cell 
lines after 72 hours. Young cells increased MHC expression to 61% ± 4.3, while old cells expressed MHC 
at a similar 63.6% ± 4.8. Following 96 hours of DM exposure, the expression of Ki67 was measured at 
0.5% ± 0.3 in the young cells and a similar (P =0.6) 0.41% ± 0.3 in old cells. There was also no significant 
difference (P = 0.31) in the expression of MHC between the cell lines. As C25 expressed MHC at 79% ± 
5 and C83 expression of MHC was 77.3% ± 5.7.  
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Figure 3.7: Expression of proliferation marker Ki67. a) The upper image panels are representative of 
Ki67 expression in young myoblasts as they differentiate to myotubes at 24, 48, 72, and 96 hours after 
exposure to differentiation media. The lower row of images are representative of Ki67 expression in 
old myoblasts as they differentiate to myotubes at 24, 48, 72, and 96 hours after exposure to 
differentiation media. The cells were stained for Ki67 (red). b) A line graph showing the percentage of 
cells positive for Ki67 between both cell lines at 24, 48, 72, and 96 hours. Data presented as a mean, 
error bars signify ± SD. n = 4 independent experiments. Bar = 50 µm. 25-year-old immortalised human 
myoblasts (C25); 83-year-old immortalised human myoblasts (C83). 
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Figure 3.8: Expression of differentiation marker myosin heavy chain. a) The upper image panels are 
representative of myosin heavy chain (MHC) expression in young myoblasts as they differentiate to 
myotubes at 24, 48, 72, and 96 hours after exposure to differentiation media. The lower row of images 
are representative of MHC expression in old myoblasts as they differentiate to myotubes at 24, 48, 72, 
and 96 hours after exposure to differentiation media. The differentiated cells with anti-myosin heavy 
chain (green), and nuclei with DAPI (blue). b) A line graph showing the percentage of cells positive for 
MHC between both cell lines at 24, 48, 72, and 96 hours. Data presented as a mean, error bars signify 
± SD. n = 4 independent experiments. Bar = 50 µm. 25-year-old immortalised human myoblasts (C25); 
83-year-old immortalised human myoblasts (C83). 
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3.2 Discussion  
 
The primary findings of this research demonstrated that immortalised human myoblasts originating 
from old or young muscle did not influence their in vitro function when cultured in matching 
microenvironments. This was determined through the analysis of various experiments including cellular 
passage of myoblasts, myoblast proliferation and differentiation, as well as the expression of markers 
demonstrating proliferative and differentiation capacity in young and old myoblasts. The passaging and 
revival of both young and old myoblasts from cryogenic suspension resulted in a net loss of viable cells 
that were able to adhere to the tissue culture surface and begin the process of proliferation. Although 
there was a significant loss of cells from the quantity seeded to the number that adhered when 
passaging cells, the numbers of myoblasts that were able to adhere and begin proliferating did not 
differ between the old and young cell lines. As serial passaging is unavoidably necessary for in vitro 
investigations of SkM formation and development, experiments moving forward were conducted with 
old and young myoblasts passaged an equal number of times to nullify any passage-induced variability 
among the cell lines. Various studies and subsequent cell line handling and utilisation guidelines have 
shown that serial passaging of cell lines can induce alterations in cell morphology and function 
(Geraghty et al., 2014). The C2C12 mouse myoblast cell line, which is one of the most commonly used 
cell line for in vitro investigations of SkM, has been shown to have dysfunctional apoptotic response 
when excessively serial passaged (Pronsato et al., 2013). This phenotypic drift may lead to the same 
cell line differing significantly between researchers and laboratories, making it difficult to distinguish 
between experimental treatments and intrinsic cellular mechanisms. Thus, to mitigate any unintended 
comparable morphological and functional changes in the two human immortalised SkMC lines used 
throughout this project, all forthcoming experiments were conducted with matched low number (< 4) 
passaged young and old myoblasts. To ascertain differences in the proliferative capacity of young and 
old myoblasts both the SkMC lines were first expanded following revival from cryogenic suspension. 
The proliferation of C25 and C83 were comparable over a period of 96 hours, with no statistical 
difference in the number of viable cells upon elimination of proliferative conditions. The expansion of 
both cell lines yielded a comparable ~10-fold increase of viable cells after 96 hours, indicating the 
intrinsic capacity for proliferation of early passaged immortalised human myoblast is not determined 
by the age of the donors muscle tissue. Research conducted with primary human myoblasts have 
similarly found that the mean population doubling of cells was not influenced by the age of the 
myoblast donor, as the replicative lifespan of both young and elderly primary myoblasts was found to 
be similar before replicative senescence occurs (Pietrangelo et al., 2009; Decary et al., 1997). However, 
the proliferative capacity of myoblasts in vitro is regulated by complex biochemical interactions, which 
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require significant elucidation before being fully understood. Next, both young and old cell lines were 
differentiated using three variations of DM. The standard in-house DM formulation (DM1) (Table 2.1) 
was tested for efficacy against a commercial serum free media formulated for primary myoblast 
differentiation (DM2) and a serum containing media used to differentiate C2C12 myoblasts (DM3). It 
was discovered that both the serum free formulations, DM1 and DM2, performed equally to induce 
cellular fusion after 48 hours of the myoblasts being incubated with the media. Various low serum 
containing DM formulations have been used to induce the differentiation of C2C12 myoblasts, with 
some studies using up to 5% FBS (Katagiri et al., 1994) and other experiments using as low as 1% FBS 
(Yoshiko et al., 2002). Thus, the standard low serum (2% horse serum) DM media formulation formerly 
used in our laboratory to induce differentiation in C2C12 myoblasts (DM3) (Al-Dabbagh et al., 2015) 
was tested for its ability to differentiate human myoblast. Although DM3 was able to induce an 
objective degree of differentiation in C25 and C83 (Figure 3.4, 3.5), myotube formation was 
morphologically abnormal and underdeveloped. Manifesting as smaller myotubes with a lower 
concentration of myonuclei. Interestingly, it has been demonstrated that that C2C12 differentiation is 
dependent on endogenous insulin-like growth factor expression and not on serum concentration 
(Yoshiko et al., 2002). These data demonstrated that DM1 was the most suitable for functional 
experiments of human myoblast-to-myotube differentiation. Once optimal DM conditions were 
determined, C25 and C83 were incubated with DM (Table 2.1) and the differentiation parameters along 
with proliferation/differentiation marker expression were evaluated every 24 hours over a 4-day 
period. The data in Figure 3.6 show no difference in myotube size when myoblasts from young or old 
muscle were differentiated. Additionally, regardless of myoblasts being young or old they displayed 
strikingly similar morphological behaviour in culture. This was also exhibited by C25 and C83 having a 
comparable ability to undergo cellular fusion, indicated by MHC expressing cells having similar 
concentrations of myonuclei between the cell lines throughout the process of differentiation. The Ki67 
protein is a cellular marker strictly associated with cell proliferation. (Scholzen and Gerdes, 2000). Thus, 
Ki67 is exclusively detected within the cell nucleus during interphase with most of the protein relocated 
to the surface of the chromosomes during mitosis (Cuylen et al., 2016). Furthermore, Ki67 is observed 
during all active phases of the cell cycle (G1, S, G2, and mitosis) and absent in non-proliferating cells 
(G0) (Bruno and Darzynkiewicz, 1992). The content of Ki67 in cells is also markedly increases during cell 
progression through S phase of the cell cycle (Darzynkiewicz et al., 2015) The data in Figure 3.7 showed 
the relative decline in the expression of Ki67 in young and old myoblasts incubated with DM was 
unaffected by the age of the donor myoblasts. The inverse increase of MHC expression also revealed 
young and old myoblasts express the differentiation marker in equal proportion when differentiated. 
The findings of this study suggest no intrinsic age-associated deficits in myogenic function between 
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young and old immortalised human myoblasts when cultured in identical microenvironments in vitro. 
This data is largely consistent with established in vitro SkM research. Experimentation with satellite 
cells (SCs) harvested from 3-month-old (young) and 32-month-old (old) rats were cultured in vitro and 
found to have comparable rates of proliferation and differentiation (Dumke and Lees, 2011). Similarly, 
in vivo single fibre engraftment assays reveal that SCs from old myofibres possess a regenerative and 
self-renewal capacity comparable to young myofibre-linked SCs (Collins et al., 2007). Interestingly, 
studies have shown that muscle from aged mice was estimated to contain around 65% fewer 
functioning SCs than muscle from young mice (Cosgrove et al., 2014) and the overall number of SCs 
was also lower in aged mouse muscle (Chakkalakal et al., 2012). However, this was not the main cause 
of age-linked muscle loss, at least not in mice, where induced depletion of SCs in young adults had little 
impact on the rate of muscle ageing (Fry et al., 2015). There is strong evidence implicating the aged 
microenvironment with reduced SC responses (Barberi et al., 2013; Chakkalakal et al., 2012). 
Transplanted muscle from young into old mice fails to regenerate, but transplanted muscle from old 
mice into a young mouse did regenerate (Carlson and Faulkner, 1989) but might have a delayed 
regenerative response (Smythe et al., 2008). Moreover, ‘rejuvenating’ the microenvironment in older 
mice enhanced activation of SCs through increased Notch signalling, as shown in heterochronic 
parabiosis models (Conboy et al., 2003; Conboy et al., 2005; Carlson et al., 2008). Furthermore, lower 
SC function with ageing was linked to increased activity of the transforming growth factor beta (TGFβ) 
family of molecules within SCs that are negative regulators of growth and restrict the proliferative 
responses (Carlson et al., 2009; Sousa-Victor et al., 2014; Yousef et al., 2015). Circulating soluble factors, 
such as hormones, or other molecules released locally into the microenvironment may influence the 
intracellular SC signalling to regulate proliferative and differentiation responses. For example, elevating 
the circulating oxytocin had rejuvenating effects for SCs (Elabd et al., 2014); increasing circulating levels 
of growth differentiation factor 11 (GDF-11) also rejuvenated SCs (Sinha et al., 2014). However, 
alternative research investigating the effect of GDF-11 on myogenesis observed a significant inhibition 
of SkM regeneration (Brun and Rudnicki, 2015). Additionally, elevated levels of osteopontin in aged 
mice was associated with impaired SC responses to damage and this was overcome by reducing 
osteopontin in vitro and in vivo (Paliwal et al., 2012). Thus, a key detail, which has not yet been fully 
understood, is how the SCs respond to the rapidly changing microenvironment occurring soon after 
muscle damage, which is heavily influenced by the infiltrating immune cells (reviewed by the author of 
this thesis in (Saini et al., 2016)). Furthermore, some studies have also shown that geriatric mice were 
able to regenerate muscle autographs similar to whole muscle grafts transplanted between 27-29 
month-old (geriatric) and 3-month-old (young) mice irrespective of the observed preliminary delay in 
myogenesis activation (Shavlakadze et al., 2010). Research with human SCs from old donors (> 76-
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years-old) transplanted into young mice has also revealed that aged human SCs can appropriately 
supply their myonuclei to facilitate regeneration of in vivo mouse muscle (Schafer et al., 2006). 
Furthermore, it has been suggested that the reduction of SC migratory function observed in old mice is 
not the underlying factor for the diminished in vivo regeneration of muscle (Collins-Hooper et al., 2012). 
Investigations of human SCs in old muscle being activated via physiological stimuli have found the 
activation to be adequate for muscle regeneration (George et al., 2010). These findings indicate 
signalling pathways required for SC activation function correctly, however, significant investigation of 
SC activity in vivo is still required to explain SC behaviour completely. In opposition to the findings of 
this study, alternative research has indicated age-linked alterations in the proliferation and 
differentiation of primary human myoblasts, though it is important to note some studies provide 
limited data as only a single young and old donor were compared (Lorenzon et al., 2004; Fulle et al., 
2005; Jacquemin et al., 2004). Additionally, some studies compare young and old SC populations that 
have varying desmin expression. This variable desmin expression may influence myogenic potential 
thus altering differentiation capacity of young and old myoblasts regardless of age (Pietrangelo et al., 
2009; Beccafico et al., 2007). Ultimately, several reports attribute the loss of in vivo myoblast 
regenerative capacity in SkM to changes in the local microenvironment and not the SCs themselves. 
Meaning young and old myoblasts are intrinsically similar, but what makes them ‘old’ or ‘young’ is their 
microenvironment.   
 
3.3 Conclusions 
 
In conclusion, in vitro cell culture conditions were successfully generated and optimised to assess the 
proliferation and differentiation of young and old immortalised human myoblast. It was discovered 
proliferative capacity, decline of proliferative markers, differentiation progression and marker 
expression were indistinguishable between myoblasts that have a ~60-year age difference when 
cultured in duplicate culture microenvironments.  
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Chapter 4: A Novel System of Immortalised Human Myoblasts Co-
cultured with Rat Embryonic Spinal Cord Explants  
 
4.0 Background 
 
4.0.0 Introduction  
 
The previous chapter examined the differences between young and old immortalised human myoblasts 
and established immortalised human myoblasts maintain their myogenic potential in vitro, regardless 
of age. These findings were consistent with similar research with primary myoblasts obtained from 
young and old donors (Alsharidah et al., 2013). Therefore, the decision was made for the impending 
research to be conducted with the 25-year-old immortalised human myoblasts (C25) only, as there was 
no distinguishable difference between the old and young myoblast cell lines. However, the capability 
of aneurally-cultured myoblasts to provide insight into neuromuscular (NM) disorders is limited due to 
the lack nervous input, which does not accurately reflect the physiological conditions observed in vivo. 
Classic research has demonstrated that monocultures of primary human myoblasts almost never 
spontaneously contract and the lack of motor neuron (MN) stimulation inhibits advanced 
differentiation of myotubes (Delaporte et al., 1986), which puts limitations on in vitro investigations of 
NM disease in cultured skeletal muscle cells (SkMCs). To overcome these limitations a novel in vitro 
nerve-muscle co-culture model could provide a system for investigating NM disorders. The essential 
requirement of such a system would be the formation of de novo neuromuscular junctions (NMJs) on 
cultured human myotubes, due to the NMJ being the crucial synapse regulating motor unit function 
and dysfunction. The importance of the NMJ in relation to NM disease has been shown in amyotrophic 
lateral sclerosis (ALS) studies where destabilisation of the NMJ is one of the early detectable signs of 
the disease. Similar observations have been made in other NM diseases, which suggest insults to the 
NMJ are more closely linked to disease progression than the death and loss of MNs (Murray et al., 2008; 
Fischer et al., 2004; Gould et al., 2006). While degeneration of the NMJ plays a fundamental role in the 
pathology of NM disease, as well as diseases not traditionally thought of as NM disorders such as 
diabetes, which leads to diverse forms of peripheral neuropathy as the major NM complication (Bril, 
2014). The existing methods to investigate the specific contribution of degenerated NMJs to the 
aetiology of NM diseases are limited. The majority of in vivo models established to explore NM disease 
are animal models that do not adequately replicate disease in humans (van der Worp et al., 2010). 
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Furthermore, typical in vitro models of NM disease are generally established using animal derived cells 
(Haase, 2006; Prather et al., 2013). As mentioned previously, in vitro models of NM disease with human 
SkMC monolayers lack the functional innervation required for NMJ formation and advanced muscle 
differentiation (Suuronen et al., 2004; Ashby et al., 1993; Wilson and Harris, 1993). Given the 
importance of SkMC innervation and formation of NMJs in the differentiation, maturation and function 
of SkM, systems and techniques that enable the analysis and manipulation of NMJs have the potential 
to enrich our understanding of NM disease pathogenesis. Furthermore, such a system may provide a 
platform to test new therapies. Some nerve-muscle co-culture models generated with mouse, rat, 
primary human myoblasts, human embryonic stem cells (hESCs) and human induced pluripotent stem 
cells (hiPSCs)-derived cells, as well as cross species systems have been established to address this 
problem (Umbach et al., 2012; Arnold et al., 2012; Demestre et al., 2015; Guo et al., 2014; Harper et 
al., 2004). However, such co-culture models suffer from inadequate experimental reproducibility, 
attributable to the intricate nature of the culture system requiring an array of growth and neurotrophic 
factors. Furthermore, serum utilised in classically established nerve-muscle co-culture systems (Giller 
et al., 1973; Nelson et al., 1993; Li et al., 2001; Daniels et al., 2000; Dutton et al., 1995) introduces 
indeterminate variables due to differences in serum composition that diminishes experimental 
reproducibility and may even disturb the influence of experimental treatments on the system. 
Therefore, the addition of serum into a co-culture system makes describing the minimum factors 
required for the generation of in vitro NMJs impractical. In fact, there is some evidence that retarded 
MN myelination in vitro may well be the consequence of serum in the culture system (Rumsey et al., 
2009). Co-culture models employing primary human SkM SCs (i.e. primary myoblasts) acquired from 
muscle biopsy have their own limitations, as they have a limited proliferative capacity, poor cell purity 
and exhibit cellular senescence due to cell expansion (Mouly et al., 2005; Webster and Blau, 1990). 
Advances in the application of cells derived from hESCs and hiPSCs to generate myoblasts (Tanaka et 
al., 2013) and MNs (Stockmann et al., 2013) may overcome part of these limitations. Nevertheless, 
besides the ethical issues of using hESCs, monocultures of stem cell-derived MNs are notoriously fragile 
in culture and require multifarious culture media formulations with mandatory neurotrophic and 
growth factors. Consequently, when co-cultured with myoblasts these trophic factors negatively affect 
SkMC differentiation. Furthermore, co-cultures of myoblasts with stem cell-derived MNs produce poor 
NMJs that are not viable for long-term studies of NMJ maturation and maintenance (Li et al., 2005). 
Thus, the use of immortalised human myoblasts in a co-culture model offers several advantages, such 
as reduced cost, ease of use, and provide an unlimited supply of material and minimise ethical concerns 
associated with the use of human tissue. Cell lines also provide a pure population of cells, which is 
valuable since it provides a consistent sample and reproducible results (Kaur and Dufour, 2012).  
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4.0.1 Aim 
 
The objective of the present study was to establish a novel simplified and easily reproducible nerve-
muscle co-culture system generating contractile myotubes and formation of NMJs. Thus, the aim was:  
 
1. Generate co-culture conditions free from serum and growth/neurotrophic factors for ED 
13.5 rat embryo spinal cord explants to innervate young immortalised human myoblasts 
during differentiation of myoblasts to myotubes.  
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4.1 Results 
 
4.1.0 Isolation of Embryonic Rat Spinal Cord  
 
Spinal cords from embryonic rats were selected and isolated as the source tissue of MNs using the 
methods described in 2.1.6 to innervate C25 in the co-culture system. Rats were chosen over mice as 
they are genetically, physiologically morphologically closer to humans than mice and provide 
substantially more material for high throughput tissue culture experimentation than mice (Zhao et al., 
2004). Additionally, microdissection of rat embryos is less technically challenging than mouse embryo 
dissection, streamlining the co-culture system for ease of reproducibility. Harvesting embryos from a 
pregnant rat when the embryos were ED 13.5 results in a yield of 13 ± 3 embryos. Each embryo was 
observable as individually compartmentalised protrusions along the uterine horn (Figure 4.0).  
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Figure 4.0: Isolation of embryos from rat. The upper left panel shows a sacrificed pregnant rat before 
extraction of the uterus, the white arrow indicates the incision site. The lower left panel indicates an 
exposed segment of the uterine horn after dissection of the sacrificed rat, highlighted by the white 
arrow. The right panel displays individual compartmentalised sections of the uterine horn during 
extraction of the uterus, each containing a single embryo; four examples are highlighted with white 
arrows.    
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Upon retrieval of the uterus, the segmented embryo compartments were individually cleaved from the 
uterine horn. A transverse incision made along the outer membrane of the embryo compartment 
resulted in the release of internal pressure and expelling of the amniotic fluid along with the embryo. 
The utilisation of 21 gauge hypodermic needles as dissection tools resulted in precision isolation of the 
spinal cord from the other tissues of the body, while allowing dorsal root ganglions (DRGs) to remain 
attached to the ventral horn. Transversely slicing the intact spinal cord into segments of 1-2 mm2 
explants provided 5 ± 1.5 spinal cord explants (SCEs) per embryo (Figure 4.1). Therefore, one pregnant 
rat yielded 65 ± 35 SCEs for each experiment.  
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Figure 4.1: Isolation of spinal cord from ED 13.5 rat embryo. The upper left image panel displays an 
individually cleaved compartmentalised section of the uterine horn, which contains a single rat embryo. 
The upper middle panel shows the embryo (white arrow) being released from the uterine 
compartment, highlighted with the black arrow. The image panel on the upper right is representative 
of an isolated ED 13.5 rat embryo. The head of the intact embryo is highlighted with the white arrow 
and the spinal cord is shown between the two red lines. The lower left panel shows a dissected intact 
spinal cord. The dorsal root ganglions are located between the red lines as they flank both side of the 
ventral horn, shown between the blue lines. The lower right panel is representative of 1-2 mm2 spinal 
cord explants cut from the intact spinal cord. The white arrows show four individual explants. 
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4.1.1 Viability of Spinal Cord Explants  
 
Before functional studies of nerve-muscle co-cultures could be conducted, the viability of SCEs cultured 
in SkMC DM (Table 2.1) were evaluated. The SCEs were plated and cultured for 24 hours in 6-well plates 
pre-coated with a 0.5% gelatin solution using the methods for SkMC culture detailed 2.1.1. Viability 
was confirmed if SCEs were able to adhere with the culture surface and sprout neurites within 24 hours 
of being plated (Figure 4.2). Phase contrast microscopy at 10X magnification was used to assess the 
percentage of adherent and sprouting SCEs. Following 24 hours of incubation, the results showed that 
92% ± 8 of the plated explants were able to adhere with the culture surface. However, only 85% ± 9 of 
the explants attached and sprouted spinal outgrowths within 24 hours.  
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Figure 4.2: Viability of spinal cord explants in differentiation media. The upper left panel shows freshly 
isolated spinal cord explants in a 150 mm dish before being plated in 6-well plates, explants are 
encircled in white. The upper right image shows explants, circled in white, being plated onto the tissue 
culture surface immediately following isolation. The panel on the lower left exemplifies spinal cord 
explant adherence with the tissue culture surface after 24 hours of incubation. The lower right panel is 
a magnified image of a single spinal cord explant sprouting neurites after 24 hours. Examples of 
substantial sprouting are highlighted in the white boxes.  
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4.1.2 Validation of Neuron Proliferation 
 
To verify the sprouting projections emerging from the SCEs were indeed neurons suitable for in vitro 
innervation of SkM myotubes, the methods detailed in 2.1.12 and 2.1.13 for immunocytochemistry 
(ICC) were applied to the cultured SCEs 72 hours after plating on the culture surface to detect protein 
expression indicating neuronal growth. The microtubule cytoskeletal element Class III β-tubulin (β-III-
tubulin) is concentrated almost entirely in neurons (Sullivan and Cleveland, 1986; Caccamo et al., 1989) 
and prominently expressed during embryonic and postnatal development (Katsetos, Legido, et al., 
2003). Making it an ideal target protein to identify neuronal growth, which has also been used to 
identify neurons in previous in vitro studies (Katsetos, Herman, et al., 2003). The use of 
immunofluorescence microscopy at 10X magnification resulted in the observation that neurite 
projections emerging from the SCEs do in fact express β-III-tubulin, verifying the proliferation of 
neurons emerging from the SCEs (Figure 4.3). 
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Figure 4.3: Neuronal outgrowth originating from ED 13.5 rat embryo spinal cord explant. A 
representative image of a cultured spinal cord explant (SCE) 72 hours after plating. The SCE is visible at 
the bottom of the image highlighted with a red star. Neurites were observed sprouting outward from 
the SCE. Stained for β-III-tubulin (green). Scale bar = 100 µm. 
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4.1.3 Characterisation of Co-culture Morphology 
 
Upon confirmation of SCE viability in culture and their ability to generate β-III-tubulin+ neurons suitable 
for the innervation of SkMCs, the preliminary requirements for nerve-muscle co-culture were attained. 
Therefore, C25 were co-cultured with SCEs from ED 13.5 rat embryos using the methods described in 
2.1.7 and 2.1.8 to induce functional innervation of differentiated myotubes and establish NMJ 
formation. A morphological assessment of the co-cultures was performed at 24, 48 and 72 hours after 
plating the explant with the myoblasts (Figure 4.4). At 24 hours, myoblasts fusion was absent and the 
cells displayed typical characteristics of mononucleated myocytes, indicating the cells were still in the 
initial stage of differentiation (Figure 4.4a). Successfully adhered explants sprouted neurites and 
expanded over the myocytes, exhibiting growth of 420 µm ± 36 emanating from the explant after 24 
hours. If explants did not adhere to the myoblasts and initiate neurite sprouting by 24 hours, they were 
removed from the culture. At 48 hours, obvious myocyte-to-myotube differentiation had commenced 
and neurite length expanded further to 962 µm ± 57 (Figure 4.4b). After 72 hours, neurite growth 
expanded to 1503 µm ± 148, with progressive myotube maturation (Figure 4.4c). Importantly, 
connections of neuronal axon terminals with myotubes were visible (Figure 4.4d) and the first 
spontaneous contractions of individual myotubes were observed. This provides initial confirmation that 
the immortalised human myoblasts were innervated by neurons from rat embryo SCEs after as little as 
3 days of co-culture. 
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Figure 4.4: Young immortalised human skeletal muscle cells co-cultured with ED 13.5 rat embryo 
spinal cord explants. a) Phase contrast image of a spinal cord explant (SCE), highlighted with the orange 
star, sprouting neurites (shown in enlarged inset) after 24 hours over undifferentiated myocytes. Scale 
bar = 100 µm. b) Multinucleated myotube formation (indicated with yellow lines) after 48 hours with 
continued expansion of neural projections (shown in enlarged inset) emanating from the spinal cord 
explant (orange star). Scale bar = 100 µm. c) Maintained neurite growth (shown in inset) and continued 
myotube formation (yellow lines) at 72 hours. Scale bar = 100 µm. d) Neuronal axons (pink arrows) 
form a visible link (circled in red) with a myotube (green arrow) at 72 hours. Scale bar = 25 µm. 
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To determine if the first observable occurrences of myotube contractions (at 72 hours) in the co-culture 
system were due to neuron-induced morphological changes to myotubes, the myotube differentiation 
parameters were measured (Table 2.2). Phase contrast microscopy was utilised to quantify any 
significant differences in the differentiation of aneurally cultured and co-cultured myoblasts after 72 
hours of incubation. Co-localisation of neuron axon terminals with differentiated myotubes were 
observed in the co-cultures (Figure 4.5a). Whereas aneurally cultured SkMCs (Figure 4.5b) display 
visually similar myotube differentiation without neurons. The fusion index (FI) did not significantly 
differ between the co-cultured and aneural cells (86.2% ± 4.6 vs. 86.8% ± 5.1, P = 0.846, Figure 4.4c). 
Additionally, no difference was detected between the myotube area (MA) of both culture 
environments (66.3% ± 3.9 in co-culture vs. 69.2% ± 7.3 for aneural culture. P = 0.458, Figure 4.4d). 
Indicating differentiation of myotubes at this time point of development occurs autonomously from 
neural input. Finally, myotube hypertrophy was determined by evaluating the aspect ratio (AR). Both 
culture conditions exhibited no difference in the AR of co-cultured cells (10.8 ± 8.3) vs. aneural cultures 
(9.9 ± 8.9, P = 0.881, Figure 4.4e). 
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Figure 4.5: Differentiation parameters of aneural and co-cultured skeletal muscle cells at 72 hours. a) 
A representative image of co-culture morphology; neuronal axons (pink arrows) making contact (circled 
in red) with myotubes (green arrows). b) The image panel displays morphology of aneurally-cultured 
myotubes at 72 hours. c) Comparison of the percentage of cellular fusion in co-cultured and aneurally-
cultured myotubes at 72 hours. d) Comparison of the myotube area in co-cultured and aneurally-
cultured myotubes at 72 hours. e) Comparison of the aspect ratio in co-cultured and aneurally-cultured 
myotubes at 72 hours. Data presented as a mean, error bars signify ± SD.  n = 3 independent 
experiments. Bar = 75 µm. 
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4.1.4 Spontaneous Myotube Contractions 
 
The earliest contractions free of any external stimuli were observed in myotubes approximately 72 
hours after co-culturing ED 13.5 rat embryo SCEs with C25. The co-cultures that had robust explant 
adherence with the myoblasts produced myotubes with contractile functionality, as long as 
atmospheric conditions were maintained at 37°C with a 5% CO2. Even though co-cultures generated 
contracting myotubes observable within the first 72 hours, only individual arrhythmically contracting 
myotubes were perceived at this time point, with myotubes closest to the explant having the most 
frequent and forceful contractions. The co-cultures were monitored every 24 hours after witnessing 
the first contractions and maintained with regular media changes to promote further innervation, and 
continued maturation of myotubes. The co-cultures exhibited increasing myotube contraction 
frequency (CF), which was defined by the number of myotube contractions per minute, and an increase 
in the number of contracting myotubes. By co-culture Day 7, the myotubes were contracting 
continuously in a systematic pattern as large networks (Video 1). Suggesting myotube contractions 
functioned as a single motor unit receiving bursts of stimulation from MNs. However, multiple points 
of innervation were still visible on individual myotubes at this stage. Interestingly, contracting 
myotubes also took on the morphological characteristics of three-dimensional tubes whereas aneural 
myotubes maintained a flat two-dimensional morphology, firmly fixed to the culture plate surface. 
 
 
 
Video 1: Phase contrast video micrograph of young immortalised human myotube contractions at 
Day 7. Illustrative video of co-cultured myotubes spontaneously contracting as a network, devoid of 
serum, growth/neurotrophic factors, and external stimulus. Video captured at 24 frames per second. 
Bar = 100 µm. https://www.youtube.com/watch?v=Wg2is-SDdkE (Saini et al., 2019). 
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4.1.5 Spinal Cord Explant Co-culture vs Disassociated Spinal Cord Co-culture  
 
To ensure optimal innervation of co-cultured myotubes, the efficiency of SCEs to induce contractions 
in the co-culture system was compared to myotubes co-cultured with disassociated spinal cord (DSC) 
cell suspensions, generated using the methods described in 2.1.10. The co-culture of myoblasts with 
DSC cell suspension was compared against SCEs due to disassociated cell suspension co-cultures being 
an established alternative to explant co-cultures (E Thomson et al., 2006). Optimal innervation of 
myotubes was quantified by analysing CF every 24 hours post co-culture for 7 days, using live phase 
contrast microscopy to assess 20 random fields of view at 10X magnification. The results revealed no 
observable myotube contractions in either SCEs or DSCs co-cultured with myoblast after the first 48 
hours. Following 3 days of co-culture, initiation of myotube contractions were observable in the SCE 
co-cultures, contracting at a frequency of 0.18 Hz ± 0.09, no contractions were witnessed in the DSC 
co-cultures. On day 4, the myotubes in the SCE co-cultures increased CF to 0.43 Hz ± 0.24; no 
contractions were witnessed in the DSC co-cultures. The first measurable contractions in the DSC co-
cultures were seen on day 5, contracting at a frequency of 0.13 Hz ± 0.08. However, this was 
significantly less (P < 0.0001) than the myotubes contracting in the SCE co-cultures, which increased CF 
further to 0.87 Hz ± 0.38. On day 6, SCE co-cultures were contracting at 1.04 Hz ± 0.36 and DSC co-
cultures were contracting a significantly reduced (P < 0.0001) rate of 0.22 Hz ± 0.15. The myotubes in 
the SCE co-cultures has increased CF further on day 7 to 1.15 Hz ± 0.35. Whereas myotubes in the DSC 
co-cultures were contracting at a significantly reduced (P < 0.0001) rate of 0.38 Hz ± 0.14 (Figure 4.6). 
After confirming co-cultured SCEs are more efficient than DSC cell suspension at inducing myotube 
contractions, subsequent co-culture experiments where conducted with SCEs.  
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Figure 4.6: Contraction frequency in myotubes co-cultured with spinal cord explants or disassociated 
spinal cord cell suspension over 7 days. A line graph comparing the onset of myotube contractions and 
contraction frequency in young immortalised human myoblasts co-cultured with spinal cord explants 
(SCEs) or disassociated spinal cord (DSC) cell suspension, generated from ED 13.5 rat embryos. Data 
presented as a mean, error bars signify ± SD.  n = 6 independent experiments. **** denotes P < 0.0001. 
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4.1.6 Expression of Rat Agrin 
 
Neural agrin is a large (∼400–600 kDa) heparan sulphate proteoglycan and is a prerequisite for NMJ 
formation. The release of agrin by motor neuron terminals (MNT) at the developing NMJ signals the 
transcription of select genes in the synaptic myonuclei to aggregate and stabilise postsynaptic 
acetylcholine receptors (AChRs) during synapse formation (Sanes and Lichtman, 2001). Accordingly, 
the methods described in 2.1.11 were applied and quantitative analysis was performed to verify the 
presence and concentration of agrin secreted in the SCE/myoblast co-cultures compared to SCE only 
cultures and myoblast only cultures. The concentration of agrin was measured at 72 hours with a rat 
agrin enzyme-linked immunosorbent assay. The results showed agrin expression in the co-cultured 
conditions was 1126 pg/mL ± 225, which was significantly higher (P = 0.04) than the agrin 
concentration in SCE only cultures (901 pg/mL ± 377) and the myoblast only cultures, which did not 
exhibit any measurable concentration of rat agrin.  
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Figure 4.7: Concentration of rat agrin after 72 hours. A bar graph showing the concentration of rat 
agrin expressed in co-cultures of 25-year-old immortalised human myoblasts (C25) with spinal cord 
explants (SCEs) from ED 13.5 rat embryos compared with SCE only cultures and aneural C25 cultures. 
Data presented as a mean, error bars signify ± SD.  * denotes P < 0.05; **** denotes P < 0.0001. 
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4.1.7 Preliminary Neuromuscular Junction Formation 
 
The finding that agrin was indeed secreted by SCEs in the co-culture system and when cultured alone 
suggested that the co-culture system possessed the obligatory agrin needed for AChR clustering and 
NMJ formation (Wu et al., 2010; Tintignac et al., 2015). Thus, the subsequent experiment set out to 
determine if myotube contractions observed in the co-culture system were truly driven via MN 
stimulation due to NMJ formation. Using the methods detailed in 2.1.12 and 2.1.13, verification of 
preliminary NMJ formation was achieved with ICC of the co-cultures on day 7, when myotubes were 
observed to be contracting as a single motor unit. The co-cultures were stained with β-III-tubulin to 
show MN growth and with α-bungarotoxin (α-BTX), which binds as a competitive antagonist to nicotinic 
AChRs, to show AChR clustering on myotubes. Phase contrast and immunofluorescence microscopy 
were used to confirm the co-localisation of MNs emerging from the SCEs with AChRs on the myotubes. 
The results revealed multiple AChR clusters on differentiated myotubes integrated with MN axons and 
MNTs (Figure 4.8). Instances of multiple MN and AChR co-localisation (i.e. multiple points of 
innervation) were observed in 83.4% ± 12.6 of myotubes, indicating the early formation of NMJs in the 
co-culture system.  
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Figure 4.8: Co-localisation of embryonic rat neuron axons with acetylcholine receptor clusters on 
myotubes at day 7. The panel on the lower left is a phase contrast image of neuronal cells in the co-
culture stained for β-III-tubulin (green). The lower right panel is phase contrast image of differentiated 
myotubes in the co-culture stained for α-bungarotoxin (α-BTX) (red). The panel on top is a combined 
immunofluorescence image showing the overlap of neuronal cells emanating from the spinal cord 
explant (indicated by the purple star) with acetylcholine receptor (AChR) clusters on the myotubes. The 
enlarged inset shows a cluster of AChRs (red) interacting with neuron axons (green). Bar = 50 µm. 
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4.2 Discussion 
 
The findings from this study detail the successful establishment of a novel minimalist in vitro nerve-
muscle co-culture system free from serum and growth/neurotrophic factors. The system enabled the 
survival of SCEs in simplified DM, promoted the proliferation of neuronal axons, generated contractile 
myotubes, and exhibited numerous instances of co-localisation between neuronal axons with AChRs, 
indicative of NMJ formation. The co-culture model was created by innervating C25 with neuronal 
outgrowths from ED 13.5 rat SCEs. This co-culture model delivers benefits beyond traditional myoblast 
monocultures as a research tool for investigating NM and muscle wasting disorders. For example, 
aneurally cultured human myotubes did not spontaneously contract in culture. However, as similarly 
witnessed in vivo, innervated myotubes in this co-culture system exhibited endogenously stimulated 
contractile functionality (Feher, 2017). Studies have been conducted using secreted proteins from rat-
nerve/human-muscle co-cultures to treat aneurally cultured human myotubes, which resulted in some 
increased AChR clustering, mostly due to agrin exposure (Arnold et al., 2004; Bandi et al., 2008). 
However, treating anural myotubes with secreted proteins harvested from co-cultures failed to 
generate contractile function. This finding suggests that factors secreted by neuronal cells, such as 
agrin, are not independently adequate to induce contractions in myotubes in vitro, signifying the 
requirement of nerve-muscle contact via NMJs for physiological development of contractile myotubes, 
which are more representative of in vivo conditions. Interestingly, the co-culture model detailed in this 
current study displayed myotube contractions as early as 72 hours post co-culture, which may possibly 
be the first time contractile functionality has been observed at this time point of development in any 
nerve-muscle co-culture system. This finding suggests the initial emergence of NMJ formation, due to 
myotubes requiring nervous input from the MNs to induce contraction (Hong and Etherington, 2011). 
In addition to the benefit of this co-culture model being more physiologically similar to in vivo 
conditions of SkM development then aneurally-cultured myotubes, the system was also optimised for 
easy reproducibility. The co-culture model was established using the minimalist culture media listed in 
Table 2.1, which was devoid of serum, neurotrophic factors, and growth factors. This model is the first 
to generate contractile innervated myotubes using this simplified culture media composition, allowing 
for a drastic reduction in experimental variability. Contrastingly, previously established nerve-muscle 
culture systems require the use of serum or trophic factors to induce myotube innervation, NMJ 
formation, and spontaneous myotube contractions (Das et al., 2010; Guo et al., 2011; Rumsey et al., 
2010; Demestre et al., 2015). Importantly, the potential reduction in experimental variability and ease 
of reproducibility this simplified co-culture model offers is evident when comparing the culture media 
formulation (Table 2.1) used to develop the co-culture model with some of the most contemporary 
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alternative nerve-muscle co-culture systems, which still require a complex of trophic factors to 
generate their systems successfully (Figure 4.9) (Guo et al., 2017).  
 
 
 
Figure 4.9: Culture media components required for successful generation of a recently established 
nerve-muscle co-culture system. Adapted from (Guo et al., 2017) 
 
 
 
Therefore, this co-culture model offers ideal conditions for high-throughput research of the 
mechanisms responsible for the formation and development of NMJs and the advanced differentiation 
of contractile myotubes. The methods applied throughout this study were designed to minimise the 
time required to induce observable spontaneous myotube contractions and produce an abundance of 
functional NMJs. Through the efficient application of embryonic material harvested from a single 
pregnant rat, a potential yield of 100 SCEs were available for each experiment, allowing for a wide 
variation of experimental conditions and time points. In this co-culture model, individual myotubes 
begin to contract by Day 3. The contracting cells continued to increase CF and synchronous unified 
contractions were apparent by Day 7 (Video 1). Previously established nerve-muscle co-culture models 
involve intricate methods requiring various culture media formulations for separate myotube or MN 
differentiation for at least 10 days before co-culturing (Guo et al., 2011). While other studies have 
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presented NMJ formation at 21 days (Demestre et al., 2015). These lengthy protocols lead to avoidable 
delays and possible unintended variation to experimental procedures. 
Neurons generated in this co-culture model were derived from ~1-2 mm2 transversally sliced SCEs with 
intact DRGs (Kobayashi et al., 1987; Arnold et al., 2012). Experiments were conducted with embryo 
spinal cords mechanically disassociated to create a neuronal cell suspension before culturing with 
myoblasts; these conditions resulted in delayed initiation of spontaneous myotube contractions, 
increased arrhythmic contractions and reduced CF. This suggests motor and sensory neurons 
originating from both the ventral horn and dorsal root function mutually to correctly innervate 
myotubes and form NMJs, representative of an in vivo environment (Mears and Frank, 1997). 
Additionally, SCEs with intact DRGs contain a range of progenitor and supporting cells types, such as 
Glial cells. For example, Schwann cells perform vital functions in MN development, differentiation, and 
maintaining NMJ integrity (Riethmacher et al., 1997).  Thus, indicating the presence of supporting cells 
may possibly encourage NMJ robustness and improved function of MNs in vitro.  
 
4.3 Conclusion 
 
In summary, a novel co-culture system was engineered using neurons from rat embryo spinal cords to 
innervate C25 for the first time, resulting in the contractile myotubes with an abundance of potentially 
functional NMJs. The similarity to in vivo contractility demonstrated by mature myotubes in this co-
culture system improves research capabilities into SkM physiology allowing for improved 
pathophysiological elucidation, diagnosis, and treatment. The simplified serum and trophic factor free 
culture media implemented in this co-culture model allows for precise manipulations in the systems 
variability, which could lead to greater insight into NMJ formation and development. This co-culture 
model offers a relevant means for high-throughput investigations of human muscle physiology, NM 
pathology, and NMJ-linked disease and disorder. 
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Chapter 5: Characterisation of in vitro Neuromuscular Junctions 
between Embryonic Rat Motor Neurons and Immortalised Human 
Myoblasts 
 
5.0 Background 
 
5.0.0 Introduction  
 
The previous chapter outlined the establishment of a novel nerve-muscle co-culture system free from 
serum and trophic factors, which was able to induce spontaneous contractile activity in differentiated 
myotubes and displayed co-localisation between neuronal axons and acetylcholine receptor (AChR) 
clusters, suggesting the formation of neuromuscular junctions (NMJs). The NMJ is highly specialised 
peripheral synapse that regulates skeletal muscle (SkM) contraction by functionally joining lower 
motor neurons with skeletal muscle cells (SkMCs). Formed during pre-natal development in vivo, the 
NMJ consist of a presynaptic motor neuron terminal (MNT), synaptic cleft, and postsynaptic motor 
end plate (MEP) (Bloch-Gallego, 2015). The pathology of a variety of neuromuscular (NM) and 
neurodegenerative (ND) diseases target either the presynaptic or the postsynaptic integrity of the 
NMJ, consequently leading to SkM loss and weakness (Punga and Ruegg, 2012). Additionally, one 
effect of old age is the degradation of AChRs on MEPs, which can induce denervation and subsequent 
age-linked muscle loss and dysfunction (Gonzalez-Freire et al., 2014). Thus, innervation of SkMCs is 
essential for the appropriate development and function of SkM. Research has shown degeneration of 
myotubes during embryonic development when SkMCs lack innervation (Ashby et al., 1993). A 
reduction in myotube size and severe deficiency in secondary myotube development (Wilson and 
Harris, 1993; Condon et al., 1990) are also evident in the absence of innervation. The findings from 
these studies provide evidence for the crucial role motor neurons (MNs) and NMJs play in regulating 
SkM fibre development, size, and maturation. In order to investigate the physiological development 
of innervated myotubes and the formation of NMJs, a small number of in vitro models have cultured 
MNs with SkMCs attempting to replicate NMJ formation (Das et al., 2010; Das et al., 2007). In more 
recent times, co-culture systems have made use of MNs derived from stem cells as well as MN cell 
lines, (Morimoto et al., 2013; Umbach et al., 2012). While other models have made use of primary or 
stem cell derived myoblasts (Demestre et al., 2015; Steinbeck et al., 2016; Chipman et al., 2014; 
Puttonen et al., 2015). Furthermore, the development of newer human induced pluripotent stem cell 
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(hiPSC) NMJ models have potential for specialised drug screening or patient-specific MN disease 
modelling (Inoue et al., 2014; Lenzi et al., 2016; Abujarour and Valamehr, 2015; Faravelli et al., 2014). 
While hiPSCs have potential for creating a fully human NMJ model there are points of contention in 
regards to maturation of the NMJ, as well as development and differentiation of MNs and SkMCs in 
such models (Siller et al., 2013). Furthermore, many of these previously established systems provide 
evidence of NMJ formation by simply demonstrating the co-localisation of neuronal axons and AChR 
clusters without analysing or confirming vital elements in MNs needed for transmission at the NMJ. 
For example, choline acetyltransferase (ChAT) and the vesicular acetylcholine transporter (VAChT) are 
essential for the synthesis and transport of ACh in MNs, making the neurotransmitter available for 
secretion into the synaptic cleft (Brandon et al., 2003; Maeda et al., 2004). Additionally, activity at the 
presynaptic MNT is observable through analysis of synaptic vesicle proteins such as Synaptotagmin 1 
(Syt1), which is a Ca2+ sensor that triggers fusion of acetylcholine (ACh) containing vesicles with the 
MNT membrane (Brose et al., 1992; Yu et al., 2013). Furthermore, co-culture systems need to be 
examined for alternative neuronal cell populations such as Glial cells, which are known to be involved 
with the formation and maintenance of the NMJs (Feng and Ko, 2008). Previously established in vitro 
NMJ models also commonly disregard the characterisation of innervated myotubes for markers of 
advanced differentiation, such markers include the formation of striated myotubes, transversal triads, 
and peripherally located nuclei. Furthermore, structures of the postsynaptic apparatus beyond AChRs 
have rarely been characterised in detail. For example, the agrin-induced formation of postsynaptic 
elements such as muscle-specific tyrosine kinase (MuSK) and the 43 kDa receptor-associated protein 
of the synapse (Rapsyn) are vital for the formation of AChRs. Therefore, experiments in this study 
were conducted with co-cultures of ED 13.5 embryonic rat spinal cord explants (SCEs) innervating 25-
year-old immortalised human myoblasts (C25) to explore the formation of NMJs and examine the 
advanced differentiation of innervated myotubes.  
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5.0.1 Aims 
 
The objective of the present study was to characterise the novel co-culture system of ED 13.5 rat SCEs 
innervating young immortalised human myoblasts established in the previous study. Thus, the aims 
were: 
 
1. Establish the optimal time for co-culture characterisation. 
 
2. Characterise pre- and post-synaptic elements of NMJs formed in the co-culture system. 
 
3. Investigate the maturation of innervated myotubes for markers of advanced 
differentiation.  
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5.1 Results 
 
5.1.0 Optimisation of Co-cultures for Characterisation 
 
To ensure optimal innervation, NMJ formation, and advanced differentiation of myotubes had occurred 
before characterisation of the co-cultured cells was conducted, the peak contraction frequency (CF) of 
co-cultured myotubes was used as an indicator of the co-culture vitality. Optimal conditions for co-
culture characterisation were determined by quantifying CF every 24 hours post co-culture for 30 days, 
using live phase contrast microscopy to assess 20 random fields of view at 10X magnification. The 
methods used to determine CF were detailed in 2.1.19. The results revealed no observable myotube 
contractions in the co-cultured myotubes after the first 48 hours. Following 3 days of co-culture, 
initiation of myotube contractions were observable, contracting at a frequency of 0.19 Hz ± 0.1. The 
co-cultured myotubes were observed gradually increasing synchronous CF over the next eleven day. 
On day 14, myotube contractions peaked at a frequency of 1.33 Hz ± 0.39 (Figure 5.0). The co-cultured 
myotubes roughly maintained peak CF until day 17, followed by a gradual decrease of contractile 
activity in the innervated myotubes. Although myotube contractions were still detectable until the 
termination of the experiment on day 30, the frequency of contractions had reduced to 0.69 Hz ± 0.33, 
with contractile activity becoming increasing asynchronous. Thus, the determination was made to 
conduct characterisation of the co-cultures on day 14.  
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Figure 5.0: Contraction frequency in co-cultured myotubes over 30 days. A line graph showing the 
onset, increase, and decline of myotube contractions frequency in 25-year-old immortalised human 
myoblasts co-cultured with ED 13.5 rat embryo spinal cord explants. Data presented as a mean, error 
bars signify ± SD.  n = 3 independent experiments. 
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5.1.1 Characterisation of Cholinergic Motor Neurons 
 
By exploiting immunocytochemistry (ICC) techniques in the previous chapter, the preliminary 
observation was made that SCEs did indeed sprout neurites that positively expressed β-III-tubulin 
(Figure 4.3, 4.8), indicating the proliferation of neuronal cells in the co-culture system. The appropriate 
formation and development of NMJs is characterised by the convergence of cholinergic MNTs with 
MEPs on the SkMCs. Therefore, the following experiments were performed to confirm that sprouting 
neuronal cells from the SCEs did in fact include cholinergic MNs and to confirm the co-localisation of 
cholinergic MNs with SkM myotubes in culture. Confirmation of co-localisation was achieved via 
antibody staining visualised with confocal microscopy, detailed in methods sections 2.1.12 and 2.1.13. 
A cytoplasmic transferase enzyme found in elevated concentration in cholinergic neurons called ChAT 
(Oda, 1999) was stained to reveal cholinergic MNs in the co-cultures (Figure 5.1). To validate the 
presence of cholinergic MNs, supplementary staining was performed using VaChT, a functional 
mediator of ACh storage and transport by synaptic vesicles (Arvidsson et al., 1997) (Figure 5.2). Staining 
myotubes for myosin heavy chain (MHC) was used to show myotube differentiation. Staining of the co-
cultured cells revealed ChAT+ and VaChT+ cholinergic MNs, with axons terminating on differentiated 
myotubes. Axon terminals were also observed establishing multiple points of contact with individual 
myotubes, comparable to similar observations of SkM innervation during embryonic myogenesis. In 
vivo, preliminary myotube innervation occurs via numerous branching axons, which originate from 
different MNs. Maturation of the innervation process causes axon pruning to occur, leaving individual 
MNs to innervate hundreds of mature muscle fibres, generating a functional motor unit (Low and 
Cheng, 2006). Notably, myotubes in this co-culture model also exhibited multiple innervations (e.g. 2 
or more NMJs per myotube; Figure 5.6) similar to what is observed in vivo before axon pruning occurs.  
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Figure 5.1: Co-localisation of cholinergic motor neurons with myotubes on Day 14. a) A representative 
image showing a single cholinergic motor neuron axon terminating on top of a single differentiated 
myotube. The co-culture stained for choline acetyltransferase (ChAT) (red), myosin heavy chain (MHC) 
(green), and DAPI (blue). Bar = 7.5 µm. Adapted from (Saini et al., 2019) 
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Figure 5.2: Confirmation of cholinergic motor neurons co-localising with myotubes on Day 14. A 
representative image showing cholinergic motor neuron axons co-localising with differentiated 
myotube. The co-cultures were stained for vesicular acetylcholine transporter (VaChT) (red), myosin 
heavy chain (MHC) (green), and DAPI (blue). Bar = 7.5 µm. 
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5.1.2 Characterisation of Neuroglia 
 
The characterisation of many established in vitro NMJ models focus predominantly on describing 
aspects of the neurons and/or the myotube formation with marginal consideration for associated cells 
involved with NMJ generation, regulation, and development. The synapse-associated glial cells known 
as non-myelinating terminal Schwann cells cap motor nerve terminals in vivo, these cells are an 
essential component in NM synaptic maintenance and repair (Balice-Gordon, 1996). Thus, revealing 
Schwann cells in the co-culture system and the subsequent detection of interactions between MNs, 
Schwann cells, and myotubes may explain the formation of NMJs generated in this co-culture system. 
Using the methods described in 2.1.12 and 2.1.13, glial fibrillary acidic protein (GFAP), an intermediate 
filament cytoskeletal component involved in the structure and function of the neuroglia cytoskeleton 
(Jessen et al., 1990) was used as a marker to reveal the existence of non-myelinating Schwann cells. 
Neuronal cells were shown by staining the microtubule cytoskeletal component for β-III-tubulin (Figure 
5.3). Myotubes were visualised by staining for MHC (Figure 5.4). The results showed co-localisation of 
neurons and Schwann cells was evident throughout the co-cultures. The enlarged inset image in Figure 
5.3 illustrates the interaction between these cells, which may be indicative of Schwann cells capping 
axons, as observed in vivo. Furthermore, the results displayed co-localisation of Schwann cells and 
differentiated myotubes apparently throughout the co-cultures. The discovery of co-localisation and 
cellular interaction between myotubes, motor neurons, and Schwann cells within the co-culture system 
supports the concept that this co-culture model provides functional and robust innervation of 
myotubes via precisely coordinated NMJ formation, comparable to in vivo conditions. 
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Figure 5.3: Interaction between neuronal axons and non-myelinating Schwann cells on Day 14. Image 
is representative of neuronal cells in the co-culture stained for β-III-Tubulin (green), Schwann cells 
stained for glial fibrillary acidic protein (GFAP) (red), and DAPI (blue). Enlarged Inset shows cellular 
interaction. Bar = 10 µm. 
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Figure 5.4: Co-localisation of non-myelinating Schwann cells and myotubes on Day 14. Image is 
representative of the interaction between myotube in the co-culture stained for myosin heavy chain 
(MHC) (green) and Schwann cells stained for glial fibrillary acidic protein (GFAP) (red), DAPI (blue). Bar 
= 5 µm. 
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5.1.3 Characterisation of NMJ formation  
 
Following characterisation and validation of the co-localisation between cholinergic MN axon terminals 
and myotubes in the co-culture system, experiments were conducted to verify and characterise the 
formation of NMJs. The formation of NMJs is characterised by the substantial aggregation of AChRs on 
the myotube membrane in apposition of MN axon terminals. Using the methods described in 2.1.12 
and 2.1.13, ICC was performed on the co-cultures, and axon terminals were identified by staining MNs 
for β-III-tubulin (Figure 5.5). To further validate NMJ formation, supplementary staining for MNs was 
also performed using neurofilament heavy (NFH) (Figure 5.6), an intermediate filament found in the 
cytoplasm of neurons (Lees et al., 1988). The accumulation of AChRs on the myotubes was 
characterised with fluorescently labelled α-bungarotoxin (α-BTX), known to bind specifically with 
AChRs on the myotube membrane (Young et al., 2003). The results revealed MN axons and terminals 
overlaying AChR clusters accumulated on the myotubes surface. Similar to in vivo observations, the 
AChR clusters in the co-cultures exhibited the greatest concentrations where MN axons and terminals 
overlapped the clusters, signifying the successful formation of NMJs. Experiments were also conducted 
to compare the development of NMJ morphologies in co-cultured myotubes in contrast to aneurally-
cultured myotubes. Distinctive NMJ morphologies were quantified into five established NMJ 
morphological classifications (Valdez et al., 2010; Lee et al., 2013; Kummer et al., 2004; Sahashi et al., 
2012), detailed in the methods section 2.1.14. Specifically, NMJ morphology was classified as mature, 
fragmented, faint, premature or denervated. The results showed no mature NMJs in the aneurally 
cultured myotubes. However, 43.5% ± 12.7 of the NMJs observed in the co-cultures were classified as 
exhibiting a mature morphology (Figure 5.7). When examining NMJs with a fragmented morphology, 
6% ± 2.6 of the NMJs in the co-cultured cells were considered fragmented, no fragmented NMJs were 
observed in the aneural myotubes. The co-cultures displayed 4% ± 2.7 of NMJs classified as faint, no 
faint NMJs were seen in the aneural myotube cultures. The NMJ morphologies of mature, fragmented, 
and faint were all significantly higher (P < 0.0001) in the co-cultured myotubes when compared to the 
aneural myotube cultures. However, when comparing premature NMJ morphology, the aneurally-
cultured myotube displayed 14.7% ± 5 as having premature NMJs, which was significantly higher (P < 
0.0001) then the percentage of premature NMJs in the co-cultured cells (1.6% ± 1.6). Comparing the 
percentage of denervated myotubes resulted in 90.5% ± 6.2 of aneural cultures showing denervation, 
which was significantly higher than the 8.5% ± 5 of denervated myotubes in the co-cultured conditions.     
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Figure 5.5: Characterisation of neuromuscular junction formation on Day 14. A Representative image 
showing an individual motor neuron axon terminal interacting with an acetylcholine receptor cluster in 
culture. The co-cultures were stained for β-III-tubulin (green), alpha-bungarotoxin (α-BTX) (red), and 
DAPI (blue). Scale bar = 5 µm. Adapted from (Saini et al., 2019) 
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Figure 5.6: Confirmation of neuromuscular junction formation on Day 14. A Representative image 
showing motor neuron axons interacting with multiple acetylcholine receptor clusters on a 
differentiated myotube in culture. The co-cultures were stained for neurofilament heavy (NFH) (green), 
myosin heavy chain (MHC) (purple) alpha-bungarotoxin (α-BTX) (red), and DAPI (blue). Scale bar = 25 
µm. 
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Figure 5.7: Neuromuscular Junction Morphologies on Day 14. A bar graph comparing the percentages 
of distinct neuromuscular junction (NMJ) morphologies in myotubes co-cultured with ED 13.5 rat 
embryo spinal cord explants against myotubes cultured aneurally. Each bar presents a mean of all wells 
with error bars signify ± SD from at least 100 NMJs. n = 4 independent experiments. **** denotes P < 
0.0001. Adapted from (Saini et al., 2019) 
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5.1.4 Characterisation of Presynaptic Activity 
 
Following confirmation of NMJ formation, subsequent experiments were conducted to assess NMJ 
functionality through the examination and characterisation of the presynaptic apparatus. When an 
action potential (AP) arrives at a presynaptic terminal, the local increase in the Ca2+ concentration 
triggers the release of ACh. This calcium-dependent exocytosis involves the precise docking of synaptic 
vesicles to the presynaptic membrane, which is regulated in part by the calcium sensor Syt1 (Brose et 
al., 1992). The methods described in 2.1.12 and 2.1.13 were used to confirm presynaptic NMJ activity, 
staining for NFH was used to visualise MN axons while activity at the terminal was shown by staining 
MN for Syt1 (Figure 5.8). The results revealed an elevated expression of Syt1 aggregated at the MNT, 
signifying presynaptic activity at the NMJ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
 
 
Figure 5.8: Characterisation of presynaptic neuromuscular junction activity on Day 14. A 
representative image of an individual neuronal axon expressing activity at the axon terminal. The co-
cultures were stained for neurofilament heavy (NFH) (green), synaptotagmin 1 (Syt1) (red), and DAPI 
(blue). Bar = 7.5 µm. 
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5.1.5 Characterisation of Postsynaptic Elements 
 
Upon determining MNT activity in the co-cultured cells, the next experiments were conducted to 
identify postsynaptic proteins known to co-localise with AChRs at the MEP. Agrin is crucial for AChR 
clustering in the MEP and is vital for precise NMJ formation. Presynaptic secretion of agrin by MNs 
induces activation and development of MuSK, which forms an initial scaffold for Rapsyn to advance 
recruitment of other postsynaptic MEP elements (Apel et al., 1995; Apel et al., 1997). The methods 
described in 2.1.12 and 2.1.13 were used to verify maturation and appropriate development of the 
MEP. The co-culture was stained with α-BTX to visualise AChRs along with antibodies for MuSK and 
Rapsyn. The results showed that both Rapsyn and MuSK were precisely overlaid the structure of the 
AChR clusters on the postsynaptic membrane (Figure 5.9). 
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Figure 5.9: Characterisation of postsynaptic neuromuscular junction formation at Day 14. a) Image is 
representative of co-culture stained for alpha-bungarotoxin (α-BTX) (red), MuSK (magenta) and DAPI 
(blue). b) Image is representative of co-culture stained for alpha-bungarotoxin (α-BTX) (red), Rapsyn 
(green), and DAPI (blue). c) Image reveals interaction and detailed conformation of postsynaptic 
proteins MuSK (magenta) and Rapsyn (green) at the AChR stained with α-BTX (red), DAPI (blue). Scale 
bar = 25 µm 
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5.1.6 Characterisation of Innervated Myotubes 
 
Mature myotubes in vivo display several features indicative of advanced differentiation. For instance, 
appropriately developed myotubes feature triads, which are arranged in a transversal manner. The 
structural composition of triads detected in myotubes having undergone advanced differentiation is 
formed by a transverse tubule (T tubule) with a sarcoplasmic reticulum (SR) known as the terminal 
cisterna on each side (Marty et al., 1994). The methods described in 2.1.12, 2.1.13, and 2.1.15 were 
used to determine if the co-culture system endorsed innervated myotubes to undergo advanced 
differentiation similar to developing myotubes observed in vivo, characterisation of both co-cultured 
and aneurally cultured myotubes was performed via antibody staining. T-tubules were identified by 
staining for dihydropyridine receptor (DHPR) a voltage-dependent calcium channel located in the T-
tubule membrane (Rios and Brum, 1987). Antibody marking was also used to identify the ryanodine 
receptor (RyR), which is responsible for the release of Ca2+ from intracellular stores during excitation-
contraction coupling in skeletal muscle and is located on the membrane of the SR (Coronado et al., 
1994). Differentiated myotubes in the co-cultures were compared to aneurally-cultured myotubes to 
ascertain any differences in the percentage of myotubes exhibiting indicators of advanced 
differentiation. In each experiment (n = 3), twenty random fields of view from five different plates were 
assessed to determine percentage of myotubes displaying advanced differentiation. The data from all 
experiments was totalled and used to calculate the mean percentage ± SD from all observed fields of 
view. The results showed 32.4% ± 9.6 of innervated myotubes in the co-cultures had well developed 
and appropriately organised transversal triads (Figure 5.10), whereas aneural myotubes did not exhibit 
any triad formation. Along with the formation of transversal triads being an indicator of progressing 
advanced differentiation in innervated myotubes, peripherally located nuclei were also used to reveal 
features of advanced differentiation. The methods detailed in 2.1.12, 2.1.13, and 2.1.16 were used to 
perform characterisation of both co-cultured and aneurally cultured myotubes via antibody staining 
with MHC and DAPI to determine any differences in the percentage of myotubes having peripheral 
nuclei. The results showed 59.3% ± 17.1 of innervated myotubes in the co-cultures had peripherally 
located nuclei (Figure 5.11), contrastingly, no myotubes in the aneural cultures presented peripheral 
nuclei. Another feature of advanced differentiation in myotubes is the development of striations. Thus, 
myotube staining was performed with MHC and DAPI to determine any differences in the percentage 
of myotubes displaying striations in co-cultured and aneural conditions, using the methods detailed in 
2.1.12, 2.1.13, and 2.1.17. The results show 46.2% ± 9.7 of the myotubes in the co-cultures presented 
with striations on their membranes. There was a significant reduction (P < 0.0001) in the percentage of 
striated myotubes (14.1% ± 3.5) when examining the aneural cultures (Figure 5.12). The methods 
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detailed in 2.1.18 were used to do a comparison of myotube thickness between co-cultured myotubes 
displaying features of advanced differentiation and aneurally-cultured myotubes. The results revealed 
that innervation and subsequent advanced differentiation endorsed the formation of thicker 
myotubes. The thickness of myotubes with characteristics of advanced differentiation was 20.3 µm ± 
7.1, whereas aneurally cultured myotubes were measured at a significantly less (P < 0.0001) 11.2 µm ± 
4.3 (Figure 5.13).  
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Figure 5.10: Formation of transversal triads on Day 14. a) The upper image panel is representative of 
an innervated myotube co-cultured with ED 13.5 rat embryo spinal cord explant displaying appropriate 
arrangement of transverse tubules and terminal cisterna. The lower image panel is representative of 
aneurally-cultured myotubes lacking formation of transversal triads. Myotubes were stained for 
ryanodine receptor (RyR) (green) and dihydropyridine receptor (DHPR) (red). b) A bar graph comparing 
percentage of myotubes with triad formation in the co-cultured conditions against aneural myotube 
conditions. Data presented as a mean, error bars signify ± SD.  n = 3 independent experiments. **** 
denotes P < 0.0001. Bar = 7.5 µm. Adapted from (Saini et al., 2019) 
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Figure 5.11: Generation of peripheral nuclei at Day 14. a) The upper image panel is representative of 
an innervated myotube co-cultured with ED 13.5 rat embryo spinal cord explant displaying peripherally 
located nuclei protruding from the myotube. The lower image panel is representative of aneurally-
cultured myotubes with centrally located nuclei. Myotubes were stained for myosin heavy chain (MHC) 
(green) and DAPI (blue). b) A bar graph comparing percentage of myotubes with peripheral nuclei in 
the co-cultured conditions against aneural myotube conditions. Data presented as a mean, error bars 
signify ± SD.  n = 3 independent experiments. **** denotes P < 0.0001. Bar = 10 µm.  
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Figure 5.12: Myotube striations on Day 14. a) The upper image panel is representative of an innervated 
myotube co-cultured with ED 13.5 rat embryo spinal cord explant displaying striations on the myotube 
membrane. The lower image panel is representative of aneurally-cultured myotubes lacking striations. 
Myotubes were stained for myosin heavy chain (MHC) (green) and DAPI (blue). b) A bar graph 
comparing percentage of striated myotubes in the co-cultured conditions against aneural myotube 
conditions. Data presented as a mean, error bars signify ± SD.  n = 3 independent experiments. **** 
denotes P < 0.0001. Bar = 2 µm. 
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Figure 5.13: Myotube thickness on Day 14. A bar graph comparing the thickness of myotubes 
displaying features of advanced differentiation in the co-cultured conditions against aneurally cultured 
myotubes. Data presented as a mean, error bars signify ± SD.  n = 3 independent experiments. *** 
denotes P < 0.0001.  
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5.2 Discussion 
 
The primary outcome of this study presented characterisation of the in vitro NMJ model established in 
the previous chapter. The co-cultures of rat embryo SCEs with C25 demonstrated the co-localisation of 
cholinergic MNs with differentiated myotubes and promoted the interaction between neurons, 
myotubes, and neuroglia. Furthermore, co-cultures generated the formation and development of 
mature NMJs with presynaptic activity and postsynaptic structural organisation. Innervated myotubes 
in the co-cultures were also found to exhibit structural characteristics indicating the development of 
advanced differentiation. When preliminary experiments were conducted with the co-cultures to 
determine the optimal time for characterisation of the system, CF was used as the benchmark for NMJ 
formation and maturation. The observation that innervated myotubes were contracting at peak 
frequency after 14 days in the co-culture system provided evidence of effective mature NMJ 
development, which was reflected after characterisation was completed and revealed suitably 
differentiated MNs, NMJs, and myotubes. In comparison, some previously established co-culture 
systems require more than 20 days before NMJ formation occurs and involve extensive prior MN or 
myotube differentiation, further increasing the timeline of experimentation (Southam et al., 2013; Das 
et al., 2010). Moreover, contrasting the co-culture system presented in this current study, these 
previous co-culture models exhibited premature development of NMJs and myotubes lacked advanced 
differentiation. Although co-cultures were characterised on Day 14, the preliminary experiments used 
to determine the optimal date for characterisation also revealed long-term co-culture studies were 
possible with this novel simplified system, considering that myotube contractions persisted until 
experimental termination on Day 30, which could have been maintained further if desired. The 
characterisation of cholinergic MNs with ChAT and VaChT in the co-cultures resulted in the observation 
that interactions between MNs, ACh, and myotubes occurred in the system. Studies conducted with 
ChAT-/- mice have shown that embryos lacking ChAT have deficits in postsynaptic nerve potentials, 
resulting in embryo death at birth. The ChAT-/- mice display hyper-innervation due to excessive 
presynaptic nerve branching, smaller MNTs, and increased quantity of AChR agregations with fewer 
presynaptic contacts (Brandon et al., 2003; Misgeld et al., 2002). Although structural synaptic elements 
were present in the ChAT-/- mice, an assortment of both pre- and post-synaptic irregularities were 
evident at the NMJ. The findings from these in vivo ChAT deficient mice studies showed that 
neurotransmission is not the only function of ACh and synaptogenesis requires ACh and its biosynthetic 
enzyme ChAT. Research conducted with VAChT-/- mice similarly find severe abnormalities in NMJ 
development (de Castro et al., 2009). As seen in ChAT-/- mice, the studies with VAChT-/- mice have 
enlarged MEPs, excessive MN growth and necrotic SkM tissue, indicating VAChT is essential for the 
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release of ACh at the synapse and normal NMJ development. Thus, characterisation of ChAT and VaChT 
in the co-cultures provided data showing the in vitro NMJs generated in the system were an accurate 
physiological representation of NMJ development seen in vivo. Appropriate formation of NMJs requires 
interaction between the axon terminals of neurons, MEPs of myotubes and terminal Schwann cells. In 
vivo studies conducted with mutant mice lacking Schwann cells show MN axons are able to grow and 
extend towards developing SkM; however, significant axonal defasciculation is observed. This finding 
suggested Schwann cells are not required for axonal projection towards target myotubes but are 
necessary for nerve fasciculation. Additionally, Schwann cell deficient mice were able to establish 
preliminary NMJ formation but unable to maintain further development of the synapse (Lin et al., 2000; 
Morris et al., 1999; Riethmacher et al., 1997; Woldeyesus et al., 1999; Wolpowitz et al., 2000). These 
studies demonstrate that Schwann cells are not required for the initiation of contact between neurons 
and axons in vivo, but are vital for the subsequent advancement and maintenance of the developing 
synapse. Therefore, confirmation of Schwann cells in the co-culture system and the subsequent 
interaction observed between MNs and Schwann cells suggests the in vitro NMJ formation observed in 
the co-cultures were matured and maintained through Schwann cell/MN communication. Crucially, 
characterisation of the presynaptic nerve terminals with antibodies for Syt1 resulted in the discovery 
of presynaptic NMJ activity occurring in the co-cultured cells. Research investigating Syt1 revealed its 
function as a calcium sensor, facilitating the release of neurotransmitters from Ca2+-dependent vesicles, 
which is mandatory for calcium-dependent vesicle exocytosis in invertebrates (Geppert et al., 1994; 
Littleton et al., 1993). However, investigations with Syt1-/- mice uncovered Syt1 was only required for 
fast synchronous release of neurotransmitters from Ca2+-dependent vesicles, as synaptotagmin 2 can 
compensate for the lack of asynchronous exocytosis in Syt1-/- mice (Geppert et al., 1994). Studies 
conducted with spinal muscular atrophy (SMA) mouse models to explore the causes of impaired 
neurotransmitter release also discovered Syt1 was downregulated during development in the MNTs of 
the severely affected muscles, but not in MNT of less susceptible muscle (Lopez-Manzaneda et al., 
2016). Therefore, identification of Syt1 in the co-cultures showed evidence that presynaptic activity at 
NMJs was illustrative of NMJ functionality, as would be similarly expected in appropriate in vivo NMJ 
formation and development. The formation of NMJs in the present co-culture system were 
characterised on the MEP with α-BTX to show the structure of postsynaptic aggregation of AChRs. 
Previously established nerve-muscle co-culture systems have demonstrated NMJ formation as diffused 
or speckled AChR clusters co-localising with MNs, primarily in the categories of faint or premature 
formation (Southam et al., 2013; Das et al., 2007). However, it is acknowledged that co-localisation 
alone does not represent in vivo NMJ formation (Thomson et al., 2012). Classic study of NMJs show 
that MN axons terminate at the MEP and overlap the AChR clusters precisely (Sanes and Lichtman, 
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1999; Englander and Rubin, 1987). Importantly, the NMJ formation observed in the co-culture system 
presented in this current study displayed MNs terminating on clusters of AChRs in the typical twisting 
knotted configuration. This finding signified in vitro NMJ formation, comparably observed in vivo. 
Confirming the co-cultures were able to generate NMJs with characteristics of maturely developed 
AChR clusters prompted the investigation of other postsynaptic NMJ elements. Essential for formation 
and maintenance of the NMJ, the observation of MuSK and Rapsyn at the MEP indicated activation of 
the MuSK signalling pathways triggered by agrin secretion from the MNT (Wu et al., 2010; Luo et al., 
2003; Zhang et al., 2008; Kim and Burden, 2008). This finding was vital as it provided evidence toward 
successful postsynaptic differentiation at the NMJ via pre- and post-synaptic communication. 
Furthermore, the association of Rapsyn with AChRs is required for in vivo AChR clustering (Apel et al., 
1997). Thus, the detection of co-localisation between Rapsyn, MuSK, and AChRs indicated that the 
postsynaptic development observed in the co-cultures were able to reach a level of maturation that 
would allow investigations of postsynaptic NMJ manipulation in the system. Co-cultured myotubes also 
displayed the morphological characteristics of advanced differentiation. Besides transversal triads 
being apparent in innervated myotubes, the co-cultured myotubes also contained peripherally located 
nuclei and the conventional actin-myosin striations expressed in mature differentiation, all 
characteristics which are similarly observed in vivo (Bruusgaard et al., 2003; Shadrin et al., 2016). This 
vital characterisation of mature innervated myotube development further exemplifies the advantage 
of this co-culture system over typical aneural in vitro myoblast cultures and previously established 
nerve-muscle co-culture models, which fail to achieve advanced stages of development. Thus, making 
this co-culture system a preferential alternative as a research tool for the accurate elucidation of 
skeletal muscle wasting and improve exploration of NM disorders. 
 
5.3 Conclusion 
 
In conclusion, this report characterised a novel in vitro NMJ system generated from ED 13.5 rat SCEs 
co-cultured with C25. The de novo formation of NMJs was verified by identifying pre- and post-synaptic 
structures of the junctional apparatus. Interactions with MN, myotubes and supporting neuroglia were 
shown to endorse the advanced differentiation of innervated myotubes. Thus, the SkMC line used in 
the generation of the system is a key aspect of this new system. The SkMC line allows for de novo 
formation of NMJs with easy reproducibility, while retaining the ability to differentiate regardless of 
the genetic programing performed on the cell line to achieve immortalisation. 
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Chapter 6: Functional Assessment of in vitro Neuromuscular 
Junctions between Embryonic Rat Motor Neurons and Immortalised 
Human Myoblasts 
 
6.0 Background 
 
6.0.0 Introduction  
 
Experiments in the previous chapter detailed characterisation of NMJs and innervated myotubes in the 
ED 13.5 rat embryo SCE / C25 co-culture system. Successful NMJ formation with presynaptic cholinergic 
MN activity, maturation of postsynaptic MEP components, as well as cellular interaction between MNs, 
SkMCs, and supporting neuroglia were confirmed throughout the co-cultures. The formation of NMJs 
and development of innervated myotubes enabled the advanced differentiation of myotubes in the co-
culture system, distinguished via characterisation of transversal triads, peripheral nuclei, and cross-
striations on the myotubes. Furthermore, characterisation of the system verified the practicality of this 
heterologous co-culture model for NMJ disease modelling, as antibodies specific for rat or human can 
be used to study disorders that affect presynaptic and/or postsynaptic regions of the NMJ. The direct 
deterioration of NMJs is featured in a variety of disorders, such as congenital myasthenic syndromes 
(CMS), Lambert-Eaton myasthenic syndrome (LEMS) and myasthenia gravis (MG) (Engel and Sine, 2005; 
Vincent et al., 1989; Gilhus, 2016). These diseases and other NM disorders that affect MNs, such as 
amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) (Rosen et al., 1993; Lefebvre et 
al., 1995), can be initiated by autoimmunity, genetic mutations, and specific drugs or toxins. All of which 
can modify the function or quantity of synaptic proteins essential for regulating communication 
between MNTs and MEPs. Furthermore, disorders such as diabetic neuropathy and myopathy are 
associated with functional and morphological changes of the NMJ associated with muscle weakness 
(Garcia et al., 2012; Monaco et al., 2017). The degeneration of NMJs is also observed in several 
conditions including age-linked sarcopenia, cancer cachexia, heart failure, and NM transmission 
disorders, all of which lead to profound muscle wasting and weakness (Rudolf et al., 2016). The 
elucidation of mechanisms involved with deterioration of NMJs due to disease progression may allow 
for the development of therapies that can improve NMJ function and halt disease development. Animal 
models have been the traditional method to investigate the pathophysiology of NM disease, but are 
limited in the data they provide that translates to disease in humans. For example, the human survival 
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motor neuron 1 (SMN1) gene is mutated in SMA patients, but presence of the survival motor neuron 2 
(SMN2) gene can mitigate some deleterious influences of the SMN1 gene mutation (Lefebvre et al., 
1995). Contrastingly, deletion of the SMN1 gene in mice results in embryonic death as the mouse 
genome does not contain the SMN2 gene (Schrank et al., 1997). Therefore, the development of the 
SMA mouse model required insertion of the human SMN2 gene into the mouse genome of SMN1-/- 
mice to prevent embryo death (Monani et al., 2000; Hsieh-Li et al., 2000). Consequently, the resulting 
mouse exhibits an atrophied SkM phenotype due to a gene that the mouse genome does not naturally 
contain, yet this in vivo animal model and other similarly developed animal models are still the closest 
genetic representation of disease pathology in humans (Sleigh et al., 2011). Similarly, The superoxide 
dismutase 1 (SOD1) mouse model of ALS is the most commonly used animal model in ALS research, but 
has been unable to provide any significant insights into the mechanism of disease or possible therapies 
(Schnabel, 2008; Benatar, 2007). Thus, for effective interpretation of disease mechanisms and the 
screening of therapies designed to rectify NMJ function in NM disorders, a structurally robust and 
stable in vitro NMJ system that accurately reflects typical in vivo functionality is required. Data obtained 
through characterisation of the co-culture model presented in this project has already shown the 
system was able to emulate appropriate in vivo structural development of NMJs and exhibited long-
term stability in culture. However, for the co-culture model to be considered a functional system the 
SkMCs contractile activity should respond physiologically to pre- or post-synaptic manipulation of the 
NMJ through pharmacological interventions. Importantly, unlike numerous SkMCs originating from 
animals, classic studies concluded that aneurally cultured human SkMCs, the most extensively utilised 
in vitro model to study human SkM (Aas et al., 2013), do not usually spontaneously contract or form 
differentiated postsynaptic components of NMJs under standard conditions (Delaporte et al., 1986; 
Kobayashi and Askanas, 1985). Thus, it is typically regarded that aneurally cultured human myotubes 
do not exhibit spontaneous contractile activity and any contraction has been considered to originate 
via innervation (Mis et al., 2017). Notably the first spontaneous aneural myotube contractions 
witnessed in differentiated human SkMCs was published in 2014 (Dixon et al., 2018), at which time the 
authors claimed that no spontaneous contraction had been reported from aneural human SkMCs in 
vitro (Guo et al., 2014). However, myotubes differentiated from the C2C12 mouse myoblast cell line 
have shown a capacity for spontaneous contractile activity when cultured aneurally (Manabe et al., 
2012), indicating the possibility exists that aneurally cultured human myotubes could contract 
spontaneously, though unlikely. To demonstrate the formation of functional NMJs, some previously 
established nerve-muscle co-culture models have used the application of excitatory neurotransmitters 
such as glutamate to stimulate MNs, resulting in increased myotube contractions. In contrast, the 
cessation of myotube contractions has also been demonstrated through the application of reversible 
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and irreversible AChR inhibitors such as tubocurarine or bungarotoxin (Guo et al., 2011; Miles et al., 
2004; Umbach et al., 2012; Bowman, 2006). Interestingly, recent research detected glutamate 
decarboxylase, which is an enzyme involved with γ-aminobutyric acid (GABA) synthesis, along with 
GABA, and a protein responsible for transmembrane transport of GABA called GAT-2, in the vertebrate 
NMJ (Nurullin et al., 2018). Though no previous compelling evidence existed that GABAminergic 
signalling occurred in the vertebrate NMJ. Furthermore, these new findings have yet to be explored in 
the context of NMJ functionality in heterologous nerve-muscle co-culture systems. Indicating that 
stimulation of in vitro NMJs with exogenous GABA is unknown, as well as the effects of GABA receptor 
antagonist such as bicuculline being insufficiently explored. Therefore, experiments in this study were 
conducted with co-cultures of ED 13.5 embryonic rat SCEs innervating C25 to explore the functional 
responses of NMJs to biochemical intervention.  
 
6.0.1 Aims 
 
The first aims of the present study was to verify spontaneous myotube contractions in the co-culture 
system were in fact driven via MN stimulation, as the unlikely possibility exists that spontaneous 
contractions may have been induced aneurally. The second aim was to ensure NMJs generated in the 
co-culture system respond to drug treatments in a physiological manner representative of in vivo NMJs. 
Thus, the objectives were: 
 
1. Establish the co-culture model exhibiting spontaneous myotube contractions. 
 
2. Treat the co-cultures with agonist and antagonist drugs (i.e. α-bungarotoxin, tubocurarine, 
bicuculline, L-glutamic acid, γ-aminobutyric acid). 
 
3. Determine the functionality of NMJs generated in the co-culture system by assessing the 
myotube contraction frequency in response to pre- and post-synaptic NMJ manipulation 
via drug treatments.  
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6.1 Results 
 
6.1.0 Functional Assessment of NMJs with α-Bungarotoxin 
 
It is well known that α-BTX is a naturally occurring neurotoxic peptide found in the venom of the 
Bungarus multicinctus snake. When in vivo NMJs are exposed to α-BTX, an irreversible competitive 
antagonistic binding occurs between the neurotoxin and the AChRs on the postsynaptic MEP of the 
NMJ, leading to SkM paralysis, respiratory failure, and death (Lavoie et al., 1976). The methods 
described in 2.1.19 were used to determine if in vitro NMJs generated in the co-culture system reflect 
the SkM paralysis observed in vivo, the co-cultures were treated with a 1:400 concentration of α-BTX 
to induce permanent blockade of the postsynaptic AChRs. Experiments were conducted on day 14, 
when peak spontaneous contraction frequency (CF) was observed, which was determined in the 
previous chapter (Figure 5.0). Before exposing the co-cultures to α-BTX treatment, the culture dishes 
were placed on the microscope stage enclosed by an incubation chamber to maintain ideal atmospheric 
conditions for spontaneous myotube contractile activity. Continuous spontaneous myotube 
contractions were observed for no less than 5 minutes before baseline measurements were taken. This 
step was included to ensure any changes in myotube CF due to fluctuations in temperature or 
environmental conditions were mitigated, thereby removing false positive results, as the co-cultures 
were extremely sensitive to these fluctuations. Importantly, changing temperature and handling the 
culture plates can potentially reduce the possibility of locally triggered action potentials. This could 
potentially be tested by probing for local action potentials or by loading neurons with a calcium probe 
that would allow for the detection of waves of depolarisation. Baseline CF was measured 30 seconds 
before the application of α-BTX (Figure 6.0). There were no differences (P = 0.64) in baseline CF 
between the negative control (1.25 Hz ± 0.27) and the positive controls before treatment (1.18 Hz ± 
0.33). All myotube contractions in the controls and α-BTX treated co-cultures stopped immediately 
upon addition of the treated and untreated diluent to the cultured cells. After 1 minute, myotube CF in 
the controls were measured at 0.08 Hz ± 0.08, while no myotube contractions were seen in the α-BTX 
treated cultures. Myotube contractions increased in the controls after 2 minutes to 0.27 Hz ± 0.08, no 
contractions were seen in the α-BTX treated cells. After 5 minutes, control myotubes were contracting 
at 0.96 Hz ± 0.19, no contractions were seen in the α-BTX treated cells. Following 10 minutes after 
treatment, CF in the controls returned to comparable baseline levels of 1.17 Hz ± 0.39. Controls 
continued to exhibit CF similar to baseline after 30mins (1.38 Hz ± 0.13) and 1 hour (1.23 Hz ± 0.2), 
though no contractions where observed in the α-BTX treated cells at these time points. The control and 
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α-BTX treated cells were washed out and fresh untreated DM was added to the cells after the 1 hour 
measurement, which resulted in the stoppage of contractions in both treated and control conditions. 
When measured again 30 minutes after washout (1 hour and 30 minutes after initial application of 
treatment), the controls were again contracting at a comparable baseline frequency of 1.18 Hz ± 0.26. 
This observation was also made 24 hours after treatment, where CF in the controls was 1.13 Hz ± 0.21. 
However, no observable contractile activity was witnessed in the α-BTX treated co-cultures at either of 
these final two time points.  
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Figure 6.0: Assessment of the functional effects of a 1:400 concentration of α-bungarotoxin on co-
cultured myotubes. A line graph comparing the contraction frequency of myotubes treated with α-
Bungarotoxin (α-BTX) and untreated controls. Data presented as a mean, error bars signify ± SD.  n = 5 
independent experiments. ** denotes P < 0.01, **** denotes P < 0.0001. Time point 1.1* indicates 
washout.  
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6.1.1 Functional Assessment of NMJs with Tubocurarine  
 
Tubocurarine is a toxic mono-quaternary alkaloid naturally occurring in the bark of the Chondrodendron 
tomentosum plant. The function of this toxin occurs by a reversible competitive binding of AChRs at the 
postsynaptic NMJ (Cooke and Grinnell, 1964). Similar to the effects of α-BTX, a sufficient dose of 
tubocurarine causes SkM paralysis and death from asphyxiation due to paralysis of the diaphragm. To 
determine if the innervated myotubes generated in the co-culture system parallels SkM paralysis 
observed in vivo, the co-cultures were treated with 8 µM tubocurarine to inhibit AChRs (Figure 6.1), as 
described in the methods section 2.1.19. There was no difference in baseline CF between treated and 
control co-cultured myotubes (1.18 Hz ± 0.25 vs 1.21 Hz ± 0.26, P = 0.75), recorded 30 seconds before 
addition of the treatment solution to the cells. Upon addition of tubocurarine to the treated cells and 
untreated diluent to the control cells, there was a halt in all observable contractions in both conditions. 
After 1 minute, CF of control myotubes was 0.12 Hz ± 0.06, no contractions were observed in the 
treated myotubes. After 2 minutes, CF of control myotubes was 0.22 Hz ± 0.06, no contractions were 
observed in the treated myotubes. After 5 minutes, myotube CF in the controls was 1.23 Hz ± 0.21, 
which was comparable to baseline CF, though no contractions were seen in the tubocurarine treated 
cultures. Controls continued to contract at a similar frequency of 1.25 Hz ± 0.31 after 10 minutes, no 
contractions were seen in the treated cells. Following 30 minutes after treatment, the tubocurarine 
treated cells were observed contracting at 0.13 Hz ± 0.09, which was significantly less (P < 0.0001) than 
the controls CF of 1.18 Hz ± 0.23. A slight increase in CF up to 0.51 Hz ± 0.16 was observed in the treated 
cells 1 hour after treatment, though this was still significantly less (P < 0.0001) than the controls, which 
were contracting at 1.03 Hz ± 0.22. Both control and treated conditions were washed out and fresh DM 
was added to the cells. The result was a complete stop of myotube contractions immediately following 
washout in both treated and control conditions.  There was no difference (P = 0.66) in CF when 
measured 30 minutes after washout, controls were contracting at 1.15 Hz ± 0.28 and treated cells at 
1.20 Hz ± 0.23. Similarly, when measuring CF 24 hours after initial treatment, the treated cells were 
contracting at 1.19 Hz ± 0.23 and the controls contracting at 1.1 Hz ± 0.17, indicating no significant 
difference (P = 0.27).    
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Figure 6.1: Assessment of the functional effects of 8 µM tubocurarine on co-cultured myotubes. A 
line graph comparing the contraction frequency of myotubes treated with tubocurarine and untreated 
controls. Data presented as a mean, error bars signify ± SD.  n = 5 independent experiments. **** 
denotes P < 0.0001. Time point 1.1* indicates washout.  
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6.1.2 Functional Assessment of NMJs with Bicuculline  
 
The phthalideisoquinoline alkaloid bicuculline is a competitive GABA receptor antagonist found in many 
plant species of the Fumarioideae subfamily (Manske, 1932). Previous studies have shown CF is 
modulated by the application of bicuculline in a homologous rat co-culture model (Mis et al., 2017). 
Thus, using the methods detailed in 2.1.19, 10 µM bicuculline was applied to the current in vitro NMJ 
system to determine its effects on myotube CF in this heterologous co-culture system (Figure 6.2). 
Baseline measurements of CF determined no difference between controls and treated cells 30 seconds 
before the addition of bicuculline treatment or untreated diluent to the co-cultures (1.26 Hz ± 0.27 vs 
1.37 Hz ± 0.18, P = 0.26). All contractions stopped immediately upon addition of bicuculline or DM in 
both treated and untreated cells. After 1 minute, controls were observed contracting at 0.08 Hz ± 0.06, 
yet no contractions were seen in the treated cells. Measuring CF after 2 minutes showed an increase in 
the controls to 0.19 Hz ± 0.04, no contractions were observed in the bicuculline treated cells. 
Measurements of CF at 5 minutes found the bicuculline treated cells to be contracting at a rate of 0.05 
Hz ± 0.04, which was significantly less (P < 0.0001) than the CF of controls, which were contracting at 
1.1 Hz ± 0.19. After 10 minutes, a slight increase in CF was observed in the treated cells to 0.67 Hz ± 
0.07, whereas CF in the controls was significantly higher (P < 0.0001) at 1.11 Hz ± 0.11. The CF measured 
30 minutes after treatment in the controls was significantly higher than the treated cells (1.06 Hz ± 0.14 
vs 0.6 Hz ± 0.13, P < 0.0001). Following 1 hour after treatment, the treated cells increased CF to 0.87 
Hz ± 0.13, yet was still significantly less (P = 0.003) than the controls, which were measured at 1.06 Hz 
± 0.12. All contraction stopped when the co-cultures were observed immediately following washout 
and replacement of DM in both conditions. When measured again 30 minutes after washout, there was 
no difference between the treated and control conditions (1.2 Hz ± 0.19 vs 1.1 Hz ± 0.15, P = 0.2). 
Similarly, after 24 hours no differences were seen between the treated and control conditions (1.27 Hz 
± 0.23 vs 1.2 Hz ± 0.25, P = 0.51). 
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Figure 6.2: Assessment of the functional effects of 10 µM bicuculline on co-cultured myotubes. A line 
graph comparing the contraction frequency of myotubes treated with bicuculline and untreated 
controls. Data presented as a mean, error bars signify ± SD.  n = 5 independent experiments. ** denotes 
P < 0.01, *** denotes P < 0.001, **** denotes P < 0.0001. Time point 1.1* indicates washout.  
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6.1.3 Functional Assessment of NMJs with L-Glutamic Acid 
 
Upon determining contractile activity of myotubes in the co-culture system could be stopped or 
attenuated by the application of antagonist drugs that act on AChRs at the NMJ MEP, the next 
experiment set out to determine the impact of presynaptic agonist stimulation of the NMJ at the MNs. 
Thus, using the methods in 2.1.19, the excitatory neurotransmitter glutamate, in the form of 400 µM 
L-glutamic acid (L-Glut), was applied to the co-cultures to assess the influence of L-Glut on the CF of co-
cultured myotubes (Figure 6.3). Baseline measurements of CF were recorded 30 seconds before the 
application of L-Glut to the positive controls and untreated diluent to the negative controls, which 
determined no significant differences (1.1 Hz ± 0.2 vs 1.2 Hz ± 0.3, P  = 0.3). All contractions stopped 
immediately following the addition of the treatment solutions to the cultures. When CF was measured 
again 1 minute after the application of the treatment, the myotubes in the L-Glut treated cultures were 
contracting at a frequency of 0.18 Hz ± 0.05, which was significantly higher (P = 0.003) than the controls 
(0.1 Hz ± 0.05). After 2 minutes, the L-Glut treated cultures significantly increased (P < 0.0001) myotube 
CF to 1.7 Hz ± 0.18, while controls were measured at 0.23 Hz ± 0.06. After 5 minutes, myotube CF was 
measured at 1.3 Hz ± 0.22 in the controls, indicating CF had returned to levels comparable to baseline 
activity. However, myotubes in the L-Glut treated cultures were contracting at a frequency of 3.7 Hz ± 
0.15, which was 2.5 Hz greater than the controls at this time point. When measuring contractile activity 
10 minutes after application of the treatment, the myotubes in the L-Glut treated co-cultures exhibited 
a CF of 1.06 Hz ± 0.15, which was comparable to controls (P = 0.28), having a CF of 1.17 Hz ± 0.27. A 
Similar comparison was observed after 30 minutes (1.2 Hz ± 0.13 vs 1.3 Hz ± 0.14, P = 0.12) and 1 hour 
(1.26 Hz ± 0.19 vs 1.34 Hz ± 0.26, P = 0.44) between the control and L-Glut treated cultures respectively. 
Washing out and replacing the DM in both culture conditions 1 hour after the initial treatment resulted 
in stoppage of all contractions in the cultures. When measuring again 30 minutes after washout, both 
control and treated cultures where contracting at similar rates (1.1 Hz ± 0.21 vs 1.21 Hz ± 0.28, P = 0.3), 
comparable to baseline. At 24 hours following the initial treatment, both controls and L-Glut treated 
cultures showed no difference in CF (1.18 Hz ± 0.22 vs 1.23 Hz ± 0.17, P = 0.63), exhibiting spontaneous 
activity similar to baseline measurements.  
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Figure 6.3: Assessment of the functional effects of 400 µM L-glutamic acid on co-cultured myotubes. 
A line graph comparing the contraction frequency of myotubes treated with L-glutamic acid and 
untreated controls. Data presented as a mean, error bars signify ± SD.  n = 5 independent experiments. 
** denotes P < 0.01, **** denotes P < 0.0001. Time point 1.1* indicates washout.  
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6.1.4 Functional Assessment of NMJs with γ-Aminobutyric Acid 
 
Mainly found in the synapses of the CNS the inhibitory neurotransmitter GABA performs vital functions 
in the brain (Obata, 2013). Some studies have shown GABA signalling may occur in the periphery, with 
GABA transporters and receptors involved with GABA signalling being detected in a small number of 
endocrine and exocrine glands (Watanabe et al., 2002). Molecular studies have also found the GABAA 
receptor subunits α4 and β2/3 are present in cholinergic neurons (Elinos et al., 2016; Park et al., 2006). 
Although GABA functions to reduce neuronal activity in the CNS, the effects of increased GABA 
concentration in the in vitro NMJ environment requires clarification. Thus, using the methods described 
in 2.1.19 the co-cultures were treated with 1 mM GABA and CF was compared against control 
conditions (Figure 6.4). Baseline measurements of CF 30 seconds before treatment determined no 
difference between positive and negative conditions (1.32 Hz ± 0.18 vs 1.26 Hz ± 0.27, P = 0.6). There 
were no differences in myotube CF between the GABA treated and control co-cultures after 1 minute 
(0.11 Hz ± 0.05 vs 0.13 Hz ± 0.11, P = 0.65), or 2 minutes (0.19 Hz ± 0.06 vs 0.24 Hz ± 0.06, P = 0.09) 
following the addition of the treatment to the co-cultures. The CF of myotubes in the GABA treated co-
cultures was significantly higher than the controls when observed 5 minutes after the treatment (1.7 
Hz ± 0.33 vs 1.01 Hz ± 0.2, P < 0.0001). However, there were no differences in myotube CF between 
GABA and non-treated controls after 10 minutes (1.19 Hz ± 0.16 vs 1.22 Hz ± 0.23, P = 0.78), 30 minutes 
(1.08 Hz ± 0.2 vs 1.15 Hz ± 0.16, P = 0.39), 1 hour (1.11 Hz ± 0.14 vs 1.09 Hz ± 0.2, P = 0.79), 1 hour and 
30 minutes (1.09 Hz ± 0.14 vs 1.2 Hz ± 0.2, P = 0.21), and 24 hours (1.36 Hz ± 0.22 vs 1.15 Hz ± 0.25, P = 
0.07) after treatment.  
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Figure 6.4: Assessment of the functional effects of 1 mM γ-aminobutyric acid on co-cultured 
myotubes. A line graph comparing the contraction frequency of myotubes treated with γ-aminobutyric 
acid (GABA) and untreated controls. Data presented as a mean, error bars signify ± SD.  n = 5 
independent experiments. **** denotes P < 0.0001. Time point 1.1* indicates washout.  
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6.2 Discussion  
 
The main results from this chapter demonstrated the functional capacity of NMJs generated in the 
nerve-muscle co-culture system established in this project. The experiments conducted were designed 
to show spontaneous myotube contractile activity was indeed driven by MN signalling through the 
NMJ. Thus, functionality of NMJs was assessed through the analysis of myotube CF modulation, using 
agonist and antagonist pharmacological interventions that act on presynaptic MNs or postsynaptically 
on AChRs at the NMJ. The introduction of α-BTX to the co-cultures resulted in an immediate and 
permanent stoppage of spontaneous myotube contractions. This finding indicated binding of AChRs at 
the NMJ MEP with α-BTX, preventing ACh from binding with the postsynaptic receptors and 
consequently inducing paralysis in the co-cultured innervated myotubes. Although the co-cultures 
exposed to the α-BTX were washed out and reverted to normal culture conditions with fresh DM, 
spontaneous myotube contractile activity was indefinitely immobilised. Demonstrating the NMJs 
generated in this in vitro co-culture system responded physiologically to an irreversible competitive 
antagonist at the AChRs, as observed at the in vivo mammalian NMJ (Domet et al., 1995). Furthermore, 
the addition of tubocurarine to the co-cultures led to an immediate yet temporary halt in endogenously 
generated myotube contractions. Unlike the α-BTX treated cultures, which were unable to re-establish 
contractile activity, the myotubes in the tubocurarine treated co-cultures re-initiated spontaneous 
activity, beginning with low frequency irregular spasms rather than the typical synchronised 
contractions observed in control conditions. Although, the re-establishment of contractile activity was 
observed (30 minutes) after the application of tubocurarine, the spontaneous myotube contractions 
did not return to a typical synchronous frequency until the co-cultures were restored to pre-
intervention conditions. Studies have shown the effects of ACh are not abolished in the presence of 
tubocurarine, but the ability of ACh to open the receptor channels is reduced, the result of which 
resembling a reduced concentration of ACh (Bowman, 2006). Dissimilar to the irreversible receptor 
antagonist α-BTX, which functionally inactivates the AChRs, tubocurarine acts by reducing the 
probability of ACh activating the receptor instead of inactivating it completely. Tubocurarine functions 
by repetitively associating and dissociating with its binding sites, as would be expected of a reversible 
competitive receptor antagonist, rather than remaining in constant contact with the AChR like α-BTX. 
The ability of myotube contractile activity in the co-cultures to recover from tubocurarine validates the 
accurate physiological nature of the neurotransmission witnessed in this in vitro NMJ system. The 
results from examining the application of bicuculline to the co-cultures revealed a preliminary cessation 
of myotube activity. Although spontaneous contractile function did partially recover, the frequency of 
myotube contractions were significantly attenuated prior to the removal of bicuculline from the 
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cultured cells. Previous research investigating the effects of the classic GABA type A receptor antagonist 
bicuculline on AChRs has demonstrated that bicuculline dose-dependently blocks the amplitude of the 
whole-cell current in cultured embryonic rat skeletal muscle (Liu et al., 1994). This study also showed 
the ability of bicuculline to reduce the maximum inducible ACh current without altering Kd value, this 
finding indicated that bicuculline non-competitively blocked the binding of ACh to AChRs. Ultimately, 
the study concluded that bicuculline was a blocker of embryonic nicotinic AChR channels (Liu et al., 
1994). Furthermore, experiments conducted to investigate the effects of bicuculline on heteromeric 
mouse muscle αβγδ nicotinic AChRs demonstrated bicuculline diminished ACh-induced currents in a 
quick yet reversible manner, indicating the receptor is inhibited by bicuculline. Further investigation 
examining the effect of bicuculline at different membrane potentials revealed receptor inhibition was 
voltage-dependent, indicating bicuculline blocks nicotinic AChRs in a non-competitive way (Demuro et 
al., 2001). These studies provide evidence for the notion that the bicuculline-induced modulation of 
myotube contractions observed in the current co-culture system resulted from the prevention of ACh 
to bind with receptors on the MEP, further indicating that signalling at the NMJ was regulating 
contractile activity of myotubes in this in vitro NMJ model. Glutamic acid is a neuron-specific excitatory 
neurotransmitter that induces APs in MNs (Jiang et al., 1990). Despite the detection of glutamate 
receptors in mammalian NMJs, some research suggests these receptors are involved with regulation of 
muscle fibre membrane potentials via the nitric oxide synthase system (Urazaev et al., 1995), rather 
than  signalling at the NMJ. When investigating the stimulation of associated neurons in the co-cultures 
via implementation of the neuron-specific excitatory neurotransmitter L-Glut, the frequency of 
myotube contractions in the system were significantly elevated. The impact of MN stimulation with L-
Glut on myotube CF was immediately observable, causing myotubes activity to increase 1.5 Hz over the 
controls in 2 minutes and increase to 2.5 Hz greater than the controls in 5 minutes. However, myotube 
CF returned to levels comparable to spontaneous activity within 10 minutes following MN stimulation 
with L-Glut. In mammals, it is accepted that SkMC membranes are stimulated exclusively through 
AChRs, indicating that these findings show the successful enhancement of myotube contractions in the 
co-cultures via introduction of L-glut into the system was most probably achieved via the increased 
release of ACh from the cultured MNs into the synaptic cleft of the NMJs. Generally recognised as an 
inhibitory neurotransmitter in CNS synapses, GABA performs important tasks in neuronal function and 
development via activation of ionotropic and metabotropic receptors (i.e. GABAA and GABAB 
respectively) (Obata, 2013; Bowery et al., 2002; Olsen and Sieghart, 2008). Intriguingly, studies have 
shown that GABAB receptor 1 & 2 were detectable at the MNT in the synapses of rat extensor digitorum 
longus muscles and the soleus muscles (Malomouzh, Nurullin, et al., 2015). Further research 
investigating the effects of GABA on quantal and non-quantal ACh release from MNT suggests GABA 
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could reduce ACh release via activation of the GABAB receptors found in mammalian NMJs, mediated 
by phospholipase C (Malomouzh, Petrov, et al., 2015). Although recent studies have shown 
components of GABA synthesis and transport at the AChRs in mammalian NMJs, a determination could 
not be made on whether GABA plays the role of a co-mediator of ACh or as a gliotransmitter at the 
NMJ (Nurullin et al., 2018). However, the researchers maintain that activation of GABAB receptors 
influences the intensity of ACh release. Interestingly, when GABA was introduced into the co-culture 
system, the contractile activity of myotubes was increased. A transient but significant elevation in 
myotube CF was observed in the GABA treated cultures in the first 5 minutes following treatment. This 
finding suggests ACh release and binding at the NMJ was enhanced in the co-culture system, 
contrasting the findings in the above-mentioned studies. However, some research has shown that 
GABAA receptors are found at the embryonic vertebrate SkMCs and the expression of several 
transmitter receptor classes exist in early embryonic muscle and neuron development, including 
glutamate, glycine, ACh, as well as GABA (Borodinsky and Spitzer, 2007). Thus, further examination into 
the role and dynamic functions of GABA at the embryonic and mature mammalian NMJ is required, 
before the mechanisms of GABA action at the NMJ can be fully elucidated. Ultimately, the results in 
this chapter provided evidence that this nerve-muscle co-culture system permits assessment of NMJ 
functionality in real time. Offering a high-content platform for the evaluation of innovative therapies 
and in vitro disease modelling, as well as a system for refining the comprehension of NMJ formation 
and function in both healthy and disordered conditions. 
 
6.3 Conclusion 
 
In summary, a simplified in vitro nerve-muscle co-culture system was evaluated for NMJ functionality. 
Firstly, it was discovered that spontaneous myotube contractions in the co-cultures were indeed driven 
by MN signalling through NMJs. Additionally, it was verified the co-culture model responded in a 
physiologically appropriate manner to the drugs used in this study. Confirmed by reversible and 
irreversible paralysis of myotube contractile activity with AChRs antagonists, as well as augmenting 
myotube contractions with MN agonists.  
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Chapter 7: Investigation of Growth and Neurotrophic Factor 
Concentrations in Co-Cultures of Human Myoblasts Innervated by Rat 
Embryonic Spinal Cord Explants Compared with Human Myoblast 
Monocultures. 
 
7.0 Background 
 
7.0.0 Introduction 
 
In the previous chapter, experiments were performed to validate the functionality of NMJs in the in 
vitro NMJ co-culture model comprised of human myoblasts co-cultured with embryonic rat nerves. 
Successful modulation of myotube contractile activity via manipulation of NMJs with postsynaptic AChR 
antagonists and presynaptic MN agonists was confirmed throughout the co-cultures. Indicating this in 
vitro NMJ system physiologically reflects in vivo mammalian NMJ function in response to known drugs 
and toxins. Thus, this novel co-culture system free from serum, growth, and neurotrophic factors would 
be an ideal in vitro NMJ model for screening potential drugs and molecules of interest in research 
concerning NM and ND disorders such as CMS, LEMS, MG, ALS, SMA, diabetic neuropathy and 
myopathy, sarcopenia, cancer cachexia and heart failure. The simplified nature of the co-culture system 
(i.e. serum, growth/neurotrophic factor free) also assures reliability in drug screening protocols. As the 
introduction of exogenous complex neural growth factors, as seen in alternative nerve-muscle co-
culture models (Das et al., 2007; Guo et al., 2011; Guo et al., 2014; Rumsey et al., 2010; Puttonen et al., 
2015), has the potential to influence and alter drug screening and development (Dugger et al., 2018). 
However, endogenously occurring growth factors and neurotrophins are vital for survival, 
development, plasticity, function and death of neurons in vivo (Oppenheim, 1991; Reichardt, 2006), as 
well as the maturation of  myoblasts (Syverud et al., 2016). Accordingly, significant research has been 
conducted on the role of growth/neurotrophic factors in nervous system development and function. 
However, evidence from further research studies indicate that these factors have important functions 
in various cell populations across many tissues. One cell population of particular interest is that of 
SkMCs, which express receptors for several growth factors, cytokines, and neurotrophins, suggesting 
neurotrophic signalling occurs within SkMCs during formation, development and innervation 
(Griesbeck et al., 1995; Chevrel et al., 2006; Gonzalez et al., 1999). To our knowledge, the co-culture 
system established in this project is the first co-culture model engineered without exogenous neural 
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growth factors, suggesting all the factors required for the formation and maturation of NMJ, advanced 
differentiation of SkMCs, and maturation MNs were secreted endogenously. Studies with 
neurotrophin-4 (NT-4) and neurotrophin-5 (NT-5) null mice display clear defects in muscle development 
and function, indicating NT-4/5 are involved with SkM fibre differentiation (Carrasco and English, 2003). 
Additionally, neurotrophin-3 (NT-3) has been implicated in the formation of muscle spindles (Ernfors 
et al., 1994) and some dystrophic muscle pathologies have been linked with altered nerve growth factor 
(NGF) (Capsoni et al., 2000). Brain-derived neurotrophic factor (BDNF) expression studies have also 
shown various physiological and pathological conditions can influence the SkMC expression of BDNF 
(Chevrel et al., 2006). For example, research with healthy humans as well as people with multiple 
sclerosis has shown circulating BDNF can be increased with physical exercise (Ferris et al., 2007; Rojas 
Vega et al., 2006; Gold et al., 2003). Studies have also demonstrated that exercise with an ergometer 
bicycle for 2 hours was able to induce BDNF mRNA production in SkM (Matthews et al., 2009). 
Furthermore, the concentrations of SkM neurotrophins is altered in denervated SkMCs and studies 
with diabetic mice reveal reductions in the expression of NT-3 and NGF mRNA and increased expression 
of BDNF mRNA in the muscle (Fernyhough, Diemel, Brewster, et al., 1995; Fernyhough, Diemel, Hardy, 
et al., 1995; Ihara et al., 1996; Fernyhough et al., 1998; Fernyhough et al., 1996). The glial-cell-line-
derived neurotrophic factor (GDNF) is known for its role in the support of CNS dopaminergic neurons 
and was first discovered in glial cells (Lin et al., 1993). Research has shown that overexpression of GDNF 
in SkM incudes hyper innervation of NMJs through increased MN sprouting (Nguyen et al., 1998). It has 
been suggested that GDNF can function to maintain cholinergic MNs throughout aging (Ulfhake et al., 
2000) and a significant yet transient expression of GDNF at NMJs during embryonic myogenesis is also 
witnessed in vivo. Interestingly, GDNF expression has also been shown to be increased in denervated 
human SkM (Lie and Weis, 1998). The results from characterisation and functional assessment of the 
co-culture system communicated in the previous chapters of this project provided evidence that the 
NMJs generated in system physiologically mirror in vivo functionality and structural development. As 
mentioned in prior chapters of this project, alternative established nerve-muscle co-culture models 
typically require a complex neural growth media that contain serum and/or a cocktail of neural growth 
factors (some of which may derived from animals). This further complicates drug discovery and 
toxicology studies due to possible cross-communication of the novel compounds being studied with 
factors contained within culture media formulation, possibly explaining why many promising therapies 
do not translate to clinics. Even the most recent systems requiring up to 18 different trophic factors to 
establish their model successfully (Table 4.0). Furthermore, many systems induce myotube 
contractions via the application of electrical or chemical stimulation, which does not replicate the 
native physiological stimulation required for muscle contractions. Thus, the question remains how the 
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current co-culture model engineered during this project generated robust functional NMJs without 
serum and trophic factors, suggesting MNs and SkMCs in the system release all of the necessary factors 
needed to stimulate sprouting of MN axons and formation of NMJs with myotubes. Thus, to aid in 
clarifying this simplified co-culture system’s ability to generate robust NMJs without the inclusion of 
exogenous serum, growth and neurotrophic, as is required by previously established nerve-muscle co-
culture system, ELISA-based microarray experiments were conducted in the following study to examine 
the concentration of endogenously secreted growth factors and neurotrophins in this in vitro NMJ 
system.  
 
7.0.1 Aims 
 
The objective of the present study was to determine the concentration of growth and neurotrophic 
factors endogenously occurring in the co-cultures. Thus, the aim was: 
 
1. Establish the co-culture model. 
 
2. Culture myoblasts aneurally.  
 
3. Collect, analyse, and compare the supernatant of C25 co-cultured with ED 13.5 rat embryo 
SCEs against aneurally cultured human myoblasts using an ELISA-based human growth 
factor microarray.   
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7.1 Results 
 
7.1.0 Quantification of Growth and Neurotrophic Factors 
 
To determine if there were any significant differences in the secretion of growth/neurotrophic factors 
in the supernatant of co-cultured and aneurally cultured human myoblasts, an ELISA-based microarray 
analysis of growth/neurotrophic factor concentrations was performed and compared between the two 
conditions. The methods used to perform the microarray analysis were described in section 2.1.20. The 
concentration of 40 growth/neurotrophic factors were quantified on day 7, shown in Table 7.0. The 
results revealed that twelve of the factors analysed were significantly different (P < 0.05) between co-
cultures and aneural myotube cultures. Specifically, the concentrations of brain-derived neurotrophic 
factor (BDNF), fibroblast growth factor 7 (FGF-7), glial cell-derived neurotrophic factor (GDNF), insulin-
like growth factor-binding protein (IGFBP) -1, -3, -4, -6, insulin-like growth factor 1 (IGF-1), 
neurotrophin (NT) -3, -4, placental growth factor (PIGF), and vascular endothelial growth factor (VEGF) 
were significantly higher in the supernatant collected from the co-cultures compared to the 
supernatant from aneurally-cultured myotubes.  
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Table 7.0: ELISA-based microarray analysis of growth and neurotrophic factor in supernatant collected 
from co-cultured and aneurally-cultured myotubes on Day 7. 
 
Growth 
factors 
Co-culture 
(pg/mL) 
Aneural 
(pg/mL) 
Fold 
change 
P - value Log-Log 
regression 
standard 
curve R2 
AR 4.03 ± 5.27 1.61 ± 1.87 2.5 0.26 0.987 
BDNF 52.33 ± 39.14 4.88 ± 1.73 10.72 0.005 ** 0.976 
bFGF 2.55 ± 5.1 0.65 ± 1.06 3.91 0.31 0.943 
BMP-4 10.55 ± 13.6 1.44 ± 3.25 7.33 0.09 0.961 
BMP-5 215.8 ± 431.6 94.38 ± 109.3 2.29 0.45 0.996 
BMP-7 3.67 ± 6.76 0.83 ± 1.55 4.42 0.26 0.994 
b-NGF 0.4 ± 0.5 0.24 ± 0.29 1.6 0.48 0.991 
EGF 0 0.01 ± 0.01 0 0.51 0.984 
EGF R 179.2 ± 89.26 111.5 ± 32.68 1.61 0.08 0.995 
EG-VEGF 0.43 ± 0.78 0.18 ± 0.36 2.39 0.45 0.986 
FGF-4 16.65 ± 33.3 3 ± 8.49 5.55 0.28 0.997 
FGF-7 11.13 ± 7.19 2.91 ± 3.09 3.8 0.02 * 0.996 
GDF-15 410.3 ± 99.25 345.5 ± 71.91 1.18 0.22 0.999 
GDNF 7.37 ± 6.72 1.51 ± 1.43 6.41 0.05 * 0.996 
GH 0.83 ± 1.65 0.61 ± 1.11 1.39 0.79 0.994 
HB-EGF 0.38 ± 0.45 0.48 ± 0.67 0.79 0.77 0.971 
HGF 10.25 ± 11.84 13.85 ± 6.36 1.35 0.49 0.991 
IGFBP-1 50.43 ± 34.91 10.98 ± 2.98 4.59 0.008 ** 0.997 
IGFBP-2 965.2 ± 1251 231 ± 74.01 4.18 0.11 0.999 
IGFBP-3 46859 ± 17230 14678 ± 2508 3.19 0.0003 *** 0.988 
IGFBP-4 30130 ± 14177 8351 ± 2221 3.61 0.001 ** 0.999 
IGFBP-6 877.6 ± 265.6 520.9 ± 149.9 1.68 0.01 * 0.987 
IGF-1 86.73 ± 53.36 19.89 ± 46.82 4.36 0.05 * 0.975 
Insulin 3809 ± 3821 3796 ± 2547 1 0.99 0.989 
MCSF R 1.33 ± 2.58 1.21 ± 1.82 1.1 0.93 0.991 
NGF R 129.1 ± 81.12 161.8 ± 44.51 1.25 0.38 0.987 
NT-3 35.1 ± 10.32 10.08 ± 3.77 3.48 0.0002 *** 0.997 
NT-4 4 ± 4.1 0.64 ± 0.72 6.25 0.03 * 0.999 
OPG 1117 ± 194.7 875.7 ± 247.1 1.28 0.12 0.996 
PDGF-AA 2378 ± 812.7 1828 ± 613.4 1.3 0.22 0.996 
PlGF 221.3 ± 36.89 171.8 ± 29.89 1.3 0.03 * 0.987 
SCF 0.73 ± 1.2 0.28 ± 0.4 2.61 0.34 0.996 
SCF R 1.23 ± 1.46 0.66 ± 1.12 1.86 0.47 0.998 
TGFa 0 0.01 ± 0.04 0 0.51 0.889 
TGFb1 98.63 ± 197.3 15.71 ± 44.44 6.28 0.26 0.984 
TGFb3 0.3 ± 0.6 0.21 ± 0.46 1.43 0.78 0.979 
VEGF 1060 ± 154.7 609.1 ± 105.9 1.74 0.0001 *** 0.963 
VEGF R2 4.78 ± 6.74 1.96 ± 3.51 2.44 0.35 0.999 
VEGF R3 4 ± 4.67 1.66 ± 1.92 2.41 0.23 0.991 
VEGF-D 0.15 ± 0.24 0.13 ± 0.24 1.15 0.87 0.991 
Note: * denotes P < 0.05; ** denotes P < 0.01; *** denotes P < 0.001 
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7.2 Discussion 
 
Motor neurons and SkM are co-dependent tissues, each relying on the other for trophic stimulation. 
Indicating the bidirectional communications between these cells is vital for NMJ formation and 
maintenance. To understand how this co-culture model was established in the absence of exogenous 
neural growth factors, ELISA-based arrays were employed. The results from this study presented a 
quantitative measurement of 40 human growth factors and neurotrophins endogenously produced in 
the in vitro NMJ co-culture system, compared with endogenously produced factors in aneurally-
cultured myotubes. Microarray experiments to quantify the concentration of growth factors were 
performed to show the formation and development of in vitro NMJs generated in the co-culture system 
were indeed supported by the endogenous regulation of specific growth or neurotrophic factors. When 
examining the results from Table 7.0, the concentration of a number of factors involved with NMJ 
formation, MN maintenance, and myotube development were discovered to be elevated in the co-
culture system compared with aneural myotube cultures. Studies investigating the role BDNF in the 
development of NMJs suggest SkM innervation and MN survival are enhanced by SkM-derived BDNF, 
as well as transmission at the NMJ being potentiated by BDNF (Zhang and Poo, 2002; Yan et al., 1993). 
It has also been shown that myoblasts express high levels of BDNF during embryonic development in 
vivo, which is gradually down regulated as NMJ and SkM fibre maturation occurs (Griesbeck et al., 
1995). Interestingly, research investigating chronic exposure to upregulated BDNF resulted in the 
inhibition of synaptogenesis in developing in vitro NMJs (Peng et al., 2003). Collectively, these results 
can be used as evidence to suggest that the endogenously regulated concentration of BDNF secreted 
in the present co-culture system allowed for the physiological formation and development of NMJs, 
which were representative of in vivo NMJ formation. Contrastingly, previously established nerve-
muscle co-culture systems that require the inclusion of exogenous BDNF (Das et al., 2010; Rumsey et 
al., 2010; Das et al., 2007; Guo et al., 2017; Guo et al., 2011; Guo et al., 2014; Puttonen et al., 2015; 
Vilmont et al., 2016; Smith et al., 2016) may not generate the robust NMJ formation observed in the in 
vitro NMJ system generated during this project, due to unsuitable concentrations of exogenous BDNF 
inhibiting NMJ maturation (Song and Jin, 2015).  
In addition to the significant BDNF upregulation measured in the co-cultures, FGF-7 was also 
significantly elevated. Studies have shown that organising molecules derived from SkM, such as 
members of the FGF family, have vital functions in regulating presynaptic specialisation at the NMJ 
(Umemori et al., 2004; Fox et al., 2007). An Investigation to determine if agrin can induced retrograde 
signalling of these muscle-derived organising molecules was conducted using real-time quantitative 
PCR analysis of RNA isolated from C2C12 myotubes treated with agrin. The researchers found that FGF-
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7 was significantly elevated in agrin treated myotubes. Furthermore, it was shown that FGF-7 mRNA 
was inhibited in the diaphragm of agrin deficient mutant mice. The determination was made that agrin 
does in fact regulate FGF expression in SkM for the purpose of supporting presynaptic differentiation 
at the NMJ by opposing the deleterious impact of non-postsynaptic ACh signalling (An et al., 2010). 
Thus, the elevated FGF-7 observed in the co-culture system suggests interactions between agrin 
secreted by the ED 13.5 rat embryo SCE and the innervated myotubes during NMJ formation and 
development, as would be expected in vivo.  
Results from the microarray also revealed elevated GDNF in the co-cultures in comparison to myotube 
monocultures. A key factor shown to be highly effective for MN survival in vitro is GDNF (Oppenheim 
et al., 1995). Intriguingly, GDNF is another example of a target-derived factor that is expressed by SkM 
with its receptor RET tyrosine kinase expressed in the MNs (Baudet et al., 2008). When conditionally 
ablating RET tyrosine kinase in the cranial MNs of mice, the outcomes were obvious disruptions to MNT 
maturation and reduced MEP size at NMJs (Baudet et al., 2008). Experiments with frogs to create a 
nerve-muscle co-culture system found that spontaneous synaptic current frequency and amplitude 
were increased when the co-cultures were treated with GDNF, indicating its possible role as a 
retrograde signalling factor (Wang et al., 2002). Furthermore, studies with transgenic mice that 
overexpress SkM-derived GDNF results in hyperinnervation of NMJs (Nguyen et al., 1998). Another 
study similarly found motor unit enlargement, hyperinnervation of NMJs, and slowed synapse 
elimination when GDNF was injected into mice during postnatal life (Keller-Peck et al., 2001). These 
findings suggest SkM derived GDNF plays a role in the regulation of MNT maturation at the NMJ. Thus, 
elevated GDNF observed in the co-culture system described in this project indicates interaction 
between pre- and post-synaptic components of NMJs in the system.  
The growth factor IGF-1 is a potent anabolic hormone involved with growth throughout the body, 
shown to induce hypertrophic effects on SkM, which has been extensively documented in animal 
models and muscle cell culture systems (Velloso, 2008). The muscle specific expression of IGF-1 also 
functions to stabilise NMJs and enhanced motor neuronal survival (Dobrowolny et al., 2005). When 
injected directly into SkM, IGF-1 inhibits degeneration of MNs and NMJs, thus preventing age-related 
force decline in mice (Payne et al., 2006). Interestingly, the concentration of four (IGFBP -1, -3, -4, -6) 
of the five insulin-like growth factor binding proteins examined during the microarray experiments, 
along with IGF-1, were significantly elevated in the co-cultures. The primary function of the IGFBPs is 
to serve as membrane transporter proteins for IGF-1, with almost all IGF-1 being bound to at least one 
of the seven members of the IGFBP superfamily (Hwa et al., 1999). Binding to IGF-1 with a 1:1 ratio, 
IGFBP-3 is the most common protein of the superfamily and binds ~80% of circulating IGF-1 (Adachi et 
al., 2017). Noteworthy, the presence of IGFBP-3 was also the most abundant IGFBP observed in the co-
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cultures and monocultures when compared to the other IGFBP measured during the array experiment. 
Studies examining the impact of IGFBPs on circulating IGFs found IGF-1 bioavailability is enhanced 
through the activity of the IGFBPs (Stewart et al., 1993). Thus, the observed upregulation of the IGFBPs 
and IGF-1 in the co-culture system supports the notion that interaction between SCEs and SkMCs in the 
system generates the necessary factors for MN maturation, advanced differentiation of myofibres, and 
the formation of robust NMJ, representative of in vivo formation.    
Both NT-3 and NT-4 were also significantly elevated in the co-cultures when compared to aneural 
myotube cultures. Studies have demonstrated that NT-3 and NT-4 are important modulators of 
synaptic function and development and are required for maintenance of presynaptic and postsynaptic 
apparatus at the NMJ (Gonzalez et al., 1999; Belluardo et al., 2001). Studies exploring early postnatal 
development of NMJs and the NM system in NT-3 deficient mice found reductions in somal size, yet 
the number of αMNs developed normally (Woolley et al., 1999). Further research discovered decreased 
innervation of MEPs by MNTs and decreased number of SkM fibres in NT-3 deficient mice at birth, 
followed by a catastrophic postnatal loss of MNTs by postnatal development day 7 and complete 
denervation of hindlimb muscles with no observable NMJ remaining in the entire SkM endplate zones 
(Woolley et al., 2005). Additionally, mice with haploinsufficiency-induced reductions in NT-3 availability 
exhibit impaired MNT maturation, reduced recycling of synaptic vesicles, and a reduction in SkM fibre 
diameter (Sheard et al., 2010). Studies investigating NM transmission using a phrenic nerve / adult rat 
diaphragm-muscle system exposed that NT-4 treatment can improve synaptic transmission when 
transmission failure was induced in the system via repetitive nerve stimulation (Mantilla et al., 2004). 
The expression of NT-4 is also shown to be dependent on synapse activity at the NMJ, demonstrated 
via blockade of AChRs on the NMJ MEP with α-BTX causing reduced NT-4 expression, while electrical 
stimulation of MNs enhances SkM-derived NT-4 expression (Funakoshi et al., 1995). Considering these 
studies, it can be appreciated that the significantly elevated NT-3 and 4 expression observed in the co-
culture system was due to NMJ formation, development and synaptic activity. 
Intriguingly, the concentration of VEGF and PlGF, which is a member of the VEGF sub-family, were also 
significantly elevated in the co-cultures when compared to the anural myotube cultures. Originally 
described for their regulatory role in vascular growth and development (Ferrara, 2004), the VEGF family 
of factors have also demonstrated important functions in MN growth, guidance, migration, and survival 
(Rosenstein et al., 2010; Ruiz de Almodovar et al., 2009). Research with ALS transgenic mice found 
systemic administration of VEGF was able to increase the number of NMJs in the diseased mice (Zheng 
et al., 2007). Furthermore, Amelioration of SkM innervation is observed following administration of 
VEGF in mice with ischemic injury, promoting both regrowth and maintenance of damaged MN axons 
in the mice (Shvartsman et al., 2014). The researchers in that study also found VEGF was able to induce 
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the upregulation of GDNF and NGF to aid in MN axon regeneration (Shvartsman et al., 2014), pointing 
to the  synergistic effects of growth factors during NMJ formation.  
Finally, the results from the experiments conducted in this chapter provided important insights into the 
cellular signalling of this simplified co-culture system. Furthermore, the results demonstrated the 
capacity of the co-culture system to endogenously regulate formation and development of NMJ, as well 
as provide the conditions to allow the advanced differentiation of immortalised human myotubes in 
vitro, through the precise expression of essential growth factors and neurotrophins.  
 
7.3 Conclusion 
 
In conclusion, this report analysed the concentration of 40 human growth factors and neurotrophins in 
the in vitro NMJ system generated from ED 13.5 rat SCEs co-cultured with C25. Elevated concentrations 
of 12 factors involved with MN, SkM, and NMJ development were measured in the co-cultures system, 
providing evidence the in vitro NMJ generated in this project were representative of in vivo conditions.  
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Chapter 8: General Discussion & Conclusions 
 
8.0 Discussion 
 
The overarching aim of this project was to establish and validate a novel and simplified nerve-muscle 
co-culture system capable of generating functional in vitro NMJs, without the use of serum, growth, 
and/or neurotrophic factors. Thus providing a defined platform to investigate disease and disorders of 
the NM system via examination of NMJ formation and functionality. The fulfilment of this aim was first 
addressed through the optimisation of cell culture conditions for the two immortalised human SkMC 
lines newly acquired for this project. Optimisation of culture conditions for the two cell lines, one young 
(25 years old) and one old (83 years old), was completed before any co-culture studies were conducted, 
as both these cell lines had not been previously established  or used in our laboratory. Upon successfully 
optimising culture conditions for the two cell lines, the myogenic potential of both C25 and C83 cells 
was compared to determine any differences in the in vitro proliferation and differentiation of 
immortalised human myoblasts originating from old or young muscle. Through the analysis of cellular 
passaging, examination of proliferative capacity and differentiation parameters, as well as investigating 
the expression of the proliferation marker Ki67 and differentiation marker MHC, the determination was 
made that in vitro function of immortalised human myoblasts was not influenced by the intrinsic age 
of the donor SkM. Preliminary cellular passaging experiments of both cell lines found that myoblasts 
from young or old origins had similar proliferative capacity and responses to cryogenic revival.  
Importantly, to eliminate any variability between the cell lines, possibly induced through serial 
passaging, experiments were conducted with myoblasts having been passaged an equal number of 
times. Studies have shown that serial passaging of cell lines can lead to phenotypic drift in the cell line 
(Geraghty et al., 2014). Thus, to diminish possible passage-induced phenotypic changes among the 
young and old cell lines, experiments were conducted with cells cryogenically passaged no more than 
four times. Subsequent investigations comparing the proliferative capacity of myoblasts between the 
young and old cell lines determined similar rates of cellular expansion when the cells were cultured, 
which was reflective of the published literature (Pietrangelo et al., 2009; Decary et al., 1997). Similarly, 
comparing the capacity of young and old myoblasts to differentiate using three different DM 
formulations revealed cellular fusion occurred at equal rates among the two cell lines in each of the 
three culture conditions. Further experimentation examining the differences between young and old 
myoblasts detailed the prominent similarities in the differentiation parameters and the expression of 
the proliferation and differentiation markers. Ultimately, the cell culture conditions generated in this 
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project revealed that immortalised human myoblasts maintained their myogenic potential and function 
when cultured in vitro, despite an almost 6-decade difference in the age of the donor SkM.  Importantly, 
these finding coincide with studies utilising primary human myoblasts, which also showed persevered 
in vitro myogenic functionality regardless of the age of the donor SkM (Alsharidah et al., 2013). 
Indicating that age-linked changes to the SkM microenvironment rather than then intrinsic age of 
myoblasts induces the faulty SkM regeneration observed in aged SkM (Conboy et al., 2005; Carlson and 
Faulkner, 1989). 
Upon determining no morphological differences between the young and old cell lines, the subsequent 
objectives of this project were executed utilising only the C25 cell line, as both cell lines performed 
equally when cultured under identical conditions. The next objective achieved in the fulfilment of the 
primary aim of this project was the generation of a novel simplified in vitro nerve-muscle co-culture 
system, free from serum, growth factors, and neurotrophins. Importantly, one of the biggest challenges 
in translating data from in vitro research to human trials is the inclusion of serum in the in vitro system. 
The role of serum in cell culture is extremely complex due to the occurrence of both growth factors and 
inhibitors. Thus, the use of serum in cell culture has many substantial drawback that can lead to 
misinterpretations of experimental results (Barnes and Sato, 1980; Ulreich and Chvapil, 1982; 
Sandstrom et al., 1994). For example, serum composition lacks uniformity, quality testing is required 
of each batch before use, growth-inhibiting factors may be present, an increased risk of contamination 
is possible, and the existence of serum in media can impede the isolation and purification of cells in 
culture. The experimental procedures conducted in the creation of the co-culture system permitted 
the proliferation of MN axons from ED 13.5 rat SCEs while simultaneously promoting  innervation 
during myoblast-to-myotube differentiation of C25. Motor axons and their terminals were observed 
overlapping AChRs on contractile myotubes within the system, suggesting the formation of preliminary 
in vitro NMJs in the co-cultures. Importantly, myotubes in the co-culture system displayed contractile 
activity. This finding demonstrated the preliminary benefits of the co-culture system as a platform for 
studying SkM disorders in comparison to monocultures of SkMCs, which are less representative of in 
vivo conditions, as they do not exhibit contractile activity. In studies of SkMC monocultures treated 
with MN-derived growth factors involved with NMJ formation, such as agrin, no contractile activity is 
observed (Arnold et al., 2004; Bandi et al., 2008). Indicating that secreted factors alone did not promote 
the contractile activity observed in the co-culture system and cellular signalling via NMJ formation was 
most probably responsible for the contractile activity observed in the system. Myotube contractions in 
the system were observed as early as 72 hours after the co-culture of the SCEs with the C25. To the 
author’s knowledge, this is the first nerve-muscle co-culture system to exhibit spontaneous myotube 
contractions at this stage of development without supplementing the co-culture environment with 
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serum, growth and/or neurotrophic factors. Thus, the simplified composition of the co-culture system 
allowed for easy reproducibility, along with being a more accurate reflection of in vivo SkM 
development compared to SkMC monocultures. Furthermore, previous co-culture systems attempting 
to induce in vitro innervation of myotubes have all required the inclusion of at least one growth factor 
in their systems in order to generate spontaneous contractile activity in myotubes via NMJ formation 
(Das et al., 2010; Das et al., 2007; Rumsey et al., 2010; Rumsey et al., 2009; Guo et al., 2017; Guo et al., 
2011; Guo et al., 2014; Chipman et al., 2014; Demestre et al., 2015; Umbach et al., 2012; Vilmont et al., 
2016; Puttonen et al., 2015; Morimoto et al., 2013; Larkin et al., 2006). The simplified methods and 
efficient use of resources used to generate the co-culture model were able to induce myotube 
contractions in as little as three days post co-culture and by seven days post co-culture myotube 
contractions were exhibiting synchronicity, implying an abundance NMJ formation generated in a time 
efficient manner. This observation suggested the co-culture model offers ideal conditions for high-
throughput research of the mechanisms responsible for the formation of NMJs. Contrastingly, most of 
the previously established models cited above require weeks of separately cultured MNs and SkMCs 
before co-culturing the cells and several more weeks before NMJ formation and myotube contraction 
are observed. Thus, providing further evidence that the co-culture model generated in this project 
offers many advantages over the established systems. Additionally, other advantages of this system 
being free of serum and growth/neurotrophic factors include it being cost-effective as well as saving 
on labour. The co-culture model was also designed with the neural component originating from SCEs 
as opposed to a cell suspension created from intact embryo spinal cords. This was due to experiments 
revealing SCEs induced synchronous and high frequency myotube contractions in the shortest 
timeframe, suggesting ventral horn and dorsal root neurons as well as supporting cells types at the 
DRGs, such as glial cells function mutually to correctly innervate myotubes and form NMJs in the 
system.  
After establishing the co-culture model, the next objective in this project was to characterise the system 
to verify the occurrence of physiological NMJ formation. Before characterisation of the co-cultures was 
performed, experiments were conducted to determine the optimal time point indicative of mature NMJ 
formation. Peak contraction frequency was used to determine mature NMJ formation, which was 
observed 14 days after co-culture. Additionally, these preliminary experiments also revealed the long-
term viability of the co-cultured cells, as the experiments were not terminated until 30 days after co-
culture and could have been maintained longer if required. Cholinergic MNs were identified and 
characterised in the system using antibodies for ChAT and VaChT, which revealed the interaction 
among cholinergic MNs and myotubes in the system. This important finding reflects NMJ development 
seen in vivo, as both ChAT and VaChT are required for correct MN development and function (Brandon 
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et al., 2003; Misgeld et al., 2002). Along with MN and SkMC interactions during in vivo NMJ formation, 
the presence of terminal Schwann cells is also required. Studies with mice have shown that preliminary 
NMJ formation is possible without Schwann cells, but for appropriate synapse development to occur in 
vivo Schwann cells must be involved (Lin et al., 2000; Morris et al., 1999; Riethmacher et al., 1997; 
Woldeyesus et al., 1999; Wolpowitz et al., 2000). Thus, characterisation of Schwann cells in the co-
culture system with antibodies for GFAP suggests the interaction between MNs, myotubes, and 
Schwann cells in the system promoted the maintenance and maturation of the in vitro NMJs generated 
in the system. The co-cultures were then stained for Syt1, a presynaptic calcium sensor that can be 
used to expose presynaptic MNT activity and is known to be crucial for facilitating the release of 
neurotransmitters from Ca2+ dependent vesicles (Geppert et al., 1994; Littleton et al., 1993). Identifying 
Syt1 at MNTs in the co-culture system provided further evidence of successful structural formation of 
NMJs in the system as would be expected during in vivo signal transmission at the NMJ. Subsequently, 
NMJ characterisation was performed to show postsynaptic AChRs at the NMJ MEP co-localising with 
MNs and their terminals. Accordingly, evidence of physiological in vitro NMJ formation, comparably 
observed in vivo was attained by the identification of AChRs on the MEP in the typical twisting knotted 
configuration overlapped by MNs, which endorsed the notion that the co-cultures were generating 
NMJs and exhibiting attributes of successful maturation. Postsynaptic characterisation of the co-
cultures was also conducted to determine if NMJs in the system exhibited appropriate postsynaptic 
development and structural organisation. Observations of MuSK and Rapsyn at the MEP suggested 
agrin secretion from the MNT was able to trigger the MuSK signalling pathways. This finding 
demonstrated synaptic communication at the NMJ allowed for successful postsynaptic differentiation, 
as was shown by the co-localisation between Rapsyn, MuSK, and AChRs. Co-cultured myotubes also 
displayed the morphological characteristics of advanced differentiation. Specifically, transversal triads, 
which are the precisely developed excitation-contraction coupling apparatus characterised by the tight 
apposition of RYRs on the SR membranes and DHPRs on the T-tubules, physiological sarcomeric 
development as demonstrated by the presence of striations on the myotube membrane, and 
peripherally nuclei were all observed in the co-culture system. All of which are observed in vivo during 
advanced differentiation of SkMCs (Bruusgaard et al., 2003; Shadrin et al., 2016). Thus, the advantage 
of this co-culture system over typical aneural in vitro myoblast cultures and previously established 
nerve-muscle co-culture models is apparent, as they do no exhibit the level of advanced myotube 
differentiation seen in this co-culture system. Thus, this co-culture system is a superior tool for 
researching SkM wasting associated with ageing (e.g. sarcopenia) and disease (e.g. cancer cachexia) 
and investigating NM disorders. Through characterisation of the co-culture system, evidence was 
provided showing the interaction between neurons, myotubes, and neuroglia, as well as confirmation 
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of mature NMJs with presynaptic activity and postsynaptic structural organisation, and advanced 
differentiation of myotubes.  
Once characterised, the next objective was to ensure NMJs function physiologically and confirm 
spontaneous myotube contractions in the co-culture system were MN-driven via signalling at the NMJ. 
This was accomplished with agonist and antagonist drug-response experiments, designed to act 
presynaptically on MNs and postsynaptically on AChRs at the NMJ, consequently influencing myotube 
CF. When exposed to α-BTX a permanent stoppage of spontaneous contractions occurred. 
Demonstrating that NMJs in the co-cultures reacted correctly to an irreversible competitive antagonist 
at the AChRs, as observed at the in vivo NMJ (Domet et al., 1995). Co-cultures treated with tubocurarine 
similarly demonstrated a stop in myotube contractions. However, unlike the α-BTX treated cultures, 
contractile activity was able to restart in the tubocurarine treated co-cultures, which would also be 
expected of a reversible competitive receptor antagonist acting on NMJs to modulate the contractile 
activity of SkM in vivo. Therefore, the re-initiation of contractile activity in the co-cultures verified 
recovery from tubocurarine exposure and validated the accurate neurotransmission observed in this in 
vitro NMJ system. Interestingly, co-cultures treated with bicuculline resulted in a preliminary cessation 
of myotube contractions before the reestablishment spontaneous activity. Research with mice has 
shown that bicuculline can non-competitively block ACh from binding with AChRs (Liu et al., 1994; 
Demuro et al., 2001). Accordingly, results from these studies can be used to suggest that bicuculline 
was able to modulate NMJ activity, which was reflected in myotube contractions being diminished in 
the co-culture system by preventing ACh from binding with receptors at the postsynaptic NMJ, further 
indicating that signalling at the NMJ was regulating contractile activity of myotubes in the co-culture 
system. The co-cultures were also treated with L-Glut to determine if MNs in the system were receptive 
to the excitatory neurotransmitter. A marked but short-lived increase in myotube CF was observed 
within the co-cultures when exposed to L-Glut. As it is known that SkMC membranes are stimulated 
through AChRs, the increased CF witnessed after the application L-Glut indicated that MNs were 
stimulated by the neurotransmitter to increase the release of ACh into the synaptic cleft of the NMJ in 
the co-culture system, thus inducing the increased myotube activity. The final treatment applied to the 
co-cultures was with the inhibitory CNS neurotransmitter GABA, to determine if GABA signalling was 
occurring at the in vitro NMJs in this system. Interestingly, a brief increase in myotube activity was 
observed following GABA exposure. Contrasting this result, studies have shown GABAB receptors exist 
in vivo at MNTs and their modulation via GABA binding could reduce ACh release at the MNT 
(Malomouzh, Nurullin, et al., 2015; Malomouzh, Petrov, et al., 2015). However, the full function of 
GABA and its role in modulating ACh via GABAB receptors at the presynaptic NMJ is yet to be clarified 
(Nurullin et al., 2018). Alternately, Research has shown several transmitter receptor classes exist in 
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early embryonic muscle, with GABAA receptors expressed on embryonic SkMCs (Borodinsky and 
Spitzer, 2007). Thus, the role of GABA at the embryonic and mature NMJ requires additional exploration 
before GABA functions at the NMJ can be fully understood. Ultimately, through real time functional 
assessment of NMJs in the co-culture system, evidence was provided to show this system has the 
potential for use as a high-content platform for the evaluation of innovative therapies and in vitro 
disease modelling, as well as improve the understanding of NMJ formation, development, and function.  
Although establishing this model without exogenous growth factors and neurotrophins is a significant 
breakthrough in in vitro NMJ modelling, it was not surprising as MNs and SkM are co-dependent tissues 
that rely on each other for trophic support and synaptic transmission/stimulation. Additionally, the 
crosstalk between SkM and MNs is essential for the formation and development of SkM, MNs, and 
NMJs. Following the functional assessment of NMJs engineered in the absence of growth factors and 
neurotrophins, indicating cells in the system secreted all required factors to establish this functional 
system. The final objective was to quantify the concentration of growth and neurotrophic factors in the 
co-culture system in comparison to aneurally-cultured myotubes, to determine if the endogenous 
upregulation of specific trophic factors supported the formation and development of NMJs generated 
in the co-culture system. This was accomplished via ELISA-based microarray experiments, which 
revealed elevated expression of twelve growth factors. Studies have shown that BDNF, which is 
commonly used in in vitro NMJ systems, is involved with SkM innervation and MN survival in vivo, along 
with potentiation of signal transmission at the NMJ (Zhang and Poo, 2002; Yan et al., 1993). Thus, the 
upregulation of BDNF in the co-cultures provided evidence that the system permitted physiological 
formation and development of NMJs via endogenously regulated BDNF, which was representative of 
in vivo NMJ formation. The upregulation of FGF-7 was also observed in the co-cultures. Importantly, 
this organising molecule can function in regulating presynaptic specialisation at the NMJ (Umemori et 
al., 2004; Fox et al., 2007). Studies have also shown agrin can regulate FGF expression in SkM to support 
presynaptic NMJ differentiation (An et al., 2010). Thus, elevated FGF-7 in the co-culture system 
indicated interaction between MN-secreted agrin and innervated myotubes during NMJ formation and 
development, as would be expected in vivo. Another factor upregulated in the co-cultures was GDNF, 
which is known to be important for in vitro MN survival (Oppenheim et al., 1995). Studies have also 
argued GDNF may act as a retrograde signalling factor (Wang et al., 2002). Additionally, GDNF over 
expression experiments in mouse models result in abnormal MN overgrowth (Keller-Peck et al., 2001; 
Nguyen et al., 1998). Findings from these studies suggest GDNF is involved with MNT maturation. Thus, 
elevated GDNF observed in the co-culture system indicated interaction between pre- and post-synaptic 
NMJs elements in the system. When quantifying IGF-1 and the IGFBPs 1, 2, 3, 4, and 6 in the co-cultures, 
all were significantly elevated in the system except IGFBP-2. It is known that IGF-1 has important 
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functions in SkM, MN, and NMJ formation, development, and maintenance (Velloso, 2008; Dobrowolny 
et al., 2005) and 80% of IGF-1 is bound to at least one IGFBP (Adachi et al., 2017). Importantly, the 
elevation of the IGFBPs, which serve as membrane transporter proteins for IGF-1, have also been shown 
to enhance IGF-1 bioavailability (Stewart et al., 1993). Therefore, the observed elevated expression of 
IGF-1 and its binding proteins in the co-culture system suggests SCE and SkMC interaction in the system 
induced the upregulation of these factors to support MN maturation, advanced differentiation of 
myofibres, and the formation of robust NMJ, representative of in vivo formation. Both NT-3 and NT-4, 
which are essential for in vitro NMJ modelling, were also elevated in the co-cultures, which are involved 
with the modulation of synaptic function and required for maintenance of NMJs (Gonzalez et al., 1999; 
Belluardo et al., 2001). Animal studies have demonstrated lack of NT-3 causes disruptions in NMJ 
development and maintenance, as well as reductions in the size of SkM fibres (Woolley et al., 1999; 
Woolley et al., 2005). Studies investigating NT-4 expression reveal NT-4 is expressed dependent on 
synapse activity and functions to regulate NM transmission. Thus, it can be asserted that the elevated 
NT-3 and NT-4 observed in the co-cultures was most probably caused by NMJ formation, development 
and synaptic activity. The final two growth factors that were significantly elevated in the co-cultures 
were VEGF and PlGF. Both of which belong to the VEGF family of growth factors and prominently known 
for their functions in vascular growth and development (Ferrara, 2004), Importantly, these factors have 
demonstrated functions in MN growth, guidance, migration, and survival (Rosenstein et al., 2010; Ruiz 
de Almodovar et al., 2009). These factors have also been linked with improved reinnervation of SkM 
after injury, as well as VEGF having the ability to upregulate GDNF and NGF to support MN axon 
regeneration (Shvartsman et al., 2014), indicating the synergy of growth factors during NMJ formation. 
Thus, the observed upregulation of VEGF and PlGF in the co-cultures suggests these factors were 
needed for appropriate MN develop and NMJ formation the system.  
Having examined the results from the microarray experiments valuable insights were gained 
concerning the cellular signalling of this simplified co-culture system. Additionally, the determination 
was made that the co-culture system had the capacity to self-regulate NMJ formation and promoted 
advanced differentiation of SkMCs via the specific expression of essential growth and neurotrophic 
factors.  
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8.1 Conclusion & Future Directions 
 
In conclusion, this project detailed the establishment of a novel and simplified in vitro NMJ co-culture 
system, engineered for the first time with immortalised human skeletal muscle myoblasts innervated 
with neurons from rat embryo spinal cords. This unique breakthrough co-culture system free from 
serum, growth and neurotrophic factors generated contractile myotubes with indicators of advanced 
differentiation and the formation of structurally appropriate and functional NMJs, representative of in 
vivo conditions. Therefore, this in vitro co-culture system provides a platform for expanding research 
into skeletal muscle physiology, as well as NMJ formation and development. Furthermore, the nature 
of this co-culture system offers a relevant means for high-throughput investigations of neurological 
and/or muscular disease modelling, drug discovery, and regenerative medicine, through precise 
manipulation of components in the system.  
For example, new potential drugs and molecules of interest that are being developed for the treatment 
of NM and ND disorders such as CMS, LEMS, MG, ALS, SMA, diabetic neuropathy/myopathy, and 
sarcopenia can be tested on this NMJ model as single or multiple doses over a protracted time interval, 
mimicking real drug evaluation conditions, which can be used to quantify how the NM system responds 
to the intervention. The model provides an accurate replica of live NMJs in vivo, permitting for fast, 
realistic, and non-invasive drug testing. Regardless of the ethical concerns of using live animal subjects 
to test drugs, animal testing is known to be extremely inaccurate. Studies have shown that only one 
out of 50 drugs that are tested on animals in vivo are suitable for human use, as well as the approval 
process for drug use in humans based on animal testing being a complex and largely unsuccessful 
endeavour. In contrast, the functional data generated by this in vitro NMJ model can be directly 
compared to what clinicians may be observing in clinical human trials. Thus, this model may influence 
the design of future clinical trials, and reduce the time required for drug development. Furthermore, 
the sensitivity of this model provides a highly accurate screening tool for new drugs due to the model 
having the capability to quantify the degree of loss-of-function caused by neuromuscular blocking 
agents with various modes of action. This model can also allow for future research into the behaviour 
of disease progression in the NM system, resulting in more informed treatment decisions for clinical 
patients. There is also the potential for future versions of this NMJ model being developed with 
diseased MNs or SkMCs, which could also be used to develop innovative therapies to treat 
neuromuscular diseases.  
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Appendix 
Appendix A 
 
An example of raw data generated from ELISA-based microarray analysis of supernatant from spinal 
cord explants co-cultured with 25-year-old immortalised human myoblasts vs. supernatant from 
aneurally-cultured 25-year-old immortalised human myoblasts. 
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Appendix B 
 
This appendix shows published papers that were produced using the research that was conducted 
throughout the duration of this thesis. The first publication details the NMJ model created during this 
project. The second publication is a review paper exploring how the immune system influences SkM 
repair and regeneration. The author of this thesis was also a contributing author for the final paper in 
this appendix. The final paper details a fully human NMJ model, which is an alternative system to the 
model detailed in this thesis.  
212 
 
 
213 
 
 
214 
 
 
215 
 
216 
 
217 
 
218 
 
219 
 
220 
 
221 
 
222 
 
223 
 
224 
 
225 
 
226 
 
227 
 
228 
 
229 
 
230 
 
231 
 
232 
 
233 
 
234 
 
235 
 
236 
 
237 
 
238 
 
239 
 
 
 
 
 
